Medicines in Development for Cancer

Transcription

2012 Report
Medicines in Development
Cancer
presented by america’s biopharmaceutical
research companies
More Than 900 Medicines and Vaccines in
Clinical Testing Offer New Hope in the Fight
Against Cancer
Medicines in Development
for Selected Cancer Types
More Than
1.6 million
New Cases
of Cancer
121
Are Expected
This Year
117
111
94
67
66
Few things cause more fear and apprehension
than a cancer diagnosis. But today—because
of early detection and a steady stream of new
and improved treatments—cancer increasingly
can be managed and even beaten. But patients
and their families are looking for more and better treatments, and America’s biopharmaceutical research companies are responding.
er
r
nc
Ca
Sk
in
an
ce
a
Pr
os
tat
eC
ph
nc
Ly
m
Ca
om
er
r
ce
ng
Lu
nc
cta
Ca
re
ea
st
Co
lo
Br
lC
an
er
Biopharmaceutical researchers are now working on 981 medicines for cancer. Many are
high-tech weapons to fight the disease, while
some involve innovative research into using
existing medicines in new ways.
Researchers’ deep commitment to patients and
advancing science is at the core of the remarkable progress made in fighting cancer. In recent years we have seen significant declines in
cancer deaths. The number of cancer survivors
living in the United States has increased from
3 million in 1971 to nearly 12 million in 2008.
The increase in survivors is attributed in large
measure to earlier diagnosis and detection and
better treatments and follow-up care.
America’s biopharmaceutical research companies are working on many new cutting-edge
approaches to fight cancer. They include:
•A
medicine that interferes with the metabolism of cancer cells by depriving them
of the energy provided by glucose.
•A
medicine for acute myeloid leukemia
(AML) that inhibits cancer cells with a
mutation found in about a third of AML
sufferers.
•A
therapy that uses nanotechnology to
target the delivery of medicines to cancer
cells, potentially overcoming some limitations of existing treatments.
Despite recent progress, cancer remains the
second leading cause of death by disease
in the United States, exceeded only by heart
disease. In 2012, some 577,190 Americans are
expected to die of cancer—more than 1,500
people a day. The hundreds of new medicines
to treat cancer now being developed are our
best hope for lessening the burden of cancer to
patients, their families and society.
Medicines in Development for Cancer*
Bladder Cancer
9
Brain Cancer
62
Breast Cancer
Cervical Cancer
111
8
Colorectal Cancer
66
Head/Neck Cancer
25
Kidney Cancer
35
Leukemia
120
Liver Cancer
36
Lung Cancer
121
Lymphoma
117
Multiple Myeloma
57
Ovarian Cancer
63
Pancreatic Cancer
58
Prostate Cancer
Sarcoma
94
21
Skin Cancer
67
Solid Tumors
280
Stomach Cancer
23
Cancer-Related Conditions
38
Other Cancers
102
Unspecified Cancer
72
* Some medicines are listed in more than one category.
Bladder Cancer
Product Name
Sponsor
Indication
Development Status*
Abraxane®
albumin-bound paclitaxel
Celgene
Summit, NJ
second-line bladder cancer
(see also breast, lung, ovarian,
pancreatic, skin)
Phase II
(908) 673-9000
AEZS-108
AEterna Zentaris
Basking Ridge, NJ
(see also ovarian, prostate, other)
Phase II
(908) 626-5428
BC-819
(gene therapy)
BioCancell Therapeutics
Jerusalem, Israel
(see also ovarian, pancreatic)
Phase II
www.biocancell.com
EN3488
(mycobacterium cell wall-DNA
complex)
Endo Pharmaceuticals
Chadds Ford, PA
non-muscle invasive bladder cancer
(Fast Track)
Phase III
(610) 558-9800
**For more information about a specific medicine in this report, please call the telephone number listed.
2
Medicines in Development Cancer 2012
Bladder Cance
Product Name
Sponsor
Indication
Development Status
EOquin®
apaziquone
Allergan
Irvine, CA
Spectrum Pharmaceuticals
Irvine, CA
non-invasive bladder cancer
(Fast Track)
Phase III
(949) 788-6700
Folotyn®
pralatrexate
(Orphan Drug)
Allos Therapeutics
Westminster, CO
(see also breast, lung, lymphoma)
Phase II
(303) 426-6262
icrucumab
(LY3012212/IMC-18F1)
Eli Lilly
Indianapolis, IN
ImClone
Bridgewater, NJ
(see also breast, colorectal)
Phase II
(800) 545-5979
tesetaxel
Genta
Berkeley Heights, NJ
second-line bladder cancer
(see also breast, prostate, skin,
stomach)
Phase II
(908) 286-9800
VB4-845
Viventia Biotechnologies
Mississauga, Canada
(see also head/neck)
Phase II
(905) 362-2973
Product Name
Sponsor
Indication
Development Status
8H9 I-131 mAb
United Therapeutics
Silver Spring, MD
(see also sarcoma, other)
Phase I
(301) 608-9292
ABT-888
(veliparib)
(PARP inhibitor)
Abbott Laboratories
Abbott Park, IL
(see also breast, colorectal, lung,
lymphoma, ovarian, prostate, skin,
other)
Phase I
(847) 937-6100
AC480
(pan-HER inhibitor)
Ambit Biosciences
San Diego, CA
glioma
(see also breast, lung)
Phase I
(858) 334-2100
AEE788
Novartis Pharmaceuticals
East Hanover, NJ
glioblastoma
Phase I/II
(888) 669-6682
afatinib
(BIBW2992)
Boehringer Ingelheim
Pharmaceuticals
Ridgefield, CT
glioblastoma
(see also breast, head/neck, lung)
Phase I/II
(800) 243-0127
APN301
(ch14.18 mAb/interleukin-2
fusion protein)
Apeiron Biologics
Vienna, Austria
neuroblastoma in children
(see also skin)
Phase II completed
www.apeiron-biologics.com
Brain Cancer
3
Brain Cancer
Product Name
Sponsor
Indication
Development Status
AR-67
Arno Therapeutics
Flemington, NJ
glioblastoma
(see also leukemia, solid tumors)
Phase II
(862) 703-7170
ARC-100
Archer Biosciences
New York, NY
glioblastoma (recurrent)
(see also breast, prostate, skin)
-------------------------------------------------neuroblastoma
(combination therapy)
-------------------------------------------------medulloblastoma
Phase II
(646) 747-9090
------------------------------------------Phase I/II
(646) 747-9090
------------------------------------------Phase I
(646) 747-9090
AT-101
(oral pan Bcl-2 inhibitor)
Ascenta Therapeutics
Malvern, PA
glioblastoma
(see also leukemia, lung, lymphoma,
prostate, stomach)
Phase II
(610) 408-0301
Avastin®
bevacizumab
Genentech
South San Francisco, CA
first-line glioblastoma multiforme
ovarian, other)
Phase III
(800) 626-3553
Azedra™
metaiodobenzylguanidine I-131
(Orphan Drug)
Molecular Insights Pharmaceuticals
Cambridge, MA
neuroblastoma (pediatric)
(Fast Track), paraganglioma,
pheochromocytoma (Fast Track)
Phase II
(617) 492-5554
bafetinib
CytRx
Los Angeles, CA
second-line brain cancer
(see also leukemia, prostate)
Phase I
(310) 826-5648
BKM120
(PI3K inhibitor)
East Hanover, NJ
glioblastoma
(see also breast, lung, other)
Phase I/II
(888) 669-6682
ch14.18 mAb
(Orphan Drug)
United Therapeutics
Silver Spring, MD
neuroblastoma (children)
Phase III
(301) 608-9292
cilengitide
(Orphan Drug)
EMD Serono
Rockland, MA
newly-diagnosed glioblastoma
(see also prostate)
Phase III
(800) 283-8088
cintredekin besudotox
(Orphan Drug)
INSYS Therapeutics
Phoenix, AZ
glioma (adolescents and children)
(Fast Track)
Phase I
(602) 910-2617
Cotara®
monoclonal antibody TNT-1
(Orphan Drug)
Peregrine Pharmaceuticals
Tustin, CA
recurrent glioblastoma
(Fast Track)
Phase II
(714) 508-6000
CPP-1X
(eflornithine)
Cancer Prevention Pharmaceuticals
Tucson, AZ
neuroblastoma
Phase I
(520) 908-7774
4
Brain Cancer
Product Name
Sponsor
Indication
Development Status
crenolanib
(CP-868-596)
AROG Pharmaceuticals
Dallas, TX
glioma (adults)
(see also stomach)
-------------------------------------------------glioma (pediatric)
Phase II
(214) 594-0002
------------------------------------------Phase I
(214) 594-0002
DCVax®-Brain
brain cancer vaccine
(Orphan Drug)
Northwest Biotherapeutics
Bethesda, MD
glioblastoma
Phase II
(240) 497-9024
E7050
Eisai
Woodcliff Lake, NJ
second-line glioblastoma
(see also head/neck, liver, skin,
solid tumors, stomach)
Phase I/II
(888) 422-4743
E7080
(lenvatinib)
Eisai
Woodcliff Lake, NJ
glioma
(see also skin, other)
Phase II
(888) 422-4743
EPO-806
(patupilone)
East Hanover, NJ
brain metastases from lung cancer
(see also prostate)
Phase II
(888) 669-6682
G-100 prophage cancer vaccine
(vitespen)
(Orphan Drug)
Agenus
Lexington, MA
newly-diagnosed glioma
Phase II
(781) 674-4400
G-200 prophage cancer vaccine
(vitespen)
(Orphan Drug)
Agenus
Lexington, MA
recurrent glioma
Phase II
(781) 674-4400
GliAtak™
gene therapy
(Orphan Drug)
Advantagene
Auburndale, MA
glioma
Phase II
(617) 916-5445
------------------------------------------Phase I
(617) 916-5445
GMB-Vax
dendritic cell cancer vaccine
Activartis Biotech
Vienna, Austria
first-line glioblastoma
Phase II
www.activartis.com
GRN1005
(LRP directed peptide-drug
conjugate)
Geron
Menlo Park, CA
brain metastases
Phase II
(650) 473-7700
------------------------------------------Phase I completed
(650) 473-7700
GSK2118436
(BRaf protein kinase inhibitor)
GlaxoSmithKline
Rsch. Triangle Park, NC
brain metastases from melanoma
(see also lung, skin)
Phase II
(888) 825-5249
Hycamtin®
topotecan
GlaxoSmithKline
metastatic brain cancer
Phase III
(888) 825-5249
-------------------------------------------------brain cancer (children)
-------------------------------------------------glioma
5
Brain Cancer
Product Name
Sponsor
Indication
Development Status
ICT-107
(dendritic cell vaccine)
(Orphan Drug)
ImmunoCellular Therapeutics
Woodland Hills, CA
glioblastoma
Phase II
(818) 992-2907
Levulan® PDT
aminolevulinic acid
DUSA Pharmaceuticals
Wilmington, MA
lonafarnib
Merck
Whitehouse Station, NJ
glioblastoma
Phase I
(800) 672-6372
Lucanix®
belagenpumatucel-L
NovaRx
San Diego, CA
glioma
(see also lung)
Phase I
(858) 522-8600
macitentan
Actelion Pharmaceuticals US
glioblastoma (combination therapy)
Phase I
(650) 624-6900
MEDI-575
(anti-PDGFR-alpha mAb)
AstraZeneca
Wilmington, DE
MedImmune
Gaithersburg, MD
glioblastoma
(see also lung)
Phase II
(800) 236-9933
(301) 398-0000
mibefradil
(T-type calcium channel
inhibitor)
(Orphan Drug)
Tau Therapeutics
Charlottesville, VA
glioblastoma
Phase I
(434) 974-6969
motexafin gadolinium
Pharmacyclics
Sunnyvale, CA
glioblastoma (combination therapy)
Phase II
(408) 774-0330
nimotuzumab
(Orphan Drug)
YM Biosciences USA
Lehigh Valley, PA
metastatic brain cancer,
recurrent glioma (pediatric)
(see also breast, prostate)
Phase II
(610) 560-0600
olaratumab
(LY3012207)
Eli Lilly
Indianapolis, IN
ImClone Systems
Bridgewater, NJ
glioblastoma
(see also ovarian)
Phase II
(800) 545-5979
Opaxio™
paclitaxel poliglumex
Cell Therapeutics
Seattle, WA
glioma, glioblastoma
(see also lung, ovarian, stomach,
other)
Phase II
(800) 215-2355
perifosine
AEterna Zentaris
Basking Ridge, NJ
refractory metastatic glioma
(see also colorectal, kidney,
leukemia, lung, lymphoma, multiple
myeloma, sarcoma, solid tumors,
stomach)
Phase II
(908) 626-5428
6
Phase II
(978) 657-7500
Brain Cancer
Product Name
Sponsor
Indication
Development Status
PLX3397
(CSF-1R kinase inhibitor)
Plexxikon
Berkeley, CA
recurrent glioblastoma
(see also leukemia, lymphoma,
solid tumors)
Phase II
(510) 647-4000
Poly-ICLC
(Orphan Drug)
Oncovir
Washington, DC
anaplastic astrocytoma (adolescents
and children), glioblastoma
(adolescents and children)
Phase II
www.oncovir.com
PX-866
Oncothyreon
Seattle, WA
second-line glioblastoma
(see also head/neck, lung, prostate)
Phase II
(206) 801-2100
Reolysin®
reovirus
Oncolytics Biotech
Calgary, Canada
glioma
(see also colorectal, head/neck, lung,
ovarian, pancreatic, sarcoma,
skin, solid tumors)
Phase I/II
(403) 670-7377
rindopepimut
(Orphan Drug)
Celldex Therapeutics
Needham, MA
first-line glioblastoma
(Fast Track)
-------------------------------------------------second-line glioblastoma
(Fast Track)
Phase III
(781) 433-0771
------------------------------------------Phase II
(781) 433-0771
SB-313-xTZ
Sangamo Biosciences
Richmond, CA
glioblastoma
Phase I
(510) 970-6000
SBG
Biotec Pharmacon
Tromsø, Norway
neuroblastoma (pediatric)
Phase I/II completed
www.biotec.no
SL-701
(brain cancer vaccine)
Stemline Therapeutics
New York, NY
glioma (adults)
Phase I/II
(212) 831-1111
------------------------------------------Phase I/II
(212) 831-1111
SPRYCEL®
dasatinib
Bristol-Myers Squibb
Princeton, NJ
glioblastoma
(see also breast, pancreatic,
prostate, other)
in clinical trials
(800) 332-2056
Tarceva®
erlotinib
(Orphan Drug)
Genentech
OSI Pharmaceuticals
Farmingdale, NY
late-stage brain metastases,
recurrent ependymoma (children),
glioblastoma
(see also breast, head/neck,
leukemia, liver, lung, other)
Phase II
(800) 626-3553
(631) 962-0600
terameprocol
Erimos Pharmaceuticals
Houston, TX
glioma (intravenous)
(see also cervical, head/neck,
solid tumors, other)
Phase I/II
(713) 541-2000
TGF-ß R1 inhibitor
(LY2157299)
Eli Lilly
Indianapolis, IN
(see also liver)
Phase II
(800) 545-5979
-------------------------------------------------glioma (children)
7
Brain Cancer
Product Name
Sponsor
Indication
Development Status
TH-302
Threshold Pharmaceuticals
astrocytoma
(see also leukemia, multiple
myeloma, pancreatic, sarcoma)
Phase II
(650) 474-8200
Toca 511/Toca FC
(cytosine deaminase gene
therapy)
Tocagen
San Diego, CA
glioblastoma
Phase I/II
(858) 412-8400
trans-sodium crocetinate (TSC)
(Orphan Drug)
Diffusion Pharmaceuticals
Charlottesville, VA
gliobastoma
Phase I/II
(434) 220-0718
TVI-Brain-1
(cellular immunotherapy
vaccine)
TVAX Biomedical
Lenexa, KS
glioma
Phase II
(913) 492-2221
VAL-083
Del Mar Pharmaceuticals
Vancouver, Canada
grade IV malignant glioma
Phase I/II
(604) 629-5989
VB-111
VBL Therapeutics
Or Yehuda, Israel
glioblastoma
(see also other)
Phase I/II
www.vblrx.com
Xeloda®
capecitabine
Genentech
newly-diagnosed glioma
(adolescents and children)
(see also colorectal, liver, stomach)
Phase I
(800) 626-3553
Zelboraf®
vemurafenib
Genentech
Plexxikon
Berkeley, CA
brain metastases
(see also colorectal, other)
Phase II
(800) 626-3553
Product Name
Sponsor
Indication
Development Status
18F-fluorothymidine
Merck
breast cancer (diagnosis)
Phase II
(800) 672-6372
Abraxane®
Celgene
Summit, NJ
first-line metastatic breast cancer
(see also bladder, lung, ovarian,
pancreatic, skin)
Phase II
(908) 673-9000
ABT-888
(veliparib)
(PARP inhibitor)
Abbott Laboratories
Abbott Park, IL
(see also brain, colorectal, lung,
other)
Phase II
(847) 937-6100
AC480
(pan-HER inhibitor)
Ambit Biosciences
San Diego, CA
(see also brain, lung)
Phase I
(858) 334-2100
Breast Cancer
8
Breast Cancer
Product Name
Sponsor
acolbifene
(4th-generation SERM)
EndoCeutics
Quebec, Canada
AE37 peptide vaccine
Antigen Express
Worcester, MA
(see also ovarian)
Phase II
(508) 852-8783
afatinib
(BIBW2992)
Pharmaceuticals
Ridgefield, CT
second-line metastatic breast cancer
(see also brain, head/neck, lung)
-------------------------------------------------first-line breast cancer
Phase III
(800) 243-0127
------------------------------------------Phase II
(800) 243-0127
afimoxifene
ASCEND Therapeutics
Herndon, VA
breast cancer (prevention)
Phase II
(703) 471-4744
Afinitor®
everolimus
East Hanover, NJ
HER2-positive breast cancer
(see also kidney, lymphoma)
Phase III
(888) 669-6682
AFP464
Kirax
Bonita Springs, FL
amrubicin
Celgene
Summit, NJ
late-stage breast cancer
(see also lung)
Phase I/II
(908) 673-9000
ARC-100
Archer Biosciences
New York, NY
(see also brain, prostate, skin)
Phase II
(646) 747-9090
ARRY-380
(HER2 inhibitor)
Array BioPharma
Boulder, CO
AUY922
(Hsp90 inhibitor)
East Hanover, NJ
Indication
Development Status
Phase II
(418) 653-0033
Phase II
(239) 444-5400
Phase I
(877) 633-2436
breast cancer (monotherapy)
(see also colorectal, lung, multiple
myeloma, stomach)
-------------------------------------------------breast cancer (combination therapy)
Phase II
(888) 669-6682
------------------------------------------Phase I/II
(888) 669-6682
9
Breast Cancer
Product Name
Sponsor
Indication
Development Status
Avastin®
bevacizumab
Genentech
adjuvant HER2-negative breast cancer, adjuvant HER2-positive breast
cancer, adjuvant triple negative
breast cancer
ovarian, other)
Phase III
(800) 626-3553
AZD8931
(erbB kinase inhibitor)
AstraZeneca
Wilmington, DE
advanced breast cancer
(see also solid tumors)
Phase II
(800) 236-9933
BAY 86-5044
(lonaprisan)
Bayer HealthCare Pharmaceuticals
Wayne, NJ
metastatic breast cancer
Phase II completed
(888) 842-2937
BIIB 2024
Biogen Idec
Cambridge, MA
(see also stomach)
Phase II completed
(617) 679-2000
BKM120
(PI3K inhibitor)
East Hanover, NJ
second-line breast cancer
(see also brain, lung, other)
Phase I/II
(888) 669-6682
breast cancer vaccine
Quantum Immunologics
Tampa, FL
brostallicin
Cell Therapeutics
Seattle, WA
triple-negative breast cancer
Phase I
(800) 215-2355
BTSCAN
Molecular Targeting Technologies
West Chester, PA
Phase I
(610) 738-7938
BZL-101
Bionovo
Emeryville, CA
cabozantinib
(XL184)
Exelixis
(see also kidney, lung, ovarian,
prostate, other)
Phase II
(650) 837-7000
cancer vaccine
MabVax Therapeutics
San Diego, CA
(see also sarcoma)
Phase I
(858) 259-9405
CDX-011
(glembatumumab vedotin)
Needham, MA
breast cancer (Fast Track)
(see also skin)
Phase II
(781) 433-0771
CV-301
(cancer vaccine)
BN ImmunoTherapeutics
Mountain View, CA
Phase II
(650) 681-4660
D-1MT
NewLink Genetics
Ames, IA
Phase I/II
(515) 296-5555
10
Phase I/II
(866) 213-4594
Phase I
(510) 601-2000
Breast Cancer
Product Name
Sponsor
Indication
Development Status
dalotuzumab
(MK-0646)
Merck
second-line breast cancer
(see also lung, pancreatic, other)
-------------------------------------------------first-line breast cancer
Phase II
(800) 672-6372
------------------------------------------Phase I
(800) 672-6372
DPX-0907
Immunovaccine
Halifax, Canada
(see also ovarian, prostate)
Phase I
(902) 492-1819
eniluracil
Adherex Technologies
Phase II
(919) 636-4530
entinostat
Syndax Pharmaceuticals
Waltham, MA
leukemia, lung, lymphoma)
Phase II
(781) 419-1400
etirinotecan pegol
(NKTR-102)
Nektar Therapeutics
San Francisco, CA
(see also colorectal, ovarian,
solid tumors)
Phase III
(855) 482-6587
EZN-2208
(PEG-SN38, firtecan pegol)
Enzon Pharmaceuticals
Piscataway, NJ
(see also colorectal, solid tumors)
Phase II
(973) 980-4500
Faslodex®
fulvestrant
AstraZeneca
Wilmington, DE
first-line advanced breast cancer
Phase III
(800) 236-9933
folate binding protein (E39)
vaccine
Galena Biopharma
Lake Oswego, OR
(see also ovarian, other)
Phase I
(855) 855-4253
Folotyn®
pralatrexate
Allos Therapeutics
Westminster, CO
(see also bladder, lung, lymphoma)
Phase II
(303) 426-6262
ganetespib
(Hsp90i)
Synta Pharmaceuticals
Lexington, MA
(see also colorectal, leukemia, liver,
lung, multiple myeloma, pancreatic,
prostate, skin, stomach)
Phase II
(781) 274-8200
ganitumab
(AMG 479)
Amgen
Thousand Oaks, CA
combination therapy
(see also colorectal, lung, pancreatic,
sarcoma)
Phase II
(800) 772-6436
GDC-0980
(PI3 kinase/mTOR dual
inhibitor)
Genentech
hormone receptor-positive breast
cancer
(see also lymphoma, solid tumors)
Phase II
(800) 626-3553
GSK2302024A
(WT1 antigen-specific cancer
immunotherapeutic)
GlaxoSmithKline
neoadjuvant breast cancer
Phase I/II
(888) 825-5249
GVAX® Breast
cancer vaccine
BioSante Pharmaceuticals
Lincolnshire, IL
Phase I
(847) 478-0500
11
Breast Cancer
Product Name
Sponsor
HER2 antigen-specific cancer
immunotherapeutic
GlaxoSmithKline
icrucumab
(LY3012212/IMC-18F1)
Eli Lilly
Indianapolis, IN
ImClone
Bridgewater, NJ
(see also bladder, colorectal)
Phase II
(800) 545-5979
imetelstat
Geron
Menlo Park, CA
(see also leukemia, lung,
multiple myeloma)
Phase II
(650) 473-7700
IMT-1012 immunotherapeutic
vaccine
Immunotope
Doylestown, PA
(see also ovarian)
Phase I
(215) 253-4180
indibulin
(ZIO-301)
ZIOPHARM Oncology
New York, NY
Phase I/II
(646) 214-0700
iniparib
(BSI-201)
Sanofi US
Bridgewater, NJ
(see also lung, ovarian)
Phase II
(800) 981-2491
KW-2450
Kyowa Hakko Kirin Pharma
Princeton, NJ
first-line breast cancer, second-line
breast cancer
Phase I/II
(609) 919-1100
LFA102
(anti-prolactin receptor antibody)
East Hanover, NJ
XOMA
Berkeley, CA
(see also prostate)
Phase I
(888) 669-6682
LGK974
(WNT signaling pathway
inhibitor)
East Hanover, NJ
(see also skin)
Phase I
(888) 669-6682
linifanib
Abbott Laboratories
Abbott Park, IL
breast cancer (combination therapy)
(see also colorectal, kidney, liver,
lung)
Phase II
(847) 937-6100
liposome encapsulated
paclitaxel (LEP-ETU)
Insys Therapeutics
Phoenix, AZ
litronesib
(LY2523355)
Eli Lilly
Indianapolis, IN
(see also lung)
Phase II
(800) 545-5979
LOR-2040
Lorus Therapeutics
Toronto, Canada
leukemia, prostate)
Phase II
(416) 798-1200
Lymphoseek®
Tc-99m tilmanocept
Navidea Pharmaceuticals
Dublin, OH
(see also head/neck, skin)
application submitted
(614) 793-7500
12
Indication
Development Status
Phase II
(888) 825-5249
Phase II
(602) 910-2617
Breast Cancer
Product Name
Sponsor
Indication
Development Status
maraciclatide
GE Healthcare
Waukesha, WI
in clinical trials
www.gehealthcare.com
MK-0752
(notch signaling pathway
inhibitor)
Merck
early-stage breast cancer,
(see also other)
Phase I
(800) 672-6372
MK-2206
(c-akt inhibitor)
Merck
HER2-positive breast cancer
(see also other)
Phase I
(800) 672-6372
MM-111
Merrimack Pharmaceuticals
Cambridge, MA
Phase I/II
(617) 441-1000
MM-302
(anti-HER2 antibody
doxorubicin conjugate)
Cambridge, MA
motesanib
Amgen
Thousand Oaks, CA
MVA-BN® HER2
(HER-2/neu-based MVA
vaccine)
Mountain View, CA
Myocet™
doxorubicin liposomal
Sopherion Therapeutics
Princeton, NJ
first-line breast cancer
(combination therapy) (Fast Track)
Phase III
(609) 986-2020
NeuVax™
cancer vaccine E75
Galena Biopharma
Lake Oswego, OR
early-stage breast cancer
(prevention of relapse)
(see also prostate)
Phase III
(855) 855-4253
Nexavar®
sorafenib
Wayne, NJ
(see also colorectal, head/neck,
kidney, leukemia, liver, lung, multiple
myeloma, ovarian, other)
Phase III
(888) 842-2937
nimotuzumab
YM Biosciences USA
Lehigh Valley, PA
(see also brain, prostate)
Phase I
(610) 560-0600
NK-012
Nippon Kayaku
Tokyo, Japan
(see also lung)
Phase II
www.nipponkayaku.co.jp
OBP-301
Oncolys Biopharma
Tokyo, Japan
(see also head/neck, liver, lung)
Phase I
www.oncolys.com
OGX-427
OncoGenex Pharmaceuticals
Bothell, WA
Phase I
(425) 686-1500
Phase I
(617) 441-1000
(see also colorectal, lung, other)
Phase I/II
(800) 772-6436
Phase I
(650) 681-4660
13
Breast Cancer
Product Name
Sponsor
Indication
Development Status
onartuzumab
Genentech
(see also colorectal, lung)
Phase II
(800) 626-3553
OPT-822/OPT-821
Optimer Biotechnology
San Diego, CA
PB-272 (neratinib)
Puma Biotechnology
Los Angeles, CA
second-line breast cancer,
Phase II
(424) 248-6500
pertuzumab
Genentech
first-line metastatic breast cancer
(800) 626-3553
------------------------------------------Phase II
(800) 626-3553
pertuzumab companion
diagnostic
(HER2 FISH pharmDx™)
Dako
Glostrup, Denmark
Genentech
breast cancer (diagnostic)
Phase III
www.dako.com
(800) 626-3553
pertuzumab companion
diagnostic
(HercepTest™)
Dako
Glostrup, Denmark
Genentech
Phase III
www.dako.com
(800) 626-3553
pixantrone
Cell Therapeutics
Seattle, WA
breast cancer (Fast Track)
(see also lymphoma)
Phase II
(800) 215-2355
PTC299
PTC Therapeutics
South Plainfield, NJ
(see also solid tumors, other)
Phase I/II
(908) 222-7000
Quinamed®
amonafide
Cephalon
Frazer, PA
Phase II
(610) 344-0200
ramucirumab
(IMC-1121B)
Eli Lilly
Indianapolis, IN
ImClone Systems
Bridgewater, NJ
(see also colorectal, stomach)
Phase III
(800) 545-5979
Reximmune-C®
personalized cancer vaccine
Epeius Biotechnologies
San Marino, CA
Rexin-G®
San Marino, CA
14
Phase II/III
(858) 909-0736
-------------------------------------------------second-line late-stage breast cancer
Phase I/II
(626) 441-6695
(see also pancreatic, sarcoma)
Phase I/II
(626) 441-6695
Breast Cancer
Product Name
Sponsor
Indication
Development Status
ridaforolimus
ARIAD Pharmaceuticals
Cambridge, MA
Merck
(see also kidney, lung, prostate,
sarcoma, other)
Phase II
(800) 672-6372
rucaparib
Clovis Oncology
Boulder, CO
(see also ovarian)
Phase II
(303) 625-5000
sagopilone
Wayne, NJ
Phase II completed
(888) 842-2937
samarium SM-153 lexidronam
injection
EUSA Pharma
Langhorne, PA
(see also multiple myeloma, prostate,
sarcoma, other)
Phase II
(800) 833-3533
SAR245408
(XL147)
(oral PI3K inhibitor)
Sanofi US
Bridgewater, NJ
Exelixis
(see also other)
Phase II
(800) 981-2491
(650) 837-7000
SAR245409
(XL765)
(PI3K/mTOR inhibitor)
Sanofi US
Bridgewater, NJ
Exelixis
(see also lymphoma)
Phase II
(800) 981-2491
(650) 837-7000
SAR256212
(MM-121)
(anti-ErbB3 mAb)
Cambridge, MA
Sanofi US
Bridgewater, NJ
Phase II
(800) 981-2491
SF1 (sonodynamic therapy)
SonneMed
Boston, MA
Phase I/II
www.sonnemed.com
SPRYCEL®
dasatinib
Princeton, NJ
(see also brain, pancreatic, prostate,
other)
in clinical trials
(800) 332-2056
SR 16234
SRI International
Menlo Park, CA
Tarceva®
erlotinib
Genentech
OSI Pharmaceuticals
Farmingdale, NY
(see also brain, head/neck, leukemia,
liver, lung, other)
Phase II
(800) 626-3553
(631) 962-0600
tesetaxel
Genta
first-line breast cancer
(see also bladder, prostate, skin,
stomach)
Phase II
(908) 286-9800
Phase II
(650) 859-2000
15
Breast Cancer
Product Name
Sponsor
Indication
Development Status
ThermoDox®
Celsion
Lawrenceville, NJ
recurrent breast cancer
(see also colorectal, liver)
Phase I/II
(609) 896-9100
tigatuzumab
(anti-DR5 antibody)
Daiichi Sankyo
Parsippany, NJ
(see also colorectal, liver, lymphoma,
ovarian, pancreatic)
Phase II
(973) 944-2600
tivozanib
(ASP4130/AV-951)
Astellas Pharma US
Deerfield, IL
AVEO Pharmaceuticals
Cambridge, MA
(see also colorectal, kidney)
Phase I/II
(800) 695-4321
(617) 299-5000
TKI258
(dovitinib)
East Hanover, NJ
(see also kidney, multiple myeloma,
prostate, skin, other)
Phase II
(888) 669-6682
trabectedin
Johnson & Johnson Pharmaceutical
Research & Development
Raritan, NJ
(see also ovarian, prostate, sarcoma)
Phase III
(800) 817-5286
trastuzumab-DM1
(RG3502)
Genentech
trastuzumab-DM1
companion diagnostic
(HercepTest™)
Dako
Glostrup, Denmark
Genentech
Phase III
www.dako.com
(800) 626-3553
trastuzumab-DM1
(HER2 FISH pharmDx™)
Dako
Glostrup, Denmark
Genentech
Phase III
www.dako.com
(800) 626-3553
TRC 105
(ENG protein inhibitor)
TRACON Pharmaceuticals
San Diego, CA
(see also ovarian, prostate, other)
Phase I/II
(858) 550-0780
trebananib
(AMG386)
Amgen
Thousand Oaks, CA
ovarian, stomach, other)
Phase II
(800) 772-6436
Tykerb®
lapatinib
GlaxoSmithKline
inflammatory breast cancer
(see also colorectal, head/neck,
stomach)
-------------------------------------------------adjuvant breast cancer, first-line
-------------------------------------------------neoadjuvant breast cancer
(888) 825-5249
upamostat
(WX-671)
16
Wilex
Munich, Germany
Phase III
(800) 626-3553
------------------------------------------Phase III
(888) 825-5249
------------------------------------------Phase II
(888) 825-5249
Phase II
www.wilex.de
Breast Cancer
Product Name
Sponsor
Indication
Development Status
varlitinib
ASLAN Pharmaceuticals
Singapore
VeriStrat®
companion diagnostic test
EGFR-TKI
Biodesix
Boulder, CO
(diagnosis-outcome test in
HER2-overexpressing tumors)
Phase III
(303) 417-0500
YM155
(sepantronium)
Astellas Pharma US
Deerfield, IL
(see also lymphoma)
Phase II
(800) 695-4321
Zolinza®
vorinostat
Merck
multiple myeloma, other)
Phase II
(800) 672-6273
Zytiga®
abiraterone
Janssen Biotech
Horsham, PA
(see also prostate)
Phase II
(800) 526-7736
Product Name
Sponsor
Indication
Development Status
ADXS-HPV
Advaxis
Princeton, NJ
cervical cancer, cervical
intraepithelial neoplasia
Phase II
(609) 452-9813
PM-00104
PharmaMar
Madrid, Spain
(see also sarcoma, other)
Phase II
www.pharmamar.com
PV701
(replication-competent oncolytic
virus)
Wellstat Biologics
Gaithersburg, MD
(see also colorectal)
Phase II
(240) 683-2500
terameprocol
Houston, TX
cervical intraepithelial neoplasia
(intravaginal)
(see also brain, head/neck, solid
tumors, other)
Phase II
(713) 541-2000
V503
(HPV virus-like particle (VLP)
vaccine)
Merck
prevention of cervical cancer,
prevention of vulvovaginal cancer
Phase III
(800) 672-6372
V505
(HPV vaccine)
Merck
prevention of cervical cancer
Phase II completed
(800) 672-6372
Phase II
www.aslanpharma.com
Cervical Cancer
17
Cervical Cancer
Product Name
Sponsor
Indication
Development Status
verpasep caltespen
(cancer vaccine)
Akela Pharma
Austin, TX
Phase I completed
(512) 834-0449
VGX-3100
(DNA cancer vaccine)
Inovio Pharmaceuticals
Blue Bell, PA
Phase II
(877) 446-6846
Colorectal Cancer
Product Name
Sponsor
Indication
Development Status
ABT-888
(veliparib)
(PARP inhibitor)
Abbott Laboratories
Abbott Park, IL
(see also brain, breast, lung,
other)
Phase II
(847) 937-6100
Aptocine™
talaporfin
Light Sciences Oncology
Bellevue, WA
metastatic colorectal cancer
Phase III
(425) 957-8900
AUY922
(Hsp90 inhibitor)
East Hanover, NJ
second-line colorectal cancer
(see also breast, lung, multiple
myeloma, stomach)
Phase I
(888) 669-6682
Avastin®
bevacizumab
Genentech
(treatment beyond progression)
(see also brain, breast, lung, ovarian,
other)
Phase III
(800) 626-3553
AVX701
(CEA cancer immunotherapy)
AlphaVax
colorectal cancer prevention in
patients with advanced or metastatic
CEA-expressing malignancies
Phase I/II
(919) 595-0400
belinostat
Henderson, NV
colorectal cancer (combination
therapy)
(see also leukemia, liver, lung,
lymphoma, ovarian, other)
Phase I/II
(702) 835-6300
brivanib
(VEGFR/FGFR kinase inhibitor)
Princeton, NJ
(see also liver, sarcoma)
Phase II
(800) 332-2056
CPX-1
(irinotecan/floxuridine)
Celator Pharmaceuticals
Princeton, NJ
CT-011
CureTech
Yavne, Israel
E7820
Eisai
Woodcliff Lake, NJ
18
Phase II completed
(609) 243-0123
first-line metastatic colorectal cancer
(see also leukemia, lymphoma)
Phase II
www.curetechbio.com
Phase II
(888) 422-4743
Colorectal Cancer
Product Name
Sponsor
Indication
Development Status
efatutazone
Daiichi Sankyo
Parsippany, NJ
(see also lung, other)
Phase II
(973) 944-2600
EGEN-001
EGEN
Huntsville, AL
Phase I/II
(256) 512-0077
EGFR antagonist
QIAGEN
Valencia, CA
colorectal cancer (diagnosis)
www.qiagen.com
encapsulated cell therapy
(macrobeads)
Rogosin Institute
New York, NY
refractory metastatic colorectal
cancer
(see also pancreatic, prostate)
Phase II
(212) 746-1566
entinostat
Waltham, MA
(see also breast, kidney, leukemia,
lung, lymphoma)
Phase II
(781) 419-1400
ERBITUX®
cetuximab
Princeton, NJ
Eli Lilly
Indianapolis, IN
first-line colorectal cancer
(see also stomach)
in clinical trials
(800) 332-2056
(800) 545-5979
etirinotecan pegol
(NKTR-102)
Nektar Therapeutics
San Francisco, CA
(see also breast, ovarian, solid
tumors)
Phase II/III
(855) 482-6587
EZN-2208
Piscataway, NJ
(see also breast, solid tumors)
Phase II
(973) 980-4500
FANG™ Vaccine
autologous tumor cell vaccine
Gradalis
Carrollton, TX
(see also ovarian, skin)
Phase II
(214) 442-8100
ganetespib
(Hsp90i)
Lexington, MA
refractory, metastatic colorectal
cancer
(see also breast, leukemia, liver,
Phase II
(781) 274-8200
ganitumab
(AMG 479)
Amgen
Thousand Oaks, CA
second-line metastatic colorectal
cancer (combination therapy)
(see also breast, lung, pancreatic,
sarcoma)
Phase II
(800) 772-6436
GI-4000
(cancer vaccine)
GlobeImmune
Louisville, CO
(see also lung, pancreatic)
Phase II
(303) 625-2700
19
Colorectal Cancer
Product Name
Sponsor
Indication
Development Status
GM-CT-01
Galectin Therapeutics
Newton, MA
colorectal cancer
Phase II
(617) 559-0033
GS-6624
(monoclonal antibody)
Gilead Sciences
Foster City, CA
(see also pancreatic)
Phase II
(800) 445-3235
GVAX® Colorectal
cancer vaccine
Lincolnshire, IL
icrucumab
(LY3012212/IMC-18F1)
Eli Lilly
Indianapolis, IN
ImClone
Bridgewater, NJ
(see also bladder, breast)
Phase II
(800) 545-5979
IMO-2055
(TLR9 agonist)
Idera Pharmaceuticals
Cambridge, MA
(see also head/neck, lung)
Phase I
(617) 679-5000
Imprime PGG®
Biothera
Eagan, MN
(see also leukemia, lung, skin)
Phase III
(651) 675-0300
JX-594
(pexastimogene devacirepvec)
Jennerex Biotherapeutics
San Francisco, CA
(see also liver)
Phase I/II
(415) 281-8886
KRN-330
Princeton, NJ
colorectal cancer
-------------------------------------------------colorectal cancer (monotherapy)
Phase I/II
(609) 919-1100
------------------------------------------Phase I
(609) 919-1100
labetuzumab I-131
(IMMU-111)
Immunomedics
Morris Plains, NJ
Phase II
(973) 605-8200
labetuzumab-SN-38
(IMMU-130)
Immunomedics
Morris Plains, NJ
Phase I
(973) 605-8200
LGX818
(RAF inhibitor)
East Hanover, NJ
(see also skin)
Phase I
(888) 669-6682
linifanib
Abbott Laboratories
Abbott Park, IL
(see also breast, kidney, liver, lung)
Phase II
(847) 937-6100
LOR-2040
Lorus Therapeutics
Toronto, Canada
(see also breast, kidney, leukemia,
prostate)
Phase II
(416) 798-1200
motesanib
Amgen
Thousand Oaks, CA
Phase I
(800) 772-6436
20
Phase I
(847) 478-0500
Colorectal Cancer
Product Name
Sponsor
Indication
Development Status
Nexavar®
sorafenib
Wayne, NJ
(see also breast, head/neck, kidney,
leukemia, liver, lung, multiple
Phase II
(888) 842-2937
NPC-1C
(ensituximab)
Neogenix Oncology
Rockville, MD
Phase I
(301) 917-6893
onartuzumab
Genentech
Phase II
(800) 626-3553
OncoVAX®
active specific immunotherapy
Vaccinogen
Frederick, MD
(Fast Track)
Phase I/II
(301) 668-8400
perifosine
AEterna Zentaris
Basking Ridge, NJ
refractory metastatic colorectal
(Fast Track)
(see also brain, kidney, leukemia,
lung, lymphoma, multiple myeloma,
sarcoma, solid tumors, stomach)
Phase III
(908) 626-5428
PHY906
PhytoCeutica
New Haven, CT
(see also liver, pancreatic,
cancer-related)
Phase I/II
(203) 777-3462
picoplatin
Ponaird Pharmaceuticals
Seattle, WA
(see also lung, ovarian, prostate)
Phase II
(206) 281-7001
polyclonal antibody stimulator
Cancer Advances
Durham, NC
(see also pancreatic, stomach)
Phase II
(919) 361-2162
PV701
(replication-competent oncolytic
virus)
Wellstat Biologics
Gaithersburg, MD
(see also cervical)
Phase II
(240) 683-2500
ramucirumab
(IMC-1121B)
Eli Lilly
Indianapolis, IN
ImClone
Bridgewater, NJ
(see also breast, stomach)
Phase III
(800) 545-5979
regorafenib
Wayne, NJ
(Fast Track)
(see also kidney, lung, solid tumors,
stomach)
Phase III
(888) 842-2837
Reolysin®
reovirus
Oncolytics Biotech
Calgary, Canada
(see also brain, head/neck, lung,
ovarian, pancreatic, sarcoma,
skin, solid tumors)
Phase I
(403) 670-7377
21
Colorectal Cancer
Product Name
Sponsor
Indication
Development Status
RG7160
(EGFR inhibitor)
Roche
Nutley, NJ
Phase II
(973) 235-5000
RG7414
(EGFL7 inhibitor)
Genentech
(see also lung)
Phase II
(800) 626-3553
RIGScan™
tumor-specific, radio-labeled
monoclonal antibody targeting
agent
Navidea Biopharmaceuticals
Dublin, OH
(diagnosis)
(800) 793-0079
robatumumab
Merck
(see also sarcoma, solid tumors)
Phase II completed
(800) 672-6372
Sym004
Symphogen
Lyngby, Denmark
Phase II
www.symphogen.com
TAS-102
Taiho Pharma U.S.A.
Princeton, NJ
telatinib
ACT Biotech
San Francisco, CA
(see also stomach)
Phase I
(415) 230-3900
TF2
(pretargeted radioimmunotherapy)
Immunomedics
Morris Plains, NJ
colorectal cancer
Phase I
(973) 605-8200
ThermoDox®
Celsion
Lawrenceville, NJ
adjuvant inoperable/unresectable,
(see also breast, liver)
Phase II
(609) 896-9100
tigatuzumab
(anti-DR5 antibody)
Daiichi Sankyo
Parsippany, NJ
(see also breast, liver, lymphoma,
Phase I
(973) 944-2600
tivantinib
(ARQ 197)
ArQule
Woburn, MA
Daiichi Sankyo
Parsippany, NJ
(see also kidney, liver, lung,
pancreatic, sarcoma, other)
Phase I/II
(781) 994-0300
(973) 944-2600
tivozanib
(ASP4130/AV-951)
Astellas Pharma US
Deerfield, IL
Cambridge, MA
colorectal cancer
(see also breast, kidney)
Phase II
(800) 695-4321
(617) 299-5000
trebananib
(AMG386)
Amgen
Thousand Oaks, CA
(see also breast, kidney, liver,
Phase II
(800) 772-6436
Tykerb®
lapatinib
GlaxoSmithKline
(see also breast, head/neck,
stomach)
Phase II
(888) 825-5249
22
Phase I
(609) 750-5300
Colorectal Cancer
Product Name
Sponsor
Indication
Development Status
Vectibix®
panitumumab
Amgen
Thousand Oaks, CA
first-line and second-line colorectal
cancer
(800) 772-6436
Xeloda®
capecitabine
Genentech
first-line and second-line metastatic
colorectal cancer
(see also brain, liver, stomach)
(800) 626-3553
Zaltrap™
aflibercept
Regeneron Pharmaceuticals
Tarrytown, NY
Sanofi US
Bridgewater, NJ
cancer
(see also prostate)
(914) 345-7400
(800) 981-2491
Zelboraf®
vemurafenib
Genentech
Plexxikon
Berkeley, CA
(see also brain, other)
Phase I
(800) 626-3553
Head/Neck Cancer
Product Name
Sponsor
Indication
Development Status
ACE-041
(dalantercept)
Acceleron Pharma
Cambridge, MA
(see also multiple myeloma)
Phase II
(617) 649-9200
afatinib
(BIBW2992)
Pharmaceuticals
Ridgefield, CT
second-line head/neck cancer
(see also breast, brain, lung)
Phase II
(800) 243-0127
AP5346
Access Pharmaceuticals
Dallas, TX
E7050
Eisai
Woodcliff Lake, NJ
(see also brain, liver, skin, solid
tumors, stomach)
Phase I/II
(888) 422-4743
foretinib
(GSK1363089)
GlaxoSmithKline
(see also kidney, liver, lung)
Phase II completed
(888) 825-5249
GL-0810
(Orphan Drug)
Gliknik
Baltimore, MD
GL-0817
(Orphan Drug)
Gliknik
Baltimore, MD
HF-10
Takara Bio
Shiga, Japan
Phase II
(214) 905-5100
Phase I
www.gliknik.com
Phase I
www.gliknik.com
Phase I
www.takara-bio.com
23
Head/Neck Cancer
Product Name
Sponsor
Indication
Development Status
IMO-2055
(TLR9 agonist)
Cambridge, MA
second-line head and neck cancer
Phase II
(617) 679-5000
IRX-2
IRX Therapeutics
New York, NY
(Fast Track)
Phase II
(212) 582-1199
Lymphoseek®
Tc-99m tilmanocept
Dublin, OH
head and neck cancer (diagnosis)
(see also breast, skin)
Phase III
(614) 793-7500
Multikine®
leukocyte interleukin
(Orphan Drug)
CEL-SCI
Vienna, VA
first-line head and neck cancer
Phase III
(703) 506-9460
Nexavar®
sorafenib
Wayne, NJ
(see also breast, colorectal, kidney,
Phase II
(888) 842-2937
OBP-301
Oncolys Biopharma
Tokyo, Japan
(see also breast, liver, lung)
Phase I
www.oncolys.com
PX-866
Oncothyreon
Seattle, WA
head and neck cancer (combination
therapy)
(see also brain, lung, prostate)
Phase II
(206) 801-2100
Reolysin®
reovirus
Oncolytics Biotech
Calgary, Canada
metastatic head and neck cancer
ovarian, pancreatic, sarcoma, skin,
solid tumors)
Phase III
(403) 670-7377
RG7597
(EGFR antagonist)
Genentech
seliciclib
(CYC202)
Cyclacel Pharmaceuticals
nasopharyngeal cancer
Phase II
(908) 517-7330
Tarceva®
erlotinib
Genentech
OSI Pharmaceuticals
Farmingdale, NY
first-line head/neck cancer
(see also brain, breast, leukemia,
liver, lung, other)
Phase II
(800) 626-3553
(631) 962-0600
TAS-106
Taiho Pharma U.S.A.
Princeton, NJ
24
Phase II
(800) 626-3553
Phase II
(609) 750-5300
Head/Neck Cancer
Product Name
Sponsor
Indication
Development Status
terameprocol
Houston, TX
head and neck cancer (intratumoral)
(see also brain, cervical, solid
tumors, other)
Phase I
(713) 541-2000
TNFerade™
golnerminogene pradenovec
GenVec
Gaithersburg, MD
(see also prostate, skin, stomach)
(877) 943-6832
Tykerb®
lapatinib
GlaxoSmithKline
head and neck squamous cell
carcinoma (resectable disease)
(see also breast, colorectal, stomach)
Phase III
(888) 825-5249
VB4-845
(Orphan Drug)
Viventia Biotechnologies
Mississauga, Canada
(Fast Track)
(see also bladder)
Phase II
(905) 362-2973
Vectibix®
panitumumab
Amgen
Thousand Oaks, CA
first-line head and neck cancer
-------------------------------------------------second-line head and neck cancer
Phase III
(800) 772-6436
------------------------------------------Phase II
(800) 772-6436
Product Name
Sponsor
Indication
Development Status
Afinitor®
everolimus
East Hanover, NJ
hepatocellular carcinoma
(see also breast, lymphoma)
Phase II
(888) 669-6682
AGS-003
(personalized dendritic cell
vaccine)
Argos Therapeutics
Durham, NC
renal cancer (combination therapy)
(Fast Track)
-------------------------------------------------metastatic renal cancer
(monotherapy)
Phase II
(919) 287-6300
------------------------------------------Phase II
(919) 287-6300
AMG 172
Amgen
Thousand Oaks, CA
anti-PD1
(BMS-936558)
Princeton, NJ
BNC105
Bionomics
Thebarton, Australia
cabozantinib
(XL184)
Exelixis
Kidney Cancer
Phase I
(800) 772-6436
renal cell carcinoma
Phase II
(800) 332-2056
Phase II
www.bionomics.com.au
(see also breast, lung, ovarian,
prostate, other)
Phase I
(650) 837-7000
25
Kidney Cancer
Product Name
Sponsor
Indication
Development Status
CVX 060
(PF-04856884)
(Ang2 antagonist)
Pfizer
New York, NY
Phase II
(860) 732-5156
CYT107
(interleukin-7)
Cytheris
Rockville, MD
(see also skin)
Phase I
(301) 231-0451
entinostat
Waltham, MA
(see also breast, colorectal,
leukemia, lung, lymphoma)
Phase I/II
(781) 419-1400
foretinib
(GSK1363089)
GlaxoSmithKline
(see also head/neck, liver, lung)
Phase II
(888) 825-5249
IMA901
(cancer vaccine)
immatics biotechnologies
Tüebingen, Germany
renal cancer
Phase III
www.immatics.com
Inlyta®
axitinib
(Orphan Drug)
Pfizer
New York, NY
advanced renal cell carcinoma in
treatment-naive patients
(see also liver, other)
Phase III
(860) 732-5156
Istodax®
romidepsin
Celgene
Summit, NJ
renal cancer
(see also pancreatic, prostate, other)
Phase II
(908) 673-9000
LBH589
(panobinostat)
East Hanover, NJ
renal cancer
myeloma, prostate, solid tumors)
Phase II
(888) 669-6682
linifanib
Abbott Laboratories
Abbott Park, IL
renal cancer
(see also breast, colorectal, liver,
lung)
Phase II
(847) 937-6100
LOR-2040
(Orphan Drug)
Lorus Therapeutics
Toronto, Canada
metastatic renal cancer
leukemia, prostate)
Phase II
(416) 798-1200
naptumomab estafenatox
Active Biotech
Lund, Sweden
Phase I completed
www.activebiotech.com
Nexavar®
sorafenib
Wayne, NJ
(adjuvant therapy)
head/neck, leukemia, liver, lung,
multiple myeloma, ovarian, other)
Phase III
(888) 842-2937
Oncophage®
vitespen
(Orphan Drug)
Agenus
Lexington, MA
renal cell carcinoma (Fast Track)
Phase II
(781) 674-4400
OSI-027
(TORC1/TORC2 inhibitor)
OSI Pharmaceuticals
Farmingdale, NY
renal cancer
(see also lymphoma)
Phase II
(631) 962-0600
26
Kidney Cancer
Product Name
Sponsor
Indication
Development Status
perifosine
AEterna Zentaris
Basking Ridge, NJ
metastatic renal cancer
(see also brain, colorectal, leukemia,
Phase II
(908) 626-5428
Redectane®
girentuximab I-124
Wilex
Munich, Germany
renal cancer (diagnosis)
Phase III completed
www.wilex.de
regorafenib
Wayne, NJ
renal cancer
(see also colorectal, lung,
Phase II
(888) 842-2837
Rencarex®
girentuximab
(Orphan Drug)
Wilex
Munich, Germany
clear cell renal cell carcinoma
(Fast Track)
Phase III
www.wilex.de
ridaforolimus
Cambridge, MA
Merck
(see also breast, lung, prostate,
sarcoma, other)
Phase I
(800) 672-6372
SGN-75
(vorsetuzumab mafodotin)
Seattle Genetics
Bothell, WA
renal cancer
(see also lymphoma)
Phase I
(425) 527-4000
Sutent®
sunitinib
(Orphan Drug)
Pfizer
New York, NY
(adjuvant therapy)
Phase III
(860) 732-5156
tivantinib
(ARQ 197)
ArQule
Woburn, MA
Daiichi Sankyo
Parsippany, NJ
(see also colorectal, liver, lung,
Phase II
(781) 994-0300
(973) 944-2600
tivozanib
(ASP4130/AV-951)
Astellas Pharma US
Deerfield, IL
Cambridge, MA
first-line renal cancer
Phase III
(800) 695-4321
(617) 299-5000
------------------------------------------Phase I
(800) 695-4321
(617) 299-5000
TKI258
(dovitinib)
East Hanover, NJ
(see also breast, multiple myeloma,
prostate, skin, other)
Phase III
(888) 669-6682
Torisel®
temsirolimus
(Orphan Drug)
Pfizer
New York, NY
Phase III
(860) 732-5156
trebananib
(AMG386)
Amgen
Thousand Oaks, CA
renal cancer
Phase II
(800) 772-6436
-------------------------------------------------renal cancer
27
Kidney Cancer
Product Name
Sponsor
Indication
Development Status
TVI-Kidney-1
(cellular immunotherapy
vaccine)
TVAX Biomedical
Lenexa, KS
Phase II completed
(913) 492-2221
veglin
(VEGF antisense)
VasGene Therapeutics
Los Angeles, CA
Phase I
(323) 221-7818
Votrient™
pazopanib
GlaxoSmithKline
Phase III
(888) 825-5249
Product Name
Sponsor
Indication
Development Status
ABIO-0501
(TALL104)
Abiogen Pharma
Pisa, Italy
chronic myeloid leukemia (CML)
Phase II
www.abiogen.it
AC220
(quizartinib)
Ambit Biosciences
San Diego, CA
Astellas Pharma US
Deerfield, IL
second-line and third-line acute
myeloid leukemia (AML)
(monotherapy)
-------------------------------------------------acute lymphocytic leukemia (ALL)
(combination therapy), first-line AML
Phase II
(858) 334-2100
(800) 695-4321
Leukemia
------------------------------------------Phase I
(858) 334-2100
(800) 695-4321
AC430
(JAK2 inhibitor)
Ambit Biosciences
San Diego, CA
Adcetris™
brentuximab vedotin
Millennium Pharmaceuticals
Cambridge, MA
Seattle Genetics
Bothell, WA
(see also lymphoma)
Phase II
(800) 390-5663
(425) 527-4000
AEG35156
(XIAP inhibitor)
Aegera Therapeutics
Montreal, Canada
AML
(see also lymphoma)
-------------------------------------------------chronic lymphocytic leukemia (CLL)
Phase II
(514) 288-5532
------------------------------------------Phase I/II
(514) 288-5532
AFX-9154
Afecta Pharmaceuticals
Irvine, CA
28
Phase I
(858) 334-2100
in clinical trials
(949) 253-4688
Leukemia
Product Name
Sponsor
Indication
Development Status
AGS-005
Argos Therapeutics
Durham, NC
CLL
Phase I/II
(919) 287-6300
ALD-151
Aldagen
Durham, NC
ALXN6000
(samalizumab)
Alexion Pharmaceuticals
Cheshire, CT
CLL
(203) 272-2596
aminopterin
Syntrix Biosystems
Auburn, WA
ALL
Phase II completed
(253) 833-8009
anti-CD22/CD19 mAb-toxin
conjugate
Abiogen Pharma
Pisa, Italy
ALL
Phase I
www.abiogen.com
AR-42
Arno Therapeutics
Flemington, NJ
CLL
(see also lymphoma, multiple
myeloma)
Phase I/II
(862) 703-7170
AR-67
Arno Therapeutics
Flemington, NJ
myelodysplastic syndromes
(see also brain, solid tumors)
Phase II
(862) 703-7170
Arranon®
nelarabine
(Orphan Drug)
GlaxoSmithKline
first-line ALL
(see also lymphoma)
-------------------------------------------------second-line ALL
Phase III
(888) 669-6682
------------------------------------------Phase I/II
(888) 669-6682
ARRY-520
(KSP inhibitor)
Array BioPharma
Boulder, CO
AML
(see also multiple myeloma,
solid tumors)
Phase II
(877) 633-2436
Arzerra®
ofatumumab
(Orphan Drug)
GlaxoSmithKline
first-line CLL (combination therapy)
(see also lymphoma)
Phase III
(888) 825-5249
AT-101
Malvern, PA
CLL
(see also brain, lung, lymphoma,
prostate, stomach)
Phase II
(610) 408-0301
AT-406/Debio-1143
Malvern, PA
Debiopharm
Lausanne, Switzerland
AML
(see also lymphoma)
Phase I
(610) 408-0301
www.debiopharm.com
Phase I
(919) 484-2571
29
Leukemia
Product Name
Sponsor
Indication
Development Status
AT7519
(CDK inhibitor)
Astex Pharmaceuticals
Dublin, CA
CLL
myeloma, solid tumors)
Phase II
(925) 560-0100
AT9283
(aurora/Jak2 inhibitor)
(Orphan Drug)
Dublin, CA
AML
Phase I/II
(925) 560-0100
AVL-292
(Btk inhibitor)
Celgene
Summit, NJ
second-line CLL
(see also lymphoma, unspecified)
Phase I
(908) 673-9000
AZD1208
(Pim kinase inhibitor)
AstraZeneca
Wilmington, DE
AML
Phase I
(800) 236-9933
bafetinib
(Orphan Drug)
CytRx
Los Angeles, CA
second-line CLL
(see also brain, prostate)
-------------------------------------------------ALL, CML
Phase II
(310) 826-5648
------------------------------------------Phase I
(310) 826-5648
Bcl-2 inhibitor
(ABT-199/GDC-0199)
Abbott Laboratories
Abbott Park, IL
Genentech
CLL
(see also lymphoma)
Phase I
(847) 937-6100
(800) 626-3553
belinostat
Henderson, NV
AML
(see also colorectal, liver, lung,
Phase I/II
(702) 835-6300
BI-811283
(aurora kinase B inhibitor)
Pharmaceuticals
Ridgefield, CT
AML
Phase I/II
(800) 243-0127
BI-836826
Pharmaceuticals
Ridgefield, CT
CLL
Phase I
(800) 243-0127
bosutinib
Pfizer
New York, NY
previously treated CML
(860) 732-5156
cenersen
(Orphan Drug)
Eleos
Omaha, NE
AML
Phase II completed
(402) 393-3034
Ceplene®
histamine dihydrochloride
injection
(Orphan Drug)
EpiCept
Tarrytown, NY
AML
(914) 606-3500
30
Leukemia
Product Name
Sponsor
Indication
Development Status
CLL immunotherapeutic vaccine
MaxCyte
Gaithersburg, MD
CLL
Phase I/II
(301) 944-1700
Clolar®
clofarabine injection
(Orphan Drug)
Genzyme
Cambridge, MA
AML (adults)
Phase III
(617) 252-7500
CNDO-109
(tumor activated NK cells)
Coronado Biosciences
Burlington, MA
AML
Phase I
(781) 238-6621
CPX-351
(cytarabine/daunorubicin)
(Orphan Drug)
Celator Pharmaceuticals
Princeton, NJ
AML
Phase II
(609) 243-0123
CT-011
CureTech
Yavne, Israel
second-line AML
(see also colorectal, lymphoma)
Phase II
www.curetechbio.com
CWP232291
JW Pharmaceutical
Seoul, South Korea
AML
Phase I
Dacogen®
decitabine
Eisai
Woodcliff Lake, NJ
AML
(888) 422-4743
------------------------------------------Phase II
(888) 422-4743
danusertib
Nerviano Medical Sciences
Nerviano, Italy
CML
Phase II
www.nervianoms.com
DCC-2036
Deciphera Pharmaceuticals
Lawrence, KS
ALL, CML
Phase I/II
(785) 830-2100
------------------------------------------Phase I
(785) 830-2100
DCDS-4501A
Genentech
CLL
(see also lymphoma)
Phase I
(800) 626-3553
DCDT-2980S
Genentech
recurrent CLL
(see also lymphoma)
Phase I
(800) 626-3553
Elacyt™
elacytarabine
(Orphan Drug)
Clavis Pharma
Oslo, Norway
late-stage AML
(Fast Track)
-------------------------------------------------early-stage AML
Phase III
www.clavispharma.com
------------------------------------------Phase II
www.clavispharma.com
-------------------------------------------------pediatric AML
-------------------------------------------------AML
31
Leukemia
Product Name
Sponsor
Indication
Development Status
elesclomol
Lexington, MA
AML
Phase I
(781) 274-8200
entinostat
Waltham, MA
lung, lymphoma)
Phase II
(781) 419-1400
epratuzumab
(Orphan Drug)
Immunomedics
Morris Plains, NJ
UCB
Atlanta, GA
ALL in children (combination therapy)
(see also lymphoma)
Phase II
(973) 605-8200
forodesine
(Orphan Drug)
BioCryst Pharmaceuticals
Durham, NC
CLL
(see also lymphoma)
Phase II
(919) 859-1302
ganetespib
(Hsp90i)
Lexington, MA
ALL, AML, CML
-------------------------------------------------myelodysplastic syndromes
Phase I/II
(781) 274-8200
------------------------------------------Phase I
(781) 274-8200
GNKG-168
SBI Biotech
Tokyo, Japan
CLL
Phase I
www.sbibiotech.jp
GRNVAC1
Argos Therapeutics
Durham, NC
Geron
Menlo Park, CA
AML
(see also prostate)
Phase II
(650) 473-7700
GS-1101
(PI3K delta inhibitor)
Gilead Sciences
Foster City, CA
second-line CLL
(see also lymphoma)
Phase III
(800) 445-3235
GSK2110183
(protein kinase B inhibitor)
GlaxoSmithKline
Phase II
(888) 825-5249
GSK2130579A
(WT1 antigen-specific cancer
immunotherapeutic)
GlaxoSmithKline
AML
Phase II
(888) 825-5249
GVAX® Leukemia
cancer vaccine
(Orphan Drug)
Lincolnshire, IL
AML, CML
Phase II
(847) 478-0500
HuM195-Ac-225
(lintuzumab Ac-225)
Actinium Pharmaceuticals
Newark, NJ
AML
Phase I
(973) 344-6500
32
Leukemia
Product Name
Sponsor
Indication
Development Status
HuM195-Bi-213
(lintuzumab Bi-213)
Actinium Pharmaceuticals
Newark, NJ
AML
Phase I/II
(973) 344-6500
HuM195/rGel
(lintuzumab-gelonin conjugate)
Targa Therapeutics
San Diego, CA
AML, CML, myelodysplastic
syndromes
Phase I
(858) 483-6600
ibrutinib
(PCI-32765)
Janssen Biotech
Horsham, PA
Pharmacyclics
Sunnyvale, CA
CLL
myeloma)
Phase I/II
(800) 526-7736
(408) 774-0330
imatinib sublingual
Kedem Pharmaceuticals
Mesa, AZ
CML
in clinical trials
(604) 324-4244
imetelstat
Geron
Menlo Park, CA
CLL
(see also breast, lung, multiple
myeloma)
Phase I/II
(650) 473-7700
Imprime PGG®
Biothera
Eagan, MN
CLL
(see also colorectal, lung, skin)
Phase I/II
(651) 675-0300
INNO-305
(WT-1 vaccine)
CytRx
Los Angeles, CA
AML, myelodysplastic syndromes
Phase I
(310) 826-5648
inotuzumab ozogamicin
Pfizer
New York, NY
ALL
(see also lymphoma)
Phase I
(860) 732-5156
ISF35
(recombinant
immunotherapeutic vaccine)
Memgen
San Diego, CA
CLL (monotherapy)
(see also lymphoma)
-------------------------------------------------refractory metastatic CLL
Phase II
(858) 524-5400
------------------------------------------Phase I
(858) 524-5400
JNJ-26481585
(quisinostat)
Raritan, NJ
myelodysplastic syndromes,
metastatic leukemia
(see also lymphoma)
Phase I
(800) 817-5286
JVRS-100
(lipid-DNA complex vaccine)
Colby Pharmaceutical
San Jose, CA
KX2-391
Kinex Pharmaceuticals
Buffalo, NY
Phase I
(650) 333-3152
AML in the elderly
(see also prostate)
Phase I
(716) 898-8626
33
Leukemia
Product Name
Sponsor
Indication
Development Status
LBH589
(panobinostat)
East Hanover, NJ
ALL, AML, myelodysplastic
syndromes
(see also kidney, multiple myeloma,
prostate, solid tumors)
Phase II
(888) 669-6682
LDE225
(erismodegib)
East Hanover, NJ
CML (combination therapy)
(see also pancreatic, solid tumors,
skin)
Phase I
(888) 669-6682
lestaurtinib
(Orphan Drug)
Cephalon
Frazer, PA
AML
Phase II
(610) 344-0200
leukemia DNA vaccine
Inovio Pharmaceuticals
Blue Bell, PA
University of Southampton
Southampton, United Kingdom
AML, CML
Phase II
(877) 446-6846
LG740
(activated T-cells)
Lentigen
Gaithersburg, MD
University of Pennsylvania
Philadelphia, PA
ALL, B-cell prolymphocytic leukemia,
CLL
(see also lymphoma)
Phase I
(301) 527-4200
LOR-2040
(Orphan Drug)
Lorus Therapeutics
Toronto, Canada
AML (combination therapy)
prostate)
-------------------------------------------------CML, myelodysplastic syndromes
Phase II
(416) 798-1200
------------------------------------------Phase I
(416) 798-1701
lurbinectedin
PharmaMar
Madrid, Spain
Phase I
www.pharmamar.com
Marqibo®
vincristine liposomal
(Orphan Drug)
Talon Therapeutics
San Mateo, CA
relapsed or refractory Philadelphia
chromosome-negative ALL
(Fast Track)
(see also lymphoma, skin, other)
-------------------------------------------------ALL in the elderly (Fast Track)
(650) 588-6404
------------------------------------------Phase III
(650) 588-6404
milatuzumab
Immunomedics
Morris Plains, NJ
CLL (monotherapy)
myeloma)
Phase I/II
(973) 605-8200
MK-7956
(dinaciclib)
(Orphan Drug)
Merck
CLL
(see also lymphoma)
Phase II
(800) 672-6372
34
Leukemia
Product Name
Sponsor
Indication
Development Status
MK-8242
Merck
AML
Phase I
(800) 672-6372
mocetinostat
(MGCD0103, HDAC inhibitor)
MethylGene
Montreal, Canada
CLL
Phase II completed
(514) 337-3333
Mozobil®
plerixafor
Genzyme
Cambridge, MA
AML
Phase I
(617) 252-7500
navitoclax
(ABT-263)
Abbott Laboratories
Abbott Park, IL
(see also lung, lymphoma)
-------------------------------------------------CLL, lymphoid leukemia
Phase II
(847) 937-6100
------------------------------------------Phase I
(847) 937-6100
Nexavar®
sorafenib
Wayne, NJ
head/neck, kidney, liver, lung,
Phase I/II
(888) 842-2937
obatoclax
(Orphan Drug)
Cephalon
Frazer, PA
CLL
(see also lung, lymphoma, multiple
myeloma)
(610) 344-0200
obinutuzumab
(GA101/RG7159)
Biogen Idec
Weston, MA
Genentech
(see also lymphoma)
Phase III
(781) 464-2000
(800) 626-3553
Omapro™
omacetaxine
(Orphan Drug)
Cephalon
Frazer, PA
second-line CML
-------------------------------------------------AML, myelodysplastic syndromes
(610) 344-0200
------------------------------------------Phase II
(610) 344-0200
ON 013105
Onconova Therapeutics
Newtown, PA
ALL
(see also lymphoma)
Phase I
(267) 759-3680
oral azacitidine
(Orphan Drug)
Celgene
Summit, NJ
(Fast Track)
(see also lung, lymphoma,
solid tumors)
-------------------------------------------------AML, CML
Phase II
(908) 673-9000
------------------------------------------Phase I
(908) 673-9000
35
Leukemia
Product Name
Sponsor
Indication
Development Status
oral clofaribine
Genzyme
Cambridge, MA
Phase I
(617) 252-7500
OVI-123
(Orphan Drug)
OncoVista Innovative Therapies
San Antonio, TX
TdT-positive leukemia
Phase I
(210) 677-6000
OXi4503
OXiGENE
Phase I
(650) 635-7000
perifosine
AEterna Zentaris
Basking Ridge, NJ
refractory metastatic CLL
(see also brain, colorectal, kidney,
Phase II
(908) 626-5428
PKC412
(midostaurin)
East Hanover, NJ
AML
Phase III
(888) 669-6682
PLX3397
Plexxikon
Berkeley, CA
recurrent or refractory AML
(see also brain, lymphoma,
solid tumors)
Phase I/II
(510) 647-4000
ponatinib
(Orphan Drug)
Cambridge, MA
Philadelphia-positive ALL, CML
Phase II
(617) 494-0400
------------------------------------------Phase I
(617) 494-0400
PR104
Proacta
La Jolla, CA
AML
Phase I/II
(858) 642-0386
Revlimid®
lenalidomide
(Orphan Drug)
Celgene
Summit, NJ
CLL, myelodysplastic syndromes
(see also lymphoma)
Phase III
(908) 673-9000
rigosertib
(Orphan Drug)
Newtown, PA
(intravenous)
(see also lymphoma, ovarian,
pancreatic)
-------------------------------------------------CLL
Phase III
(267) 759-3680
-------------------------------------------------AML
-------------------------------------------------AML
-------------------------------------------------myelodysplastic syndromes (oral)
36
------------------------------------------Phase II
(267) 759-3680
------------------------------------------Phase I/II
(267) 759-3680
------------------------------------------Phase I
(267) 759-3680
Leukemia
Product Name
Sponsor
Indication
Development Status
sapacitabine
(CYC682)
(Orphan Drug)
first-line AML
(see also lung, solid tumors)
-------------------------------------------------CLL (combination therapy),
Phase III
(908) 517-7330
------------------------------------------Phase II
(908) 517-7330
SB989
(pracinostat)
S*BIO
Oakland, CA
(see also solid tumors, other)
Phase I
(650) 730-2860
SB1518
(pacritinib)
S*BIO
Oakland, CA
Phase II
(650) 730-2860
------------------------------------------Phase I/II
(650) 730-2860
SF1126
(Orphan Drug)
Semafore Pharmaceuticals
Indianapolis, IN
CLL
solid tumors)
Phase I
(317) 876-3075
SGI110
(DNMT inhibitor)
Dublin, CA
Phase I/II
(925) 560-0100
SL-401
(recombinant fusion protein)
(Orphan Drug)
Stemline Therapeutics
New York, NY
Phase I/II
(646) 502-2310
tamibarotene
(Orphan Drug)
CytRx
Los Angeles, CA
acute promyelocytic leukemia (APL)
(Fast Track)
(see also lung)
-------------------------------------------------APL (combination therapy)
Phase II
(310) 826-5648
-------------------------------------------------myeloid leukemia
------------------------------------------Phase I
(310) 826-5648
Tarceva®
erlotinib
Genentech
OSI Oncology
Farmingdale, NY
(see also brain, breast, head/neck,
liver, lung, other)
Phase II
(800) 626-3553
(631) 962-0600
Tasigna®
nilotinib
(Orphan Drug)
East Hanover, NJ
CML (adolescents and children),
ALL (adolescents and children)
(see also skin, stomach)
Phase II
(888) 669-6682
Temodar®
temozolomide
Merck
AML
(see also lung)
Phase II
(800) 672-6372
TH-302
(see also brain, multiple myeloma,
pancreatic, sarcoma)
Phase I
(650) 474-8200
thiarabine
Dallas, TX
(see also lymphoma)
Phase I/II
(215) 904-5100
37
Leukemia
Product Name
Sponsor
Indication
Development Status
TL-32711
(birinapant)
TetraLogic Pharmaceuticals
Malvern, PA
AML
Phase I/II
(610) 889-9900
tosedostat
(Orphan Drug)
Chroma Therapeutics
Oxon, United Kingdom
AML
Phase II
www.chromatherapeutics.com
trametinib
GlaxoSmithKline
relapsed or refractory leukemia
(see also brain, lung, lymphoma,
multiple myeloma, pancreatic, skin)
Phase III
(888) 825-5249
Treanda®
bendamustine
Cephalon
Frazer, PA
ALL in children, AML in children
myeloma)
Phase I/II
(610) 344-0200
treosulfan
Medac
Wedel, Germany
ALL, AML, myelodysplastic
syndromes
Phase II
www.medac.de
TRU-016
(humanized anti-CD37
therapeutic)
Emergent BioSolutions
Rockville, MD
CLL
(see also lymphoma)
Phase II
(301) 795-1800
Velcade®
bortezomib
Cambridge, MA
second-line T-cell prolymphocytic
leukemia
(see also lymphoma, other,
cancer-related)
Phase II
(800) 390-5663
veltuzumab
(Orphan Drug)
Immunomedics
Morris Plains, NJ
CLL
(see also lymphoma)
Phase I/II
(973) 605-8200
Vidaza®
azacitidine
(Orphan Drug)
Celgene
Summit, NJ
AML in the elderly
(see also lymphoma)
Phase III
(908) 673-9000
vosaroxin
(Orphan Drug)
Sunesis Pharmaceuticals
second-line AML
(Fast Track)
(see also ovarian)
-------------------------------------------------AML in the elderly
Phase III
(650) 266-3739
------------------------------------------Phase II
(650) 266-3739
XmAb® 5574
(MOR208, anti-CD19 mAb)
MorphoSys
Planegg, Germany
Xencor
Monrovia, CA
recurrent CLL
Phase I
www.morphosys.com
(626) 305-5900
Zolinza®
vorinostat
Merck
(see also breast, lung, lymphoma,
Phase II
(800) 672-6273
38
Liver Cancer
Product Name
Sponsor
ALN-VSP
Alnylam Pharmaceuticals
Cambridge, MA
bavituximab
Tustin, CA
Phase I/II
(715) 508-6000
BAY 86-9766
(MEK inhibitor)
Ardea Biosciences
San Diego, CA
Wayne, NJ
first-line liver cancer
Phase II
(888) 842-2937
belinostat
Henderson, NV
inoperable/unresectable liver cancer
(see also colorectal, leukemia, lung,
Phase I/II
(702) 835-6300
BIIB 022
Biogen Idec
Cambridge, MA
(see also lung)
Phase I completed
(617) 679-2000
brivanib
Princeton, NJ
first-line liver cancer,
liver cancer (TACE)
(see also colorectal, sarcoma)
Phase III
(800) 332-2056
cixutumumab
(LY3012217/IMC-A12)
Eli Lilly
Indianapolis, IN
ImClone
Bridgewater, NJ
(see also lung)
Phase II
(800) 545-5979
darinaparsin
(ZIO-101)
ZIOPHARM Oncology
New York, NY
Phase II
(646) 214-0700
DC Bead®
doxorubicin-eluting beads
Wayne, NJ
Biocompatibles
Surrey, United Kingdom
E7050
Eisai
Woodcliff Lake, NJ
(see also brain, head/neck, skin,
Phase I/II
(888) 422-4743
foretinib
(GSK1363089)
GlaxoSmithKline
(see also head/neck, kidney, lung)
Phase I
(888) 825-5249
ganetespib
(Hsp90i)
Lexington, MA
leukemia, lung, multiple myeloma,
pancreatic, prostate, skin, stomach)
Phase II
(781) 274-8200
Inlyta®
axitinib
Pfizer
New York, NY
(see also kidney, other)
Phase II
(860) 732-5156
irinotecan eluting beads
Biocompatibles International
Surrey, United Kingdom
liver metastases from colorectal
cancer
Phase II
www.biocompatibles.com
Indication
Development Status
Phase I
(617) 551-8200
Phase II
(888) 842-2937
39
Liver Cancer
Product Name
Sponsor
Indication
Development Status
JX-594
(pexastimogene devacirepvec)
(Orphan Drug)
San Francisco, CA
Phase II
(415) 281-8886
lansoprazole
(Orphan Drug)
Apricus Biosciences
San Diego, CA
first-line liver cancer
Phase II
(858) 220-8041
linifanib
Abbott Laboratories
Abbott Park, IL
first-line liver cancer (monotherapy)
lung)
Phase III
(847) 937-6100
mapatumumab
Human Genome Sciences
Rockville, MD
liver cancer (combination therapy)
(see also lung, multiple myeloma)
Phase II
(301) 309-8504
MB07133
(HepDirect HepB inhibitor)
Ligand Pharmaceuticals
La Jolla, CA
(858) 550-7500
melphalan drug delivery system
Delcath Systems
New York, NY
(212) 489-2100
muparfostat (PI-88)
Progen Pharmaceuticals
Queensland, Australia
liver cancer (Fast Track)
(see also skin)
Phase III
www.progen.com.au
Nexavar®
sorafenib
(Orphan Drug)
Wayne, NJ
heptocellular carcinoma
(adjuvant therapy)
head/neck, kidney, leukemia, lung,
Phase III
(888) 842-2937
NV-1020
Catherex
Philadelphia, PA
OBP-301
Oncolys Biopharma
Tokyo, Japan
(see also breast, head/neck, lung)
Phase I
www.oncolys.com
PEG arginine deiminase
(ADI-PEG 20)
Polaris Pharmaceuticals
San Diego, CA
hepatocellular carcinoma
(see also prostate, skin, other)
Phase III
(858) 452-6688
PHY906
PhytoCeutica
New Haven, CT
(see also colorectal, pancreatic,
cancer-related)
(203) 777-3462
PV-10
(rose bengal sodium)
(Orphan Drug)
Provectus Pharmaceuticals
Knoxville, TN
liver cancer, liver metastases
(see also skin)
Phase I
(866) 594-5999
RG7686
Roche
Nutley, NJ
metastatic liver cancer
Phase II
(973) 235-5000
40
Liver Cancer
Product Name
Sponsor
Indication
Development Status
Tarceva®
erlotinib
Genentech
OSI Pharmaceuticals
Farmingdale, NY
first-line inoperable/unresectable liver
leukemia, lung, other)
-------------------------------------------------second-line liver cancer
Phase III
(800) 626-3553
(631) 962-0600
TGF-ß R1 inhibitor
(LY2157299)
Eli Lilly
Indianapolis, IN
(see also brain)
Phase II
(800) 545-5979
ThermoDox®
(Orphan Drug)
Celsion
Lawrenceville, NJ
first-line inoperable/unresectable liver
cancer (Fast Track)
Phase III
(609) 896-9100
tigatuzumab
(anti-DR5 antibody)
Daiichi Sankyo
Parsippany, NJ
lymphoma, ovarian, pancreatic)
Phase II
(973) 944-2600
tivantinib (ARQ 197)
ArQule
Woburn, MA
Daiichi Sankyo
Parsippany, NJ
second-line liver cancer
(see also colorectal, kidney, lung,
-------------------------------------------------liver cancer (combination therapy)
Phase II
(781) 994-0300
(973) 944-2600
-----------------------------------------Phase I
(781) 994-0300
(973) 944-2600
trebananib
(AMG386)
Amgen
Thousand Oaks, CA
Phase II
(800) 772-6436
Xeloda®
capecitabine
Genentech
biliary cancer (combination therapy)
(see also brain, colorectal, stomach)
Phase II
(800) 626-3553
Zadaxin®
thymalfasin alfa 1
(Orphan Drug)
SciClone Pharmaceuticals
Foster City, CA
(see also skin)
Phase II/III
(650) 358-3456
------------------------------------------Phase II
(800) 626-3553
(631) 962-0600
41
Lung Cancer
Product Name
Sponsor
Indication
Development Status
Abraxane®
Celgene
Summit, NJ
first-line non-small-cell lung cancer
(NSCLC)
(see also bladder, breast, ovarian,
pancreatic, skin)
(908) 673-9000
ABT-888
(veliparib)
(PARP inhibitor)
Abbott Laboratories
Abbott Park, IL
NSCLC
(see also brain, breast, colorectal,
other)
Phase II
(847) 937-6100
AC480
(pan-HER inhibitor)
Ambit Biosciences
San Diego, CA
NCSLC
(see also brain, breast)
Phase I
(858) 334-2100
Actimid®
pomalidomide
Celgene
Summit, NJ
small-cell lung cancer (SCLC)
myeloma, pancreatic)
Phase I/II
(908) 673-9000
afatinib
(BIBW2992)
Pharmaceuticals
Ridgefield, CT
first-line NSCLC
(see also brain, breast, head/neck)
-------------------------------------------------second-line NSCLC (Fast Track)
Phase III
(800) 243-0127
------------------------------------------Phase II/III
(800) 243-0127
Alimta®
pemetrexed
Eli Lilly
Indianapolis, IN
first-line and maintenance NSCLC
Phase III
(800) 545-5979
AMG888/U3-1287
(anti-HER3 antibody)
Amgen
Thousand Oaks, CA
Daiichi Sankyo
Parsippany, NJ
NSCLC
Phase II
(800) 772-6436
(973) 944-2600
amrubicin
(Orphan Drug)
Celgene
Summit, NJ
SCLC (Fast Track)
(see also breast)
-------------------------------------------------first-line SCLC
Phase III
(908) 673-9000
------------------------------------------Phase II
(908) 673-9000
amuvatinib
(MP470)
Dublin, CA
SCLC (combination therapy)
(see also lymphoma)
Phase II
(925) 560-0100
anti-PD1
(BMS-936558)
Princeton, NJ
(see also kidney, skin)
Phase II
(800) 332-2056
AP26113
Cambridge, MA
NSCLC
Phase I
(617) 494-0400
apricoxib
(TG01)
Tragara Pharmaceuticals
San Diego, CA
second-line NSCLC
Phase II
(858) 350-6900
42
Lung Cancer
Product Name
Sponsor
Indication
Development Status
astuprotimut-R
(MAGE-A3 antigen-specific
cancer immunotherapeutic)
GlaxoSmithKline
adjuvant NSCLC
(see also skin)
Phase III
(888) 825-5249
AT-101
Malvern, PA
NSCLC (combination therapy),
SCLC (combination therapy)
(see also brain, leukemia, lymphoma,
prostate, stomach)
Phase II
(610) 408-0301
AUY922
(Hsp90 inhibitor)
East Hanover, NJ
third-line NSCLC
(see also breast, colorectal, multiple
myeloma, stomach)
-------------------------------------------------second-line late-stage NSCLC
Phase II
(888) 669-6682
------------------------------------------Phase I/II
(888) 669-6682
Avastin®
bevacizumab
Genentech
adjuvant NSCLC
ovarian, other)
Phase III
(800) 626-3553
bavituximab
Tustin, CA
first-line NSCLC,
second-line NSCLC
(see also liver, pancreatic)
Phase II
(715) 508-6000
belinostat
Henderson, NV
mesothelioma
-------------------------------------------------NSCLC
Phase II completed
(702) 835-6300
-------------------------------------------------SCLC
------------------------------------------Phase I/II
(702) 835-6300
------------------------------------------Phase I
(702) 835-6300
BIIB 022
Biogen Idec
Cambridge, MA
NSCLC
(see also liver)
Phase I completed
(617) 679-2000
BKM120
(PI3K inhibitor)
East Hanover, NJ
late-stage NSCLC
(see also brain, breast, other)
Phase II
(888) 669-6682
cabozantinib
(XL184)
Exelixis
NSCLC
(see also breast, kidney, ovarian,
prostate, other)
Phase I/II
(650) 837-7000
CBP-501
(peptide mimetic)
CanBas
Shizouka, Japan
mesothelioma (combination therapy),
first-line NSCLC (combination
therapy)
Phase II
www.canbas.co.jp
43
Lung Cancer
Product Name
Sponsor
Indication
Development Status
CC-223
(mTOR inhibitor)
Celgene
Summit, NJ
NSCLC
myeloma)
Phase I
(908) 673-9000
CEP-9722
(PARP inhibitor)
Cephalon
Frazer, PA
NSCLC (combination therapy)
(see also lymphoma)
Phase II
(610) 344-0200
Chk1 inhibitor
(LY2603618)
Eli Lilly
Indianapolis, IN
NSCLC
Phase II
(800) 545-5979
cixutumumab
(LY3012217/IMC-A12)
Eli Lilly
Indianapolis, IN
ImClone
Bridgewater, NJ
NSCLC
(see also liver)
Phase II
(800) 545-5979
CLR1404-I-124
Novelos Therapeutics
Madison, WI
NSCLC (diagnosis)
Phase I/II
(608) 441-8120
CLR1404-I-131
Novelos Therapeutics
Madison, WI
NSCLC (diagnosis)
Phase I/II
(608) 441-8120
CO-1686
(EGFR inhibitor)
Clovis Oncology
Boulder, CO
second-line NSCLC
Phase I/II
(303) 625-5000
custirsen
(OGX-001/TV-1011)
Bothell, WA
Teva Pharmaceuticals
Tikva, Israel
first-line NSCLC
(see also prostate)
Phase II
(425) 686-1500
dacomitinib
(PF-00299804)
Pfizer
New York, NY
NSCLC
Phase III
(860) 732-5156
dalotuzumab
(MK-0646)
Merck
recurrent NSCLC (combination
therapy)
(see also breast, pancreatic, other)
Phase II
(800) 672-6372
EC20
(technetium Tc-99m etarfolatide)
Endocyte
West Lafayette, IN
NSCLC (diagnosis)
(see also ovarian)
Phase II
www.endocyte.com
EC145
(vintafolide)
Endocyte
West Lafayette, IN
Merck
NSCLC
(see also ovarian)
Phase II
www.endocyte.com
(800) 672-6372
efatutazone
Daiichi Sankyo
Parsippany, NJ
NSCLC
Phase II
(973) 944-2600
elesclomol
Lexington, MA
NSCLC
(see also leukemia, ovarian)
Phase I/II
(781) 274-8200
44
Lung Cancer
Product Name
Sponsor
Indication
Development Status
emepepimut-S
EMD Serono
Rockland, MA
Oncothyreon
Seattle, WA
NSCLC (Fast Track)
(see also prostate)
Phase III
(800) 283-8088
entinostat
Waltham, MA
leukemia, lymphoma)
Phase II
(781) 419-1400
ficlatuzumab
(AV-299)
Cambridge, MA
Phase II
(617) 299-5000
Folotyn®
pralatrexate
Allos Therapeutics
Westminster, CO
NSCLC
(see also bladder, breast, lymphoma)
Phase II
(303) 426-6262
foretinib
(GSK1363089)
GlaxoSmithKline
NSCLC
(see also head/neck, kidney, liver)
Phase I/II
(888) 825-5249
ganetespib
(Hsp90i)
Lexington, MA
second-line NSCLC (combination
therapy)
leukemia, liver, multiple myeloma,
pancreatic, prostate, skin, stomach)
-------------------------------------------------SCLC
Phase II/III
(781) 274-8200
------------------------------------------Phase II
(781) 274-8200
ganitumab
(AMG 479)
Amgen
Thousand Oaks, CA
first-line SCLC (combination therapy)
pancreatic, sarcoma)
Phase I/II
(800) 772-6436
GI-4000
(cancer vaccine)
GlobeImmune
Louisville, CO
NSCLC
(see also colorectal, pancreatic)
Phase I
(303) 625-2700
Gleevec®
imatinib
East Hanover, NJ
(see also prostate, skin, other)
Phase II
(888) 669-6682
GSK2118436
GlaxoSmithKline
BRAF mutation-positive disease
NSCLC
(see also brain, skin)
Phase II
(888) 825-5249
Halaven®
eribulin
Eisai
Woodcliff Lake, NJ
NSCLC
(see also prostate, sarcoma)
Phase III
(888) 422-4743
HS-110
(cancer vaccine)
Heat Biologics
Chapel Hill, NC
late-stage NSCLC (combination
therapy)
Phase I
(919) 240-7133
45
Lung Cancer
Product Name
Sponsor
Indication
Development Status
HyperAcute® Lung
lung cancer immunotherapy
NewLink Genetics
Ames, IA
metastatic NSCLC
Phase II
(515) 296-5555
IDM-2101
(multi-epitope cancer vaccine)
Biotech Synergy
San Diego, CA
NSCLC
Phase II
(858) 459-6689
imetelstat
Geron
Menlo Park, CA
late-stage NSCLC
(see also breast, leukemia,
multiple myeloma)
Phase II
(650) 473-7700
IMO-2055
(TLR9 agonist)
Cambridge, MA
(see also colorectal, head/neck)
Phase I
(617) 679-5000
Imprime PGG®
Biothera
Eagan, MN
NSCLC
(see also colorectal, leukemia, skin)
Phase II
(651) 675-0300
iniparib
(BSI-201)
Sanofi US
Bridgewater, NJ
squamous NSCLC
(see also breast, ovarian)
-------------------------------------------------non-squamous NSCLC
Phase III
(800) 981-2491
------------------------------------------Phase II
(800) 981-2491
Iressa®
gefitinib
AstraZeneca
Wilmington, DE
first-line EGFR mutation-positive
NSCLC
Phase III
(800) 236-9933
ISIS-EIF4ERx
Isis Pharmaceuticals
Carlsbad, CA
late-stage NSCLC (combination
therapy)
(see also prostate)
Phase II
(800) 679-4747
JNJ-26854165
(Hdm2 inhibitor)
Raritan, NJ
NSCLC
(see also prostate, solid tumors)
Phase I
(800) 817-5286
Karenitecin®
BNP1350
BioNumerik Pharmaceuticals
San Antonio, TX
NSCLC
(see also ovarian, solid tumors)
Phase II
(210) 614-1701
KD019
(SSKI inhibitor)
Kadmon Pharmaceuticals
Warrendale, PA
late-stage NSCLC
Phase III
(724) 778-6100
KD032
(ras/mTOR inhibitor)
Warrendale, PA
NSCLC
Phase II completed
(724) 778-6100
linifanib
Abbott Laboratories
Abbott Park, IL
NSCLC
liver)
Phase II
(847) 937-6100
litronesib
(LY2523355)
Eli Lilly
Indianapolis, IN
NSCLC
(see also breast)
Phase II
(800) 545-5979
46
Lung Cancer
Product Name
Sponsor
Indication
Development Status
lorvotuzumab mertansine
(IMGN901)
(Orphan Drug)
ImmunoGen
Waltham, MA
SCLC
Phase II
(781) 895-0600
Lucanix®
belagenpumatucel-L
NovaRx
San Diego, CA
NSCLC (Fast Track)
(see also brain)
Phase III
(858) 522-8600
mapatumumab
Rockville, MD
(see also liver, multiple myeloma)
Phase II
(301) 309-8504
MEDI-575
(anti-PDGFR-alpha mAb)
AstraZeneca
Wilmington, DE
MedImmune
Gaithersburg, MD
NSCLC
(see also brain)
Phase II
(800) 236-9933
(301) 398-0000
MGCD265
(multi-kinase inhibitor)
MethylGene
Montreal, Canada
Phase I/II
(514) 337-3333
MORAb-003
(farletuzumab)
Eisai
Woodcliff Lake, NJ
NSCLC
(see also ovarian)
Phase II
(888) 422-4743
MORAb-009
(amatuximab)
Eisai
Woodcliff Lake, NJ
mesothelioma
Phase II
(888) 422-4743
motesanib
Amgen
Thousand Oaks, CA
NSCLC
(see also breast, colorectal, other)
Phase III
(800) 772-6436
Active Biotech
Lund, Sweden
NSCLC (Fast Track)
(see also kidney, pancreatic)
Phase I completed
navitoclax
(ABT-263)
Abbott Laboratories
Abbott Park, IL
NSCLC, SCLC
Phase II
(847) 937-6100
necitumumab
(IMC-11F8)
Princeton, NJ
Eli Lilly
Indianapolis, IN
ImClone Systems
Bridgewater, NJ
NSCLC
Phase III
(800) 332-2056
(800) 545-5979
Nexavar®
sorafenib
Wayne, NJ
NSCLC
head/neck, kidney, leukemia, liver,
Phase III
(888) 842-2937
47
Lung Cancer
Product Name
Sponsor
Indication
Development Status
NGR-hTNF
(Orphan Drug)
MolMed
Milan, Italy
second-line mesothelioma
Phase III
www.molmed.com
NK-012
Nippon Kayaku
Tokyo, Japan
SCLC
(see also breast)
Phase II
www.nipponkayaku.co.jp
NTX-010
Neotropix
Malvern, PA
SCLC
(see also other)
Phase II
www.neotropix.com
obatoclax
Cephalon
Frazer, PA
first-line SCLC
multiple myeloma)
Phase II
(610) 344-0200
OBP-301
Oncolys Biopharma
Tokyo, Japan
mesothelioma
(see also breast, head/neck, liver)
Phase I
www.oncolys.com
OGX-427
Bothell, WA
NSCLC
Phase I
(425) 686-1500
ombrabulin
(AVE8062)
Sanofi US
Bridgewater, NJ
first-line NSCLC
(see also ovarian, sarcoma)
Phase II
(800) 981-2491
onartuzumab
Genentech
metastatic NSCLC
Phase III
(800) 626-3553
Oncoprex™
(TUSC2/FUS1 gene therapy)
Genprex
Austin, TX
NSCLC
Phase I
(512) 597-5900
Opaxio™
Cell Therapeutics
Seattle, WA
NSCLC
(see also brain, ovarian, stomach,
other)
Phase III
(800) 215-2355
oral azacitidine
Celgene
Summit, NJ
NSCLC
solid tumors)
Phase I
(908) 673-9000
OSI-906
(IGF-1R/1R tyrosinase kinase
inhibitor)
OSI Pharmaceuticals
Farmingdale, NY
NSCLC
Phase II
(631) 962-0600
P2045
Bryan Oncor
Somerville, MA
NSCLC, SCLC
Phase I completed
palifosfamide
(ZIO-201)
ZIOPHARM Oncology
New York, NY
SCLC
Phase I
(646) 214-0700
48
Lung Cancer
Product Name
Sponsor
Indication
Development Status
pegdinetanib
(VEGFR-2 adnectin)
(BMS-844203)
Princeton, NJ
NSCLC
Phase II
(800) 332-2056
perifosine
AEterna Zentaris
Basking Ridge, NJ
NSCLC
leukemia, lymphoma, multiple
myeloma, sarcoma, solid tumors,
stomach)
Phase I/II
(908) 626-5428
picoplatin
(Orphan Drug)
Seattle, WA
second-line SCLC
(Fast Track)
(see also colorectal, ovarian,
prostate)
Phase II
(206) 281-7001
plinabulin
(NPI-2358)
Nereus Pharmaceuticals
San Diego, CA
NSCLC
Phase II
(858) 587-4090
PRAME antigen-specific cancer
immunotherapeutic
(recombinant)
GlaxoSmithKline
NSCLC
(see also skin)
Phase I
(888) 825-5349
PT107
(allogeneic tumor cell vaccine)
Pique Therapeutics
Durham, NC
NSCLC
Phase II
(919) 806-4395
PX-866
Oncothyreon
Seattle, WA
(see also brain, head/neck, prostate)
Phase II
(206) 801-2100
ranpirnase
Tamir Biotechnology
Monmouth Junction, NJ
NSCLC
Phase II
(732) 823-1003
regorafenib
Wayne, NJ
NSCLC
Phase I
(888) 842-2837
Reolysin®
reovirus
Oncolytics Biotech
Calgary, Canada
(see also brain, colorectal,
head/neck, ovarian, pancreatic,
sarcoma, skin, solid tumors)
Phase II
(403) 670-7377
retaspimycin
Infinity Pharmaceuticals
Cambridge, MA
NSCLC
Phase II
(617) 453-1000
RG7414
(EGFL7 inhibitor)
Genentech
NSCLC
Phase II
(800) 626-3553
49
Lung Cancer
Product Name
Sponsor
Indication
Development Status
RG7599
(antibody drug conjugate)
Genentech
NSCLC
(see also ovarian)
Phase I
(800) 626-3553
ridaforolimus
Cambridge, MA
Merck
NSCLC
(see also breast, kidney, prostate,
sarcoma, other)
Phase II
(800) 672-6372
sapacitabine
(CYC682)
NSCLC
Phase II
(908) 517-7330
SAR256212 (MM-121)
(anti-ErbB3 mAb)
Cambridge, MA
Sanofi US
Bridgewater, NJ
NSCLC
Phase II
(800) 981-2491
talactoferrin alfa (oral)
(Orphan Drug)
Agennix
Princeton, NJ
NSCLC
(Fast Track)
Phase III
(609) 524-1000
tamibarotene
CytRx
Los Angeles, CA
NSCLC
(see also leukemia)
Phase II
(310) 826-5648
Tarceva®
erlotinib
Genentech
OSI Pharmaceuticals
Farmingdale, NY
adjuvant NSCLC
leukemia, liver, other)
Phase III
(800) 626-3553
(631) 962-0600
Tavocept®
dimesna
San Antonio, TX
(see also cancer-related)
Phase III
(210) 614-1701
Tc-99m ethylenedicysteine
glucosamine
(EC-G)
Cell Point
Centennial, CO
NSCLC (diagnosis)
Phase II/III
(303) 689-9693
Telcyta™
canfosfamide
Telik
Palo Alto, CA
third-line NSCLC
(see also lymphoma, ovarian)
Phase III completed
(650) 845-7700
Temodar®
temozolomide
Merck
SCLC
(see also leukemia)
Phase II
(800) 672-6372
tivantinib
(ARQ 197)
ArQule
Woburn, MA
Daiichi Sankyo
Parsippany, NJ
NSCLC
Phase III
(781) 994-0300
(973) 944-2600
50
Lung Cancer
Product Name
Sponsor
Indication
Development Status
topotecan liposomes injection
Talon Therapeutics
San Mateo, CA
SCLC
(see also ovarian)
Phase I
(650) 599-6404
trametinib
GlaxoSmithKline
second-line NSCLC
multiple myeloma, pancreatic, skin)
Phase II
(888) 825-5249
Vargatef™
intedanib
Pharmaceuticals
Ridgefield, CT
second-line late-stage NSCLC
(see also ovarian)
Phase III
(800) 243-0127
veglin
(VEGF antisense)
Los Angeles, CA
mesothelioma
(see also kidney, skin)
Phase I
(323) 221-7818
volociximab
Abbott Laboratories
Abbott Park, IL
Biogen Idec
Weston, MA
NSCLC
Phase II
(847) 937-6100
(781) 464-2000
Xalkori®
crizotinib
(Orphan Drug)
Pfizer
New York, NY
first-line ALK-positive NSCLC,
second-line ALK-positive NSCLC
-------------------------------------------------NSCLC (combination therapy)
Phase III
(860) 732-5156
YERVOY®
ipilimumab
Princeton, NJ
NSCLC, SCLC
(see also prostate, skin)
in clinical trials
(800) 332-2056
Zolinza®
vorinostat
(Orphan Drug)
Merck
mesothelioma
(see also breast, leukemia,
lymphoma, multiple myeloma, other)
Phase III
(800) 672-6273
Zybrestat™
fosbretabulin
OXiGENE
first-line NSCLC
(see also ovarian)
Phase II
(650) 635-7000
------------------------------------------Phase I/II
(860) 732-5156
51
Lymphoma
Product Name
Sponsor
Indication
Development Status
abexinostat
(HDAC inhibitor)
Pharmacyclics
Sunnyvale, CA
lymphoma
(see also sarcoma)
Phase I/II
(408) 774-0330
ABT-888
(veliparib)
(PARP inhibitor)
Abbott Laboratories
Abbott Park, IL
lung, ovarian, prostate, skin, other)
Phase I/II
(847) 937-6100
Actimid®
pomalidomide
Celgene
Summit, NJ
Waldenström’s macroglobulinemia
(see also lung, multiple myeloma,
pancreatic)
Phase I
(908) 673-9000
Adcetris™
brentuximab vedotin
Cambridge, MA
Seattle Genetics
Bothell, WA
post-transplant Hodgkin’s lymphoma
relapse prevention
(see also leukemia)
-------------------------------------------------relapsed/refractory CD30-positive
non-Hodgkin’s lymphoma, relapsed/
refractory anaplastic large-cell
lymphoma
-------------------------------------------------first-line anaplastic large-cell
lymphoma, first-line Hodgkin’s
lymphoma
Phase III
(800) 390-5663
(425) 527-4000
------------------------------------------Phase II
(800) 390-5663
(425) 527-4000
------------------------------------------Phase I
(800) 390-5663
(425) 527-4000
Adcetris™
Companion Diagnostic
brentuximab vedotin companion
diagnostic
Cambridge, MA
Seattle Genetics
Bothell, WA
Ventana Medical Systems
Tucson, AZ
cutaneous T-cell lymphoma
(diagnosis), T-cell lymphoma
(diagnosis)
in clinical trials
(617) 679-7000
(425) 527-4000
(800) 227-2155
AEG35156
(XIAP inhibitor)
Aegera Therapeutics
Montreal, Canada
B-cell lymphoma
(see also leukemia)
Phase I/II
(514) 288-5532
AEZS-112
AEterna Zentaris
Basking Ridge, NJ
Phase I
(908) 626-5428
Afinitor®
everolimus
East Hanover, NJ
mantle cell lymphoma
(see also breast, kidney)
Phase II
(888) 669-6682
AFM13
Affimed Therapeutics
Heidelberg, Germany
second-line Hodgkin’s disease
Phase I
www.affimed.com
Alocrest™
vinorelbine liposomal
Talon Therapeutics
San Mateo, CA
non-Hodgkin’s lymphoma
Phase I
(650) 588-6404
52
Lymphoma
Product Name
Sponsor
Indication
Development Status
AME-133v
(ocaratuzumab)
MENTRIK Biotech
Dallas, TX
Phase II completed
(214) 593-0500
Amplimexon®
imexon
AmpliMed
Tucson, AZ
second-line non-Hodgkin’s lymphoma
Phase II
(520) 529-1000
amuvatinib
(MP470)
Dublin, OH
(see also lung)
Phase I
(925) 560-0100
anti-CD22 mAb
Abiogen Pharma
Pisa, Italy
B-cell lymphoma
Phase I
www.abiogen.com
Aplidin®
plitidepsin
PharmaMar
Madrid, Spain
solid tumors)
Phase I
www.pharmamar.com
AR-12
Arno Therapeutics
Flemington, NJ
Phase I
(862) 703-7170
AR-42
Arno Therapeutics
Flemington, NJ
myeloma)
Phase I/II
(862) 703-7170
Arranon®
nelarabine
(Orphan Drug)
GlaxoSmithKline
first-line T-cell lymphoma
(see also leukemia)
-------------------------------------------------second-line T-cell lymphoma
Phase III
(888) 669-6682
------------------------------------------Phase I/II
(888) 669-6682
Arzerra®
ofatumumab
GlaxoSmithKline
second-line diffuse large B-cell
lymphoma, second-line follicular
lymphoma
(see also leukemia)
-------------------------------------------------Waldenström’s macroglobulinemia
Phase III
(888) 825-5249
------------------------------------------Phase II
(888) 825-5249
ASP3026
Astellas Pharma US
Deerfield, IL
late-stage B-cell lymphoma
Phase I
(800) 695-4321
AT-101
Malvern, PA
(see also brain, leukemia, lung,
prostate, stomach)
Phase II
(610) 408-0301
AT-406/Debio-1143
Malvern, PA
Debiopharm
Lausanne, Switzerland
lymphoma
(see also leukemia)
Phase I
(610) 408-0301
www.debiopharm.com
53
Lymphoma
Product Name
Sponsor
Indication
Development Status
AT7519
(CDK inhibitor)
Dublin, CA
Phase II
(925) 560-0100
AT9283
Dublin, CA
Phase I
(925) 560-0100
autologous cancer vaccine
Bayer Innovation
Dusseldorf, Germany
Stellar Biotechnologies
Port Hueneme, CA
follicular lymphoma
(prevention of relapse)
Phase I
(888) 842-2937
(805) 488-2800
AVL-292
(Btk inhibitor)
Celgene
Summit, NJ
second-line non-Hodgkin’s
lymphoma, second-line Waldenström’s macroglobulinemia
(see also leukemia, unspecified)
Phase I
(908) 673-9000
Bcl-2 inhibitor
(ABT-199/GDC-0199)
Abbott Laboratories
Abbott Park, IL
Genentech
(see also leukemia)
Phase I
(847) 937-6100
(800) 626-3553
belinostat
(Orphan Drug)
Henderson, NV
peripheral T-cell lymphoma (PTCL)
(Fast Track)
lung, ovarian, other)
Phase II
(702) 835-6300
Bexxar®
tositumomab and iodine
I-131 tositumomab
GlaxoSmithKline
Phase II
(888) 825-5249
BiovaxID®
B-cell lymphoma vaccine
(personalized lymphoma
vaccine)
BioVest International
Tampa, FL
indolent follicular lymphoma
(Fast Track)
-------------------------------------------------mantle cell lymphoma
Phase III
(813) 864-2554
------------------------------------------Phase II
(813) 864-2554
CC-115
(kinase inhibitor)
Celgene
Summit, NJ
solid tumors)
Phase I
(908) 673-9000
CC-122
Celgene
Summit, NJ
solid tumors)
Phase I
(908) 673-9000
CC-223
(mTOR inhibitor)
Celgene
Summit, NJ
(see also lung, multiple myeloma)
Phase I
(908) 673-9000
CEP-9722
(PARP inhibitor)
Cephalon
Frazer, PA
mantle cell lymphoma (combination
therapy)
(see also lung)
Phase I
(610) 344-0200
54
Lymphoma
Product Name
Sponsor
Indication
Development Status
Clearazide™
mechlorethamine gel
(Orphan Drug)
Ceptaris Therapeutics
Malvern, PA
(Fast Track)
(610) 975-9290
CT-011
CureTech
Yavne, Israel
diffuse large B-cell lymphoma,
second-line follicular lymphoma
(see also colorectal, leukemia)
Phase II
www.curetechbio.com
darinaparsin
(ZIO-101)
(Orphan Drug)
ZIOPHARM Oncology
New York, NY
second-line peripheral T-cell
lymphoma
(see also liver, multiple myeloma,
solid tumors)
-------------------------------------------------first-line peripheral T-cell lymphoma
(combination therapy), non-Hodgkin’s
lymphoma
Phase II
(646) 214-0700
------------------------------------------Phase I
(646) 214-0700
DCDS-4501A
Genentech
(see also leukemia)
Phase I
(800) 626-3553
DCDT-2980S
Genentech
recurrent non-Hodgkin’s lymphoma
(see also leukemia)
Phase I
(800) 626-3553
DI-Leu16-IL2
Alopexx Oncology
Waltham, MA
Phase I
(781) 497-9888
entinostat
Waltham, MA
Hodgkin’s disease
leukemia, lung)
Phase II
(781) 419-1400
enzastaurin
Eli Lilly
Indianapolis, IN
diffuse large B-cell lymphoma
Phase III
(800) 545-5979
epratuzumab
(Orphan Drug)
Immunomedics
Morris Plains, NJ
UCB
Atlanta, GA
(combination therapy), follicular
lymphoma (combination therapy)
(see also leukemia)
Phase II
(973) 605-8200
epratuzumab Y-90
Immunomedics
Morris Plains, NJ
Phase II
(973) 605-8200
------------------------------------------Phase I/II
(973) 605-8200
-------------------------------------------------recurrent non-Hodgkin’s lymphoma
55
Lymphoma
Product Name
Sponsor
Indication
Development Status
EZN-2968
(HIF1-alpha inhibitor)
Piscataway, NJ
Phase I
(973) 980-4500
Folotyn®
pralatrexate
(Orphan Drug)
Allos Therapeutics
Westminster, CO
peripheral T-cell lymphoma
(first-line therapy)
(see also bladder, breast, lung)
-------------------------------------------------B-cell non-Hodgkin’s lymphoma,
-------------------------------------------------cutaneous T-cell lymphoma
Phase III
(303) 426-6262
forodesine
(Orphan Drug)
BioCryst Pharmaceuticals
Durham, NC
(see also leukemia)
Phase II
(919) 859-1302
galiximab
Biogen Idec
Cambridge, MA
-------------------------------------------------first-line non-Hodgkin’s lymphoma
(monotherapy)
Phase II completed
(617) 679-2000
------------------------------------------Phase I completed
(617) 679-2000
GDC-0349
(small molecule)
Genentech
Phase I
(800) 626-3553
GDC-0425
(ChK1 inhibitor)
Genentech
Phase I
(800) 626-3553
GDC-0575
Genentech
Phase I
(800) 626-3553
GDC-0917
(IAP antagonist)
Genentech
Phase I
(800) 626-3553
GDC-0980
inhibitor)
Genentech
Phase I
(800) 626-3553
GS-1101
(PI3K delta inhibitor)
Gilead Sciences
Foster City, CA
indolent non-Hodgkin’s lymphoma
(see also leukemia)
Phase II
(800) 445-3235
GSK461364
(polio-like kinase inhibitor)
GlaxoSmithKline
Phase I
(888) 825-5249
GSK690693
(AKT kinase inhibitor)
GlaxoSmithKline
Phase I
(888) 825-5249
56
------------------------------------------Phase II
(303) 426-6262
------------------------------------------Phase I
(303) 426-6262
Lymphoma
Product Name
Sponsor
Indication
Development Status
GSK2126458
GlaxoSmithKline
Phase I
(888) 825-5249
GSK2141795
GlaxoSmithKline
Phase I
(888) 825-5249
iboctadekin
GlaxoSmithKline
(see also ovarian)
Phase I completed
(888) 825-5249
ibrutinib
(PCI-32765)
Janssen Biotech
Horsham, PA
Pharmacyclics
Sunnyvale, CA
myeloma)
Phase II
(800) 526-7736
(408) 774-0330
IMGN529
ImmunoGen
Waltham, MA
metastatic non-Hodgkin’s lymphoma
Phase I
(781) 895-0600
INK128
(mTOR inhibitor)
Intellikine
La Jolla, CA
(see also multiple myeloma, solid
tumors)
Phase I
(858) 768-6500
inotuzumab ozogamicin
Pfizer
New York, NY
aggressive non-Hodgkin’s lymphoma
(see also leukemia)
-------------------------------------------------diffuse large B-cell lymphoma,
indolent non-Hodgkin’s lymphoma
Phase III
(860) 732-5156
------------------------------------------Phase II
(860) 732-5156
interleukin-12 gene therapy
OncoSec Medical
San Diego, CA
(see also skin)
Phase II
www.oncosec.com
ISF35
Memgen
San Diego, CA
follicular lymphoma, diffuse large cell
lymphoma, mantle cell lymphoma,
small lymphocytic lymphoma
(see also leukemia)
Phase II
(858) 524-5400
JNJ-26481585
(quisinostat)
Raritan, NJ
(see also leukemia)
Phase II
(800) 817-5286
LEE011
(CDK4/6 inhibitor)
East Hanover, NJ
Phase I
(888) 669-6682
LG740
(activated T-cells)
Lentigen
Gaithersburg, MD
University of Pennsylvania
Philadelphia, PA
follicular lymphoma, mantle-cell
lymphoma
(see also leukemia)
Phase I
(301) 527-4200
57
Lymphoma
Product Name
Sponsor
Indication
Development Status
lucatumumab
(HDC122)
East Hanover, NJ
XOMA
Berkeley, CA
lymphoma
Phase I/II
(888) 669-6682
------------------------------------------Phase I
(888) 669-6682
Marqibo®
Talon Therapeutics
San Mateo, CA
(see also leukemia, skin, other)
Phase II
(650) 588-6404
milatuzumab
Immunomedics
Morris Plains, NJ
myeloma)
Phase I/II
(973) 605-8200
MK-7956
(dinaciclib)
Merck
(see also leukemia)
Phase II
(800) 672-6372
MK-8808
Merck
late-stage follicular lymphoma
Phase I
(800) 672-6372
MLN8237
(alisertib)
Cambridge, MA
Phase III
(800) 390-5663
MLN9708
(ixazomib)
Cambridge, MA
lymphoma, Waldenström’s
macroglobulinemia
(see also multiple myeloma, solid
tumors)
Phase I
(800) 390-5663
mocetinostat
(Orphan Drug)
MethylGene
Montreal, Canada
follicular lymphoma
Phase II
(514) 337-3333
mogamulizumab
(Orphan Drug)
Amgen
Thousand Oaks, CA
cutaneous T-cell lymphoma,
Phase II
(800) 772-6436
navitoclax
(ABT-263)
Abbott Laboratories
Abbott Park, IL
(see also leukemia, lung)
Phase I/II
(847) 937-6100
NPI-0052
(marizomib)
San Diego, CA
solid tumors)
Phase I
(858) 587-4090
obatoclax
(Orphan Drug)
Cephalon
Frazer, PA
first-line follicular lymphoma
(see also leukemia, lung, multiple
myeloma)
Phase II completed
(610) 344-0200
58
-------------------------------------------------follicular lymphoma
------------------------------------------Phase I/II completed
(610) 344-0200
Lymphoma
Product Name
Sponsor
Indication
Development Status
obinutuzumab
(GA101/RG7159)
Biogen Idec
Weston, MA
Genentech
first-line non-Hodgkin’s lymphoma
(combination therapy), second-line
non-Hodgkin’s lymphoma (combination therapy), first-line B-cell
(see also leukemia)
-------------------------------------------------second-line non-Hodgkin’s lymphoma
(monotherapy)
Phase III
(781) 464-2000
(800) 626-3553
------------------------------------------Phase II
(781) 464-2000
(800) 626-3553
ON 013105
Newtown, PA
(see also leukemia)
Phase I
(267) 759-3680
ONO-4059
ONO Pharmaceutical
Osaka, Japan
B-cell lymphoma
Phase I
www.ono.co.jp
oral azacitidine
Celgene
Summit, NJ
(see also leukemia, lung,
solid tumors)
Phase I
(908) 673-9000
OSI-027
(TORC1/TORC2 inhibitor)
OSI Pharmaceuticals
Farmingdale, NY
(see also kidney)
Phase I
(631) 962-0600
P 27600
Piramal Life Sciences
Mumbai, India
Phase II
www.piramallifesciences.com
perifosine
AEterna Zentaris
Basking Ridge, NJ
lymphoma (combination therapy),
leukemia, lung, multiple myeloma,
Phase II
(908) 626-5428
PG11047
Phase I
www.progen-pharma.com
pixantrone
Cell Therapeutics
Seattle, WA
(see also breast)
Phase III
(800) 215-2355
PLX3397
Plexxikon
Berkeley, CA
recurrent or refractory Hodgkin’s
disease
(see also brain, leukemia, solid
tumors)
Phase II
(510) 647-4000
59
Lymphoma
Product Name
Sponsor
Indication
Development Status
Revlimid®
lenalidomide
Celgene
Summit, NJ
(see also leukemia)
Phase III
(908) 673-9000
RG7602
Genentech
Phase I
(800) 626-3553
rigosertib
Newtown, PA
(see also leukemia, ovarian,
pancreatic)
Phase II
(267) 759-3680
Rituxan®
rituxumab
(fast infusion)
Biogen Idec
Weston, MA
Genentech
(781) 464-2000
(800) 626-3553
SAR245409
(XL765)
Sanofi US
Bridgewater, NJ
Exelixis
(see also breast)
Phase II
(800) 981-2491
(650) 837-7000
SGN-75
(vorsetuzumab mafodotin)
Seattle Genetics
Bothell, WA
(see also kidney)
Phase I
(425) 527-4000
SHP-141
Shape Pharmaceuticals
Cambridge, MA
Phase I
www.shapepharma.com
sotrastaurin
(AEB071)
East Hanover, NJ
Phase I
(888) 669-6682
stem cell therapy
Benitec Biopharma
Sydney, Australia
City of Hope National Medical Center
Duarte, CA
AIDS-related lymphoma
Phase I
www.benitec.com
teglarinad
Cephalon
Frazer, PA
Phase I
(610) 344-0200
Telcyta™
canfosfamide
Telik
Palo Alto, CA
mantle cell lymphoma, non-Hodgkin’s
lymphoma
Phase II
(650) 845-7700
thiarabine
Dallas, TX
(see also leukemia)
Phase I/II
(215) 904-5100
60
Lymphoma
Product Name
Sponsor
Indication
Development Status
tigatuzumab
(anti-DR5 antibody)
Daiichi Sankyo
Parsippany, NJ
Phase I completed
(973) 944-2600
TKM-PLK1
(RNAi)
Tekmira Pharmaceuticals
Burnaby, Canada
Phase I
(604) 419-3200
trametinib
GlaxoSmithKline
(see also leukemia, lung, multiple
myeloma, pancreatic, skin)
Phase I
(888) 825-5249
Treanda®
bendamustine
Cephalon
Frazer, PA
first-line non-Hodgkin’s lymphoma
myeloma)
-------------------------------------------------second-line mantle cell lymphoma
(610) 344-0200
------------------------------------------Phase II
(610) 344-0200
TRU-016
(humanized anti-CD37
therapeutic)
Rockville, MD
(see also leukemia)
Phase I/II
(301) 795-1800
UNBS-5162
Drais Pharmaceuticals
Bridgewater, NJ
Phase I
(908) 895-1200
Velcade®
bortezomib
Cambridge, MA
first-line mantle cell lymphoma
(see also leukemia, cancer-related,
other)
-------------------------------------------------non-Hodgkin’s B-cell lymphoma
Phase III
(800) 390-5663
-------------------------------------------------diffuse large B-cell lymphoma
------------------------------------------Phase III
(800) 390-5663
------------------------------------------Phase II
(800) 390-5663
veltuzumab
Immunomedics
Morris Plains, NJ
(see also leukemia)
Phase I/II
(973) 605-8200
Vidaza®
azacitidine
Celgene
Summit, NJ
(see also leukemia)
Phase III
(908) 673-9000
VTX-2337
VentiRx Pharmaceuticals
Seattle, WA
B-cell lymphoma
-------------------------------------------------lymphoma
Phase I/II
(206) 689-2259
------------------------------------------Phase I
(206) 689-2259
61
Lymphoma
Product Name
Sponsor
Indication
Development Status
XmAb®2513
(CD30-antigen inhibitor)
Xencor
Monrovia, CA
Hodgkin’s disease, T-cell lymphoma
Phase I
(626) 305-5900
YM155
(sepantronium)
Astellas Pharma US
Deerfield, IL
(see also breast)
Phase II
(800) 695-4321
zanolimumab
(Orphan Drug)
Rockville, MD
Phase II
(301) 795-1800
------------------------------------------Phase I
(301) 795-1800
Zevalin®
ibritumomab tiuxetan
Henderson, NV
second-line diffuse large B-cell
lymphoma
Phase III
(702) 835-6300
------------------------------------------Phase II
(702) 835-6300
Zolinza®
vorinostat
Merck
B-cell lymphoma
(see also breast, leukemia, lung,
Phase II
(800) 672-6273
-------------------------------------------------peripheral T-cell lymphoma
Multiple Myeloma
Product Name
Sponsor
Indication
Development Status
ACE-041
(dalantercept)
Acceleron Pharma
Cambridge, MA
Phase I
(617) 649-9200
Actimid®
pomalidomide
(Orphan Drug)
Celgene
Summit, NJ
recurrent multiple myeloma
pancreatic)
(908) 673-9000
ACY-1215
(HDAC6 inhibitor)
Acetylon Pharmaceuticals
Boston, MA
ALXN6000
(samalizumab)
Alexion Pharmaceuticals
Cheshire, CT
62
Phase I/II
(617) 245-1300
(see also leukemia)
(203) 272-2596
Multiple Myeloma
Product Name
Sponsor
Indication
Development Status
Aplidin®
plitidepsin
(Orphan Drug)
PharmaMar
Madrid, Spain
Phase III
www.pharmamar.com
AR-42
Arno Therapeutics
Flemington, NJ
Phase I/II
(862) 703-7170
ARRY-520
(KSP inhibitor)
Array BioPharma
Boulder, CO
multiple myeloma
-------------------------------------------------multiple myeloma (combination
therapy)
Phase II
(877) 633-2436
------------------------------------------Phase I
(877) 633-2436
AT7519
(CDK inhibitor)
Dublin, CA
second-line multiple myeloma
solid tumors)
Phase I/II
(925) 560-0100
AT9283
Dublin, CA
solid tumors)
Phase II
(925) 560-0100
AUY922
(Hsp90 inhibitor)
East Hanover, NJ
stomach)
Phase I/II
(888) 669-6682
BHQ880
(mAb)
East Hanover, NJ
Phase II
(888) 669-6682
BI-505
(Orphan Drug)
BioInvent International
Lund, Sweden
second-line late-stage multiple
myeloma
Phase I
www.bioinvent.com
BIW-8962
Princeton, NJ
carfilzomib
(Orphan Drug)
Onyx Pharmaceuticals
Phase I/II
(609) 919-1100
third-line multiple myeloma
(Fast Track)
therapy)
(650) 266-0000
------------------------------------------Phase I/II
(650) 266-0000
CB3304
(noscapine)
Cougar Biotechnology
Raritan, NJ
CC-115
(kinase inhibitor)
Celgene
Summit, NJ
Phase I
(908) 673-9000
CC-122
Celgene
Summit, NJ
Phase I
(908) 673-9000
CC-223
(mTOR inhibitor)
Celgene
Summit, NJ
Phase I
(908) 673-9000
Phase I/II
www.cougarbiotechnology.com
63
Multiple Myeloma
Product Name
Sponsor
CP-18770
(delanzomib)
Cephalon
Frazer, PA
CX-4945
(CK2 inhibitor)
Cylene Pharmaceuticals
San Diego, CA
daratumumab
Genmab
Princeton, NJ
darinaparsin
(ZIO-101)
ZIOPHARM Oncology
New York, NY
(see also liver, lymphoma,
solid tumors)
Phase II
(646) 214-0700
DFRF-4539A
Genentech
refractory metastatic multiple
myeloma
Phase I
(800) 626-3553
elotuzumab
(BMS-901608)
Princeton, NJ
ENMD-2076
(Orphan Drug)
EntreMed
Rockville, MD
relapsed or refractory multiple
myeloma
Phase I
(240) 864-2600
ganetespib
(Hsp90i)
Lexington, MA
leukemia, liver, lung, pancreatic,
Phase I
(781) 274-8200
GL-0817
Gliknik
Baltimore, MD
Phase II
www.gliknik.com
GSK2110183
GlaxoSmithKline
(see also leukemia)
Phase I/II
(888) 825-5249
GVAX® Myeloma
cancer vaccine
Lincolnshire, IL
ibrutinib
(PCI-32765)
Janssen Biotech
Horsham, PA
Pharmacyclics
Sunnyvale, CA
Phase II
(800) 526-7736
(408) 774-0330
imetelstat
Geron
Menlo Park, CA
(monotherapy)
(see also breast, leukemia, lung)
Phase II
(650) 473-7700
indatuximab ravtansine
(Orphan Drug)
Biotest
Dreieich, Germany
relapsed or refractory multiple
myeloma
Phase I/II
www.biotest.de
64
Indication
Development Status
Phase II
(610) 344-0200
Phase I
(858) 875-5100
Phase I/II
(609) 430-2481
Phase III
(800) 332-2056
Phase II
(847) 478-0500
Multiple Myeloma
Product Name
Sponsor
Indication
Development Status
INK128
(mTOR inhibitor)
Intellikine
La Jolla, CA
Phase I
(858) 768-6500
IPH-2101
(anti-KIR mAb)
Innate Pharma
Marseille, France
multiple myeloma (monotherapy)
therapy)
Phase II
www.innate-pharma.com
------------------------------------------Phase I/II
www.innate-pharma.com
KW-2478
Princeton, NJ
multiple myeloma (combination
therapy)
Phase I/II
(609) 919-1100
LBH589
(panobinostat)
East Hanover, NJ
(see also kidney, leukemia, prostate,
solid tumors)
Phase III
(888) 669-6682
lorvotuzumab mertansine
(IMGN901)
ImmunoGen
Waltham, MA
(see also lung)
Phase I
(781) 895-0600
mapatumumab
Rockville, MD
multiple myeloma (combination
therapy)
(see also liver, lung)
Phase II
(301) 309-8504
melphalan intravenous
(captisol-enabled)
(Orphan Drug)
CyDex Pharmaceuticals
Lenexa, KS
milatuzumab
Immunomedics
Morris Plains, NJ
Phase I/II
(973) 605-8200
MLN9708
(ixazomib)
Cambridge, MA
newly diagnosed multiple myeloma
multiple myeloma
Phase I/II
(800) 390-5663
Nexavar®
sorafenib
Wayne, NJ
(see also breast, colorectal, head/
neck, kidney, leukemia, liver, lung,
ovarian, other)
Phase I/II
(888) 842-2937
NPI-0052
(marizomib)
San Diego, CA
Phase I
(858) 587-4090
obatoclax
Cephalon
Frazer, PA
(see also leukemia, lung, lymphoma)
Phase I completed
(610) 344-0200
Phase II
www.ligand.com/cydex
65
Multiple Myeloma
Product Name
Sponsor
Indication
Development Status
perifosine
(Orphan Drug)
AEterna Zentaris
Basking Ridge, NJ
(Fast Track)
leukemia, lung, lymphoma, sarcoma,
Phase III
(908) 626-5428
RG7444
(MFGR-1877S)
Genentech
refractory metastatic multiple
myeloma
Phase I
(800) 626-3553
RG7598
Genentech
injection
EUSA Pharma
Langhorne, PA
(see also breast, prostate, sarcoma,
other)
Phase I/II
(800) 833-3533
SF1126
Indianapolis, IN
Phase I
(317) 876-3075
siltuximab
Janssen Biotech
Horsham, PA
(see also prostate, other)
Phase II
(800) 526-7736
SNS01-T
(nano-encapsulated gene
therapy)
(Orphan Drug)
Senesco Technologies
Bridgewater, NJ
Phase I/II
(908) 864-4444
TH-302
(see also brain, leukemia, pancreatic,
sarcoma)
Phase I/II
(650) 474-8200
TKI258
(dovitinib)
East Hanover, NJ
(see also breast, kidney, prostate,
skin, other)
Phase II
(888) 669-6682
trametinib
GlaxoSmithKline
multiple myeloma
pancreatic, skin)
Phase I/II
(888) 825-5249
Treanda®
bendamustine
Cephalon
Frazer, PA
Phase I/II
(610) 344-0200
Xgeva™
denosumab
Amgen
Thousand Oaks, CA
(see also cancer-related, other)
Phase II
(800) 772-6436
Zolinza®
vorinostat
(Orphan Drug)
Merck
metastatic multiple myeloma
lymphoma, other)
Phase III
(800) 672-6273
66
Phase I
(800) 626-3553
Ovarian Cancer
Product Name
Sponsor
Indication
Development Status
Å6
Angstrom Pharmaceuticals
Solana Beach, CA
(see also other)
Phase II
(858) 314-2356
abagovomab
(anti-idiotype mAb vaccine)
(Orphan Drug)
Menarini
Florence, Italy
Abraxane®
Celgene
Summit, NJ
(see also bladder, breast, lung,
pancreatic, skin)
Phase II
(908) 673-9000
ABT-888
(veliparib)
(PARP inhibitor)
Abbott Laboratories
Abbott Park, IL
lung, lymphoma, prostate, skin,
other)
Phase II
(847) 937-6100
AE37 peptide vaccine
Antigen Express
Worcester, MA
(see also breast)
Phase I
(508) 852-8783
AEZS-108
(Orphan Drug)
AEterna Zentaris
Basking Ridge, NJ
(see also bladder, prostate, other)
Phase II
(908) 626-5428
Avastin®
bevacizumab
(Orphan Drug)
Genentech
relapsed, platinum-sensitive ovarian
cancer
lung, other)
-------------------------------------------------first-line metastatic ovarian cancer
(800) 626-3553
Phase III
www.menarini.com
------------------------------------------Phase III
(800) 626-3553
BC-819
(gene therapy)
(Orphan Drug)
Jerusalem, Israel
late-stage ovarian cancer
(see also bladder, pancreatic)
Phase I/II
www.biocancell.com
belinostat
Henderson, NV
late-stage ovarian cancer
lung, lymphoma, other)
Phase II completed
(702) 835-6300
cabozantinib
(XL184)
Exelixis
(see also breast, kidney, lung,
prostate, other)
Phase II
(650) 837-7000
catumaxomab
Fresenius Biotech North America
Waltham, MA
(see also other)
Phase II
www.fresenius-biotech.com
CVac™
MUC-1 cancer vaccine
Prima BioMed
Sydney, Australia
Phase II/III
www.primabiomed.com.au
67
Ovarian Cancer
Product Name
Sponsor
DCVax®-Ovarian
dendritic cell-based vaccine
Northwest Biotherapeutics
Bethesda, MD
DMUC-5754A
Genentech
second-line ovarian cancer
(see also other)
Phase I
(800) 626-3553
DPX-0907
Immunovaccine
Halifax, Canada
Phase I
(902) 492-1819
DPX-survivac cancer vaccine
Immunovaccine
Halifax, Canada
E7850
(irofulven)
Eisai
Woodcliff Lake, NJ
Phase II
(888) 422-4743
EC20
(technetium Tc-99m etarfolatide)
Endocyte
West Lafayette, IN
ovarian cancer (diagnosis)
(see also lung)
Phase III
www.endocyte.com
EC145
(vintafolide)
Endocyte
West Lafayette, IN
Merck
platinum-resistant ovarian cancer
(see also lung)
Phase III
www.endocyte.com
(800) 672-6372
EGEN-001
(Orphan Drug)
EGEN
Huntsville, AL
Phase II
(256) 512-0077
elesclomol
Lexington, MA
Phase II
(781) 274-8200
ENMD-2076
(Orphan Drug)
EntreMed
Rockville, MD
(see also multiple myeloma, other)
Phase II
(240) 864-2600
etirinotecan pegol
(NKTR-102)
(Orphan Drug)
Nektar Therapeutics
San Francisco, CA
(see also breast, colorectal, solid
tumors)
Phase II
(855) 482-6587
FANG™ Vaccine
Gradalis
Carrollton, TX
adjuvant ovarian cancer
(see also colorectal, skin)
Phase II
(214) 442-8100
vaccine
Galena Biopharma
Lake Oswego, OR
(see also breast, other)
Phase I/II
(855) 855-4253
iboctadekin
GlaxoSmithKline
(see also lymphoma)
Phase I completed
(888) 825-5249
68
Indication
Development Status
Phase I
(240) 497-9024
Phase I
(902) 492-1819
Ovarian Cancer
Product Name
Sponsor
Indication
Development Status
IMT-1012 immunotherapeutic
vaccine
Immunotope
Doylestown, PA
(see also breast)
Phase I
(215) 253-4180
iniparib
(BSI-201)
Sanofi US
Bridgewater, NJ
Phase II
(800) 981-2491
Karenitecin®
cositecan
San Antonio, TX
advanced ovarian cancer
Phase III
(210) 614-1701
KHK-2866
Princeton, NJ
ovarian cancer (combination therapy)
Phase I
(609) 919-1100
MK-1775
(Wee1 inhibitor)
Merck
Phase II
(800) 672-6372
MORAb-003
(farletuzumab)
Eisai
Woodcliff Lake, NJ
platinum-sensitive ovarian cancer
(see also lung)
Phase III
(888) 422-4743
Nexavar®
sorafenib
Wayne, NJ
first-line ovarian cancer
lung, multiple myeloma, other)
Phase II
(888) 842-2937
OGX-427
Bothell, WA
Phase I
(425) 686-1500
olaratumab
(LY3012207)
Eli Lilly
Indianapolis, IN
ImClone
Bridgewater, NJ
(see also brain)
Phase II
(800) 545-5979
ombrabulin
(AVE8062)
Sanofi US
Bridgewater, NJ
(see also lung, sarcoma)
Phase II
(800) 981-2491
Opaxio™
Cell Therapeutics
Seattle, WA
(see also brain, lung, stomach, other)
Phase III
(800) 215-2355
oregovomab
(Orphan Drug)
Quest PharmaTech
Edmonton, Canada
OSI-906
inhibitor)
OSI Pharmaceuticals
Farmingdale, NY
OVax®
autologous cell vaccine
(Orphan Drug)
AVAX Technologies
Philadelphia, PA
Phase I/II
(780) 448-1400
(see also lung, other)
Phase II
(631) 962-0600
Phase I/II
(215) 241-9760
69
Ovarian Cancer
Product Name
Sponsor
Indication
Development Status
phenoxodiol
Marshall Edwards
San Diego, CA
second-line late-stage ovarian cancer
(Fast Track)
Phase III
(858) 792-6300
picoplatin
Seattle, WA
(see also colorectal, lung, prostate)
Phase II
(206) 281-7001
Quinamed®
amonafide
Cephalon
Frazer, PA
Phase II
(610) 344-0200
Reolysin®
reovirus
Oncolytics Biotech
Calgary, Canada
ovarian cancer (combination therapy)
head/neck, lung, pancreatic,
sarcoma, skin, solid tumors)
-------------------------------------------------ovarian cancer (monotherapy)
Phase II
(403) 670-7377
------------------------------------------Phase I
(403) 670-7377
RG7458
Genentech
RG7599
Genentech
(see also lung)
Phase I
(800) 626-3553
RG7600
Genentech
Phase I
(800) 626-3553
rigosertib
Newtown, PA
pancreatic)
Phase II
(267) 759-3680
rucaparib
Clovis Oncology
Boulder, CO
(see also breast)
Phase II
(303) 625-5000
sagopilone
Wayne, NJ
Phase II completed
(888) 842-2937
SAR256212 (MM-121)
(anti-ErbB3 mAb)
Cambridge, MA
Sanofi US
Bridgewater, NJ
Phase I
(800) 981-2491
SG2000
Spirogen
London, United Kingdom
squalamine
(Orphan Drug)
OHR Pharmaceutical
New York, NY
resistant ovarian cancer
Phase II
(212) 682-8452
Telcyta™
canfosfamide
Telik
Palo Alto, CA
Phase III completed
(650) 845-7700
70
Phase I
(800) 626-3553
Phase II
www.spirogen.com
Ovarian Cancer
Product Name
Sponsor
Indication
Development Status
tigatuzumab
(anti-DR5 antibody)
Daiichi Sankyo
Parsippany, NJ
lymphoma, pancreatic)
Phase II
(973) 944-2600
topotecan liposomes injection
Talon Therapeutics
San Mateo, CA
(see also lung)
Phase I
(650) 588-6404
trabectedin
(Orphan Drug)
Raritan, NJ
(see also breast, prostate, sarcoma)
Phase III
(800) 817-5286
TRC 105
San Diego, CA
(see also breast, prostate, other)
Phase II
(858) 550-0780
trebananib
(AMG386)
Amgen
Thousand Oaks, CA
liver, stomach, other)
Phase III
(800) 772-6436
Vargatef™
intedanib
Pharmaceuticals
Ridgefield, CT
first-line late-stage ovarian cancer
(see also lung)
Phase III
(800) 243-0127
vosaroxin
Sunesis Pharmaceuticals
(see also leukemia)
Phase II
(650) 266-3739
Votrient™
pazopanib
GlaxoSmithKline
(see also kidney, other)
Phase III
(888) 825-5249
Zybrestat™
fosbretabulin
(Orphan Drug)
OXiGENE
(see also lung)
Phase II
(650) 635-7000
Pancreatic Cancer
Product Name
Sponsor
Indication
Development Status
Abraxane®
(Orphan Drug)
Celgene
Summit, NJ
ovarian, skin)
Phase III
(908) 673-9000
Actimid®
pomalidomide
Celgene
Summit, NJ
multiple myeloma)
Phase I/II
(908) 673-9000
71
Pancreatic Cancer
Product Name
Sponsor
anti-MUC1 mAb
Quest PharmaTech
Edmonton, Canada
anti-PSCA mAb
Agensys
Santa Monica, CA
Astellas Pharma US
Deerfield, IL
metastatic pancreatic cancer
Phase II
(800) 695-4321
apricoxib
(TG01)
San Diego, CA
pancreatic (combination therapy)
(see also lung)
Phase II
(858) 350-6900
Archexin®
RX-0201
(Orphan Drug)
Rexahn Pharmaceuticals
Rockville, MD
Phase II
(240) 268-5300
ASG-5ME
Agensys
Santa Monica, CA
Seattle Genetics
Bothell, WA
(see also prostate)
Phase I
(800) 695-4321
(425) 527-4000
bavituximab
Tustin, CA
first-line pancreatic cancer
(see also liver, lung)
Phase II
(715) 508-6000
BAY 86-9766
(MEK inhibitor)
Ardea Biosciences
San Diego, CA
Wayne, NJ
(see also liver)
Phase I/II
(888) 842-2937
BC-819
(gene therapy)
(Orphan Drug)
Jerusalem, Israel
first-line late-stage pancreatic cancer
(Fast Track)
(see also bladder, ovarian)
Phase II
www.biocancell.com
Chk1 inhibitor
(LY2603618)
Eli Lilly
Indianapolis, IN
(see also lung)
Phase II
(800) 545-5979
CO-101
(lipid drug conjugate of
gemcitabine)
(Orphan Drug)
Clovis Oncology
Boulder, CO
first-line metastatic pancreatic
cancer, second-line metastatic
pancreatic cancer
Phase II
(303) 625-5000
CO-101
(hENT1 IHC assay)
Clovis Oncology
Boulder, CO
Ventana Medical Systems
Tucson, AZ
pancreatic cancer (diagnosis)
in clinical trials
(303) 625-5000
CPI-613
(Orphan Drug)
Cornerstone Pharmaceuticals
Cranbury, NJ
combination therapy
(see also other)
Phase I/II
(609) 409-7050
72
Indication
Development Status
Phase I/II
(780) 448-1400
Pancreatic Cancer
Product Name
Sponsor
Indication
Development Status
CRS-207
(cancer vaccine)
Aduro BioTech
Berkeley, CA
Phase II
(510) 848-4400
dalotuzumab
(MK-0646)
Merck
Phase I/II
(800) 672-6372
(macrobeads)
Rogosin Institute
New York, NY
refractory metastatic pancreatic
cancer
(see also colorectal, prostate)
Phase II
(212) 746-1566
FG-3019
(connective tissue growth
factor)
FibroGen
San Francisco, CA
ganetespib
(Hsp90i)
Lexington, MA
myeloma, prostate, skin, stomach)
Phase II
(781) 274-8200
ganitumab
(AMG 479)
Amgen
Thousand Oaks, CA
first-line metastatic pancreatic cancer
sarcoma)
Phase III
(800) 772-6436
GI-4000
GlobeImmune
Louisville, CO
Phase II
(303) 625-2700
glufosfamide
(Orphan Drug)
Eleison Pharmaceuticals
Princeton, NJ
pancreatic cancer (Fast Track)
Phase III completed
(215) 554-3530
GS-6624
(monoclonal antibody)
Gilead Sciences
Foster City, CA
Phase II
(800) 445-3235
GV1001
(hTERT RNA vaccine)
KAEL-GemVax
Seoul, South Korea
Phase I
www.kaelgemvax.com
GVAX® Pancreatic
cancer vaccine
(Orphan Drug)
Lincolnshire, IL
Aduro BioTech
Berkeley, CA
Phase II
(847) 478-0500
(510) 848-4400
HyperAcute® Pancreas
algenpantucel-L
(Orphan Drug)
NewLink Genetics
Ames, IA
Phase III
(515) 296-5555
IMP321
Immutep
Châtenay-Malabry, France
Phase I
www.immutep.org
INNO-206
(Orphan Drug)
CytRx
Los Angeles, CA
Phase II
(415) 978-1200
pancreatic ductal adenocarcinoma
Phase II
(310) 826-5648
73
Pancreatic Cancer
Product Name
Sponsor
Indication
Development Status
Istodax®
romidepsin
Celgene
Summit, NJ
(see also kidney, prostate, other)
Phase I/II
(908) 673-9000
Jakafi™
ruxolitinib
Incyte
Wilmington, DE
(see also other)
Phase II
(855) 446-2983
KD032
(ras/mTOR inhibitor)
Warrendale, PA
(see also lung)
(724) 778-6100
LDE225
(erismodegib)
East Hanover, NJ
neoadjuvant pancreatic cancer
(see also leukemia, solid tumors,
skin)
Phase I/II
(888) 669-6682
LE-DT
(liposomal docetaxel)
Insys Therapeutics
Phoenix, AZ
Phase II
(602) 910-2617
M402
(low molecular weight heparin)
Momenta Pharmaceuticals
Cambridge, MA
Phase I/II
(617) 491-9700
masitinib
AB Science USA
Short Hills, NJ
(see also stomach)
Phase III
(973) 218-2437
MM-398
(nanotherapeutic)
(Orphan Drug)
Cambridge, MA
Phase II
(617) 441-1000
Active Biotech
Lund, Sweden
(see also kidney, lung)
Phase I completed
NPC-1C
(ensituximab)
(Orphan Drug)
Neogenix Oncology
Rockville, MD
late-stage, metastatic pancreatic
cancer
Phase I
(301) 917-6893
paclitaxel polymeric micelle
formulation
Samyang Biopharmaceuticals
Seoul, South Korea
late-stage pancreatic cancer
Phase II
www.samyangpharm.com
PancAtak™
gene therapy
Advantagene
Auburndale, MA
PCI-27483
(factor VIIa inhibitor)
Pharmacyclics
Sunnyvale, CA
PEGPH20
(pegylated recombinant
human hyaluronidase)
Halozyme Therapeutics
San Diego, CA
74
Phase I
(617) 916-5445
Phase II
(408) 774-0330
Phase I/II
(858) 794-8889
Pancreatic Cancer
Product Name
Sponsor
Indication
Development Status
PHY906
PhytoCeutica
New Haven, CT
(see also colorectal, liver,
cancer-related)
Phase I/II
(203) 777-3462
(Orphan Drug)
Cancer Advances
Durham, NC
(see also colorectal, stomach)
Phase III
(919) 361-2162
Reolysin®
reovirus
Oncolytics Biotech
Calgary, Canada
pancreatic cancer (combination
therapy)
(see also brain, colorectal, head/
neck, lung, ovarian, sarcoma, skin,
solid tumors)
Phase II
(403) 670-7377
Rexin-G®
(Orphan Drug)
San Marino, CA
(Fast Track)
(see also breast, sarcoma)
Phase I/II
(626) 441-6695
RG7600
Genentech
platinum-resistant pancreatic cancer
(see also ovarian)
Phase I
(800) 626-3553
rigosertib
Newtown, PA
ovarian)
Phase II/III
(267) 759-3680
RP101
RESprotect
Dresden, Germany
SecreFlo™
synthetic human secretin
Repligen
Waltham, MA
pancreatic cancer (diagnosis)
Phase 0
(781) 250-0111
SPRYCEL®
dasatinib
Princeton, NJ
(see also brain, breast, prostate,
other)
in clinical trials
(800) 332-2056
TH-302
(see also brain, leukemia, multiple
myeloma, sarcoma)
Phase II
(650) 474-8200
tigatuzumab
(anti-DR5 antibody)
Daiichi Sankyo
Parsippany, NJ
lymphoma, ovarian)
Phase II completed
(973) 944-2600
tivantinib
(ARQ 197)
ArQule
Woburn, MA
Daiichi Sankyo
Parsippany, NJ
lung, sarcoma, other)
Phase I
(781) 994-0300
(973) 944-2600
trametinib
GlaxoSmithKline
multiple myeloma, skin)
Phase II
(888) 825-5249
uridine triacetate
(PN401)
Wellstat Therapeutics
Gaithersburg, MD
(see also stomach)
Phase III
(240) 631-2500
Phase II/III
www.resprotect.de
75
Pancreatic Cancer
Product Name
Sponsor
Virulizin®
Lorus Therapeutics
Toronto, Canada
Y-90 clivatuzumab
(Orphan Drug)
Immunomedics
Morris Plains, NJ
Indication
Development Status
Phase III
(416) 798-1200
(Fast Track)
Phase I/II
(973) 605-8200
Prostate Cancer
Product Name
Sponsor
Indication
Development Status
99mTc-MIP-1405
Molecular Insight Pharmaceuticals
Cambridge, MA
prostate cancer (diagnosis)
Phase I
(617) 492-5554
ABI-008
(nab®-docetaxel)
Celgene
Summit, NJ
first-line hormone-refractory prostate
cancer
Phase I/II
(908) 673-9000
ABT-888
(veliparib)
(PARP inhibitor)
Abbott Laboratories
Abbott Park, IL
lung, lymphoma, ovarian, skin, other)
Phase I
(847) 937-6100
AEZS-108
AEterna Zentaris
Basking Ridge, NJ
(see also bladder, ovarian, other)
Phase II
(908) 626-5428
anti-OX40 mAb
AgonOx
Portland, OR
AP1903
Bellicum Pharmaceuticals
Houston, TX
Apatone®
ascorbic acid/menadione
IC-MedTech
San Diego, CA
Phase I/II
(619) 749-6500
APC-100
Adamis Pharmaceuticals
San Diego, CA
Phase I/II
www.adamispharmaceuticals.
com
ARC-100
Archer Biosciences
New York, NY
hormone-refractory prostate cancer
(see also brain, breast, skin)
Phase II
(646) 747-9090
ARN-509
Aragon Pharmaceuticals
San Diego, CA
Phase I/II
(858) 369-7600
76
Phase I
(800) 979-7202
Phase I/II
(713) 341-6472
Prostate Cancer
Product Name
Sponsor
Indication
Development Status
ASG-5ME
Agensys
Santa Monica, CA
Seattle Genetics
Bothell, WA
castration-resistant prostate cancer
Phase I
(800) 695-4321
(425) 527-4000
AT-101
Malvern, PA
lymphoma, stomach)
-------------------------------------------------hormone-sensitive prostate cancer
Phase II
(610) 408-0301
------------------------------------------Phase I
(610) 408-0301
AZD3514
(androgen receptor
down-regulator)
AstraZeneca
Wilmington, DE
bafetinib
CytRx
Los Angeles, CA
BPX-101
Houston, TX
cabozantinib
(XL184)
Exelixis
ovarian, other)
Phase III
(650) 837-7000
CBLC102
(mepacrine)
Cleveland BioLabs
Buffalo, NY
Incuron
Moscow, Russia
Phase II completed
(716) 849-6810
CD1089
(seocalcitol)
Cougar Biotechnology
Raritan, NJ
cilengitide
EMD Serono
Rockland, MA
(see also brain)
Phase III
(800) 283-8088
custirsen
(OGX-011/TV-1011)
Bothell, WA
Teva Pharmaceuticals
Tikva, Israel
first-line prostate cancer (combination therapy), second-line hormonerefractory prostate cancer (combination therapy) (Fast Track)
(see also lung)
Phase III
(425) 686-1500
CYT-500
EUSA Pharma
Langhorne, PA
DPX-0907
Immunovaccine
Halifax, Canada
Phase I
(800) 236-9933
second-line metastatic hormonerefractory prostate cancer
(see also brain, leukemia)
Phase II
(310) 826-5648
Phase I/II
(713) 341-6472
Phase I
www.cougarbiotechnology.com
Phase I
(800) 833-3533
Phase I
(902) 492-1819
77
Prostate Cancer
Product Name
Sponsor
Indication
Development Status
DSTP-3086S
Genentech
metastatic hormone-refractory
prostate cancer
Phase I
(800) 626-3553
E7850
(irofulven)
Eisai
Woodcliff Lake, NJ
Phase II
(888) 422-4743
EMD-525797
(anti-integrin mAb)
EMD Serono
Rockland, MA
metastatic castration-resistant
prostate cancer
Phase II/III
(800) 283-8088
emepepimut-S
EMD Serono
Rockland, MA
Oncothyreon
Seattle, WA
newly-diagnosed prostate cancer
(see also lung)
Phase II
(800) 283-8088
(macrobeads)
Rogosin Institute
New York, NY
refractory metastatic prostate cancer
Phase II
(212) 746-1566
enzalutamide
(MDV3100)
Astellas Pharma
Tokyo, Japan
Medivation
San Francisco, CA
(Fast Track)
Phase III
(415) 543-3470
EPO-806
(patupilone)
East Hanover, NJ
(see also brain)
Phase II
(888) 669-6682
EZN-4176
(antisense oligonucleotide)
Piscataway, NJ
Firmagon®
degarelix
Ferring Pharmaceuticals
Parsippany, NJ
3-month formulation
ganetespib
(Hsp90i)
Lexington, MA
second-line hormone-refractory
prostate cancer
myeloma, pancreatic, skin, stomach)
Phase II
(781) 274-8200
Gleevec®
imatinib
East Hanover, NJ
(see also lung, skin, other)
Phase II
(888) 669-6682
GRNVAC1
Argos Therapeutics
Durham, NC
Geron
Menlo Park, CA
(see also leukemia)
Phase I/II
(650) 473-7700
78
Phase I
(973) 980-4500
-------------------------------------------------neoadjuvant therapy
Phase III
(973) 796-1600
------------------------------------------Phase III
(973) 796-1600
Prostate Cancer
Product Name
Sponsor
Indication
Development Status
GTx-758
(selective estrogen receptor
alpha agonist)
GTx
Memphis, TN
first-line advanced prostate cancer,
second-line advanced prostate
cancer
Phase II
(901) 523-9700
GVAX® Prostate
cancer vaccine
Lincolnshire, IL
Aduro BioTech
Berkeley, CA
(Fast Track)
Phase III
(847) 478-0500
(510) 848-4400
Halaven®
eribulin
Eisai
Woodcliff Lake, NJ
Phase II
(888) 422-4743
HE3235
Harbor Therapeutics
San Diego, CA
Phase I/II
(858) 587-9333
intetumumab
Janssen Biotech
Horsham, PA
(see also skin)
Phase II completed
(800) 526-7736
IRX4204
Io Therapeutics
Santa Ana, CA
ISIS-EIF4ERx
Carlsbad, CA
prostate cancer (combination
therapy)
(see also lung)
Phase II
(800) 679-4747
Istodax®
romidepsin
Celgene
Summit, NJ
(see also kidney, pancreatic, other)
Phase II
(908) 673-9000
J 591 Lu-177
(anti-PMSA mAb)
BZL Biologics
New York, NY
metastatic prostate cancer,
non-metastatic prostate cancer
Phase II
(212) 315-5575
JNJ-26854165
(Hdm2 inhibitor)
Raritan, NJ
Phase I
(800) 817-5286
KX2-391
Kinex Pharmaceuticals
Buffalo, NY
(see also leukemia)
Phase II
(716) 898-8626
LBH589
(panobinostat)
East Hanover, NJ
(see also kidney, leukemia, multiple
Phase II
(888) 669-6682
LFA102
(anti-prolactin receptor
antibody)
East Hanover, NJ
XOMA
Berkeley, CA
(see also breast)
Phase I
(888) 669-6682
LOR-2040
Lorus Therapeutics
Toronto, Canada
metastatic prostate cancer
leukemia)
Phase II
(416) 798-1200
Phase II
www.io-therapeutics.com
79
Prostate Cancer
Product Name
Sponsor
MER-104
(GnRH antagonist)
Merrion Pharmaceuticals
Wilmington, DE
Phase I
(910) 799-1847
MVA-BN® PRO
antigen cancer vaccine
Mountain View, CA
Phase I/II
(650) 681-4660
NeuVax™
cancer vaccine E75
Galena Biopharma
Lake Oswego, OR
(see also breast)
Phase I/II
(855) 855-4253
nimotuzumab
YM Biosciences USA
Lehigh Valley, PA
(see also brain, breast)
Phase II
(610) 560-0600
NX-1207
Nymox Pharmaceutical
Quebec, Canada
ODM-201
(androgen receptor antagonist)
Endo Pharmaceuticals
Chadds Ford, PA
Orion
Espoo, Finland
oncolytic virus
CZ BioMed
Tampa, FL
Phase I
(813) 600-4088
Onyvax-105
anti-idiotype cancer vaccine
105AD7
VaxOnco
Seoul, South Korea
Phase II
www.vaxonco.com
Onyvax-P
(prostate cancer vaccine)
VaxOnco
Seoul, South Korea
Phase II
ozarelix
Henderson, NV
hormone-dependent prostate cancer
Phase II
(702) 835-6300
(ADI-PEG 20)
San Diego, CA
prostate cancer
(see also liver, skin, other)
Phase I
(858) 452-6688
phenoxodiol
Marshall Edwards
San Diego, CA
prostate cancer (Fast Track)
Phase II completed
(858) 792-6300
picoplatin
Seattle, WA
(see also colorectal, lung, prostate)
Phase II
(206) 281-7001
ProstAtak™
gene therapy
Advantagene
Auburndale, MA
adjuvant prostate cancer
(Fast Track)
Phase III
(617) 916-5445
80
Indication
Development Status
Phase II
(800) 936-9669
Phase II
(800) 462-3636
Prostate Cancer
Product Name
Sponsor
prostate cancer vaccine
(anti-GnRH)
Novartis Vaccines & Diagnostics
Cambridge, MA
Pepscan Therapeutics
Lelystad, Netherlands
Prostvac™
rilimogene galvacirepvec
BM ImmunoTherapeutics
Mountain View, CA
(Fast Track)
Phase III
(650) 681-4660
Provenge®
sipuleucel-T
Dendreon
Seattle, WA
recurrent early-stage prostate cancer
Phase III
(877) 256-4545
------------------------------------------Phase II
(877) 256-4545
PRX-302
Sophiris Bio
La Jolla, CA
Phase II
(858) 777-1760
PSMA ADC
(anti-drug conjugate)
Progenics Pharmaceuticals
Tarrytown, NY
Phase I
(914) 789-2800
PSMA protein vaccine
(recombinant soluble)
Tarrytown, NY
Phase I
(914) 789-2800
PSMA VRP therapeutic vaccine
Tarrytown, NY
Phase I
(914) 789-2800
PX-866
Oncothyreon
Seattle, WA
(see also brain, head/neck, lung)
Phase II
(206) 801-2100
Quinamed®
amonafide
Cephalon
Frazer, PA
Phase II
(610) 344-0200
REIC gene therapy
Momotaro-Gene
Okayama, Japan
ridaforolimus
Cambridge, MA
Merck
sarcoma, other)
Phase II
(800) 672-6372
sagopilone
Wayne, NJ
Phase II completed
(888) 842-2937
injection
EUSA Pharma
Langhorne, PA
sarcoma, other)
Phase II
(800) 833-3533
siltuximab
Janssen Biotech
Horsham, PA
Phase I
(800) 526-7736
Indication
Development Status
Phase I/II
(617) 871-7000
-------------------------------------------------neoadjuvant early-stage prostate
cancer
Phase I
www.mt-gene.com
81
Prostate Cancer
Product Name
Sponsor
Indication
Development Status
SPRYCEL®
dasatinib
Princeton, NJ
(see also brain, breast, pancreatic,
other)
in clinical trials
(800) 332-2056
TAK-448
(KISS1R protein agonist)
Cambridge, MA
TAK-700
(orteronel)
Cambridge, MA
Phase I
(800) 390-5663
first-line metastatic prostate cancer
-------------------------------------------------prostate cancer
Phase III
(800) 390-5663
Phase III
------------------------------------------Phase I
------------------------------------------Phase II
(800) 390-5663
tasquinimod
(TASQ)
Active Biotech
Lund, Sweden
TeloB-Vax
telomerase cancer vaccine
Adamis Pharmaceuticals
San Diego, CA
tesetaxel
Genta
(see also bladder, breast, skin,
stomach)
Phase II
(908) 286-9800
tigapotide
Kotinos Pharmaceuticals
New York, NY
Phase II
(212) 935-3000
TKI258
(dovitinib)
East Hanover, NJ
(see also breast, kidney, multiple
myeloma, skin, other)
Phase II
(888) 669-6682
TNFerade™
GenVec
Gaithersburg, MD
(see also head/neck, skin, stomach)
Phase I
(877) 943-6832
TOK-001
Tokai Pharmaceuticals
Cambridge, MA
Phase I
(617) 225-4305
trabectedin
Raritan, NJ
(see also breast, ovarian, sarcoma)
Phase II
(800) 817-5286
TRC 105
San Diego, CA
(see also breast, ovarian, other)
Phase I/II
(858) 550-0780
82
-------------------------------------------------second-line metastatic prostate
cancer
Phase I
www.adamispharmaceuticals.
com
Prostate Cancer
Product Name
Sponsor
Indication
Development Status
Trofex™
iofolastat I-124
Molecular Insight Pharmaceuticals
Cambridge, MA
prostate cancer (diagnosis)
Phase I
(617) 491-5554
TroVax®
tumor-associated antigen
vaccine
Oxford BioMedica
Oxford, United Kingdom
Phase II
www.oxfordbiomedica.co.uk
VT-464
Viamet Pharmaceuticals
Morrisville, NC
YERVOY®
ipilimumab
Princeton, NJ
prostate cancer (post-hormonal
therapy), prostate cancer
(post-chemotherapy)
in clinical trials
(800) 332-2056
Zaltrap™
aflibercept
Tarrytown, NY
Sanofi US
Bridgewater, NJ
first-line androgen-independent
prostate cancer
Phase III
(914) 345-7400
(800) 981-2491
Zytiga®
abiraterone
Janssen Biotech
Horsham, PA
first-line metastatic prostate cancer
(see also breast)
-------------------------------------------------neoadjuvant prostate cancer
Phase III
(800) 526-7736
------------------------------------------Phase II
(800) 526-7736
Product Name
Sponsor
Indication
Development Status
8H9 I-131 mAb
United Therapeutics
Silver Spring, MD
soft tissue sarcoma
Phase I
(301) 608-9292
abexinostat
(HDAC inhibitor)
Pharmacyclics
Sunnyvale, CA
sarcoma
(see also lymphoma)
Phase I/II
(408) 774-0330
brivanib
Princeton, NJ
(see also colorectal, liver)
Phase II
(800) 332-2056
cancer vaccine
MabVax Therapeutics
San Diego, CA
(see also breast)
Phase II
(858) 259-9405
ganitumab
(AMG 479)
Amgen
Thousand Oaks, CA
pancreatic)
Phase II
(800) 772-6436
Halaven®
eribulin
Eisai
Woodcliff Lake, NJ
(see also lung, prostate)
Phase III
(888) 422-4743
Phase I/II
(919) 467-8539
Sarcoma
83
Sarcoma
Product Name
Sponsor
Indication
Development Status
INNO-206
(Orphan Drug)
CytRx
Los Angeles, CA
soft tissue sarcoma
(see also pancreatic, solid tumors)
Phase II
(310) 826-5648
Junovan™
mifamurtide
(Orphan Drug)
Cambridge, MA
osteosarcoma
Phase III
(800) 390-5663
ombrabulin
(AVE8062)
Sanofi US
Bridgewater, NJ
Phase III
(800) 981-2491
palifosfamide
(ZIO-201)
(Orphan Drug)
ZIOPHARM Oncology
New York, NY
first-line soft tissue sarcoma
-------------------------------------------------second-line soft tissue sarcoma
-------------------------------------------------soft tissue sarcoma (monotherapy)
Phase III
(646) 214-0700
perifosine
AEterna Zentaris
Basking Ridge, NJ
myeloma, solid tumors, stomach)
Phase II
(908) 626-5428
PM-00104
PharmaMar
Madrid, Spain
Ewing’s sarcoma
(see also cervical, other)
Phase II
www.pharmamar.com
Reolysin®
reovirus
Oncolytics Biotech
Calgary, Canada
(see also brain, colorectal, head/
neck, lung, ovarian, pancreatic, skin,
solid tumors)
Phase II
(403) 670-7377
Rexin-G®
(Orphan Drug)
San Marino, CA
osteosarcoma
(see also breast, pancreatic)
-------------------------------------------------soft tissue sarcoma
Phase II
(626) 441-6695
------------------------------------------Phase I/II
(626) 441-6695
ridaforolimus
(Orphan Drug)
Cambridge, MA
Merck
metastatic sarcoma (Fast Track)
prostate, other)
-------------------------------------------------sarcoma
(800) 672-6372
(626) 441-6695
------------------------------------------Phase II
(800) 672-6372
(626) 441-6695
robatumumab
Merck
osteosarcoma, sarcoma
(see also colorectal, solid tumors)
Phase II
(800) 672-6372
84
------------------------------------------Phase II
(646) 214-0700
------------------------------------------Phase I/II
(646) 214-0700
Sarcoma
Product Name
Sponsor
Indication
Development Status
injection
EUSA Pharma
Langhorne, PA
osteosarcoma
prostate, other)
Phase I/II
(800) 833-3533
saridegib
(Orphan Drug)
Cambridge, MA
chondrosarcoma
(inoperable/unresectable)
Phase II
(617) 453-1000
TH-302
(Orphan Drug)
soft tissue sarcoma
(see also brain, leukemia, multiple
myeloma, pancreatic)
Phase III
(650) 474-8200
tivantinib
(ARQ 197)
(Orphan Drug)
ArQule
Woburn, MA
Daiichi Sankyo
Parsippany, NJ
soft tissue sarcoma
lung, pancreatic, other)
Phase II
(781) 994-0300
(973) 944-2600
trabectedin
(Orphan Drug)
Raritan, NJ
soft tissue sarcoma
(see also breast, ovarian, prostate)
-------------------------------------------------soft tissue sarcoma (adolescents and
children)
Phase III
(800) 817-5286
------------------------------------------Phase II
(800) 817-5286
Product Name
Sponsor
Indication
Development Status
Abraxane®
(Orphan Drug)
Celgene
Summit, NJ
malignant melanoma
Phase III
(908) 673-9000
ABT-888
(veliparib)
(PARP inhibitor)
Abbott Laboratories
Abbott Park, IL
malignant melanoma
lung, lymphoma, ovarian, prostate,
other)
Phase II
(847) 937-6100
Ad-IL-12 DNA therapeutic
(INXN-2001)
ZIOPHARM Oncology
New York, NY
malignant melanoma
Phase I
(646) 214-0700
Allovectin®
velimogene aliplasmid
(Orphan Drug)
Vical
San Diego, CA
first-line malignant melanoma
Phase III
(858) 646-1100
Skin Cancer
85
Skin Cancer
Product Name
Sponsor
Indication
Development Status
ALT-801
Altor BioScience
Miramar, FL
malignant melanoma
(see also other)
Phase I/II
(954) 443-8600
anti-PD1
(BMS-936558)
Princeton, NJ
melanoma
(see also kidney, lung)
Phase II
(800) 332-2056
APN301
(ch14.18 mAb/interleukin-2
fusion protein)
Apeiron Biologics
Vienna, Austria
malignant melanoma
(see also brain)
Phase II
www.apeiron-biologics.com
ARC-100
Archer Biosciences
New York, NY
malignant melanoma (combination
therapy)
(see also brain, breast, prostate)
Phase II
(646) 747-9090
ARRY-162
(MEK inhibitor)
Array BioPharma
Boulder, CO
malignant melanoma (BRAFV600E
or NRAS mutations)
Phase II
(877) 633-2436
astuprotimut-R
(MAGE-A3 antigen-specific
cancer immunotherapeutic)
GlaxoSmithKline
malignant melanoma
(see also lung)
-------------------------------------------------inoperable/unresectable malignant
melanoma
Phase III
(888) 825-5249
------------------------------------------Phase II
(888) 825-5249
autologous stem cell therapy
California Stem Cells
Irvine, CA
malignant melanoma
Phase II
(949) 534-9149
c31510
Cytotech
Natick, MA
basal cell cancer, squamous call
cancer
Phase II
(615) 515-5438
Cavatak™
coxsackievirus A21
(Orphan Drug)
Viralytics
Pymble, Australia
malignant melanoma
Phase II
www.viralytics.com
CB-10-01
cancer vaccine
Cosmo Pharmaceuticals
Lainate, Italy
malignant melanoma
Phase II
www.cosmopharmaceuticals.
com
CDX-011
(glembatumumab vedotin)
Needham, MA
malignant melanoma
(see also breast)
Phase II
(781) 433-0771
CYT107
(interleukin-7)
Cytheris
Rockville, MD
malignant melanoma
(see also kidney)
Phase I
(301) 231-0451
DC-IL-12 DNA therapeutic
(INXN-3001)
ZIOPHARM Oncology
New York, NY
malignant melanoma
Phase I
(646) 214-0700
DEDN-6526A
Genentech
malignant melanoma
Phase I
(800) 626-3553
86
Skin Cancer
Product Name
Sponsor
Indication
Development Status
dendritic cancer cell vaccine
EMD Millipore
Billerica, MA
malignant melanoma
Phase I
(781) 533-6000
E7050
Eisai
Woodcliff Lake, NJ
late-stage malignant melanoma
(see also brain, head/neck, liver,
Phase I/II
(888) 422-4743
E7080
(lenvatinib)
Eisai
Woodcliff Lake, NJ
melanoma
Phase II
(888) 422-4743
ecromeximab
Life Science Pharmaceuticals
Darien, CT
therapy)
Phase II
(203) 656-2500
Erivedge™
vismodegib
Genentech
early-stage basal cell cancer
(resectable)
Phase II
(800) 626-3553
FANG™ Vaccine
Gradalis
Carrollton, TX
malignant melanoma
(see also colorectal, ovarian)
Phase II
(214) 442-8100
ganetespib
(Hsp90i)
Lexington, MA
malignant melanoma
myeloma, pancreatic, prostate,
stomach)
Phase II
(781) 274-8200
GDC-0973
(MEK inhibitor)
Genentech
second-line metastatic malignant
melanoma (combination therapy)
Phase I
(800) 626-3553
Gleevec®
imatinib
East Hanover, NJ
malignant melanoma
(see also lung, prostate, other)
Phase II
(888) 669-6682
GSK2118436
GlaxoSmithKline
first-line BRAF mutation-positive latestage malignant melanoma
(see also brain, lung)
Phase III
(888) 825-5249
-------------------------------------------------BRAF mutation-positive metastatic
therapy)
------------------------------------------Phase II
(888) 825-5249
GSK2241658A
(cancer vaccine)
GlaxoSmithKline
metastatic malignant melanoma
Phase I
(888) 825-5249
GSK2302025A
(cancer vaccine)
GlaxoSmithKline
first-line metastatic malignant
melanoma
Phase I
(888) 825-5249
87
Skin Cancer
Product Name
Sponsor
Indication
Development Status
HyperAcute® Melanoma
melanoma vaccine
NewLink Genetics
Ames, IA
malignant melanoma
Phase II
(515) 296-5555
IMC-gp100
(cancer vaccine)
Immunocore
Oxon, United Kingdom
malignant melanoma
Phase 0
www.immunocore.com
Imprime PGG®
Biothera
Eagan, MN
malignant melanoma
(see also colorectal, leukemia, lung)
Phase I
(651) 675-0300
INCB24360
Incyte
Wilmington, DE
malignant melanoma
Phase II
(855) 446-2983
interleukin-12 gene therapy
OncoSec Medical
San Diego, CA
malignant melanoma, merkel cell
carcinoma
(see also lymphoma)
Phase II
www.oncosec.com
intetumumab
Janssen Biotech
Horsham, PA
malignant melanoma
(see also prostate)
Phase I/II
(800) 526-7736
LDE225
(erismodegib)
East Hanover, NJ
basal cell cancer
(see also leukemia, pancreatic,
solid tumors)
Phase II
(888) 669-6682
LGK974
(WNT signaling pathway
inhibitor)
East Hanover, NJ
malignant melanoma
(see also breast)
Phase I
(888) 669-6682
LGX818
(RAF inhibitor)
East Hanover, NJ
Phase I
(888) 669-6682
Lymphoseek®
Tc-99m tilmanocept
Dublin, OH
malignant melanoma (diagnosis)
(see also breast, head/neck)
(614) 793-7500
M-200 prophage cancer vaccine
(vitespen)
(Orphan Drug)
Agenus
Lexington, MA
metastatic melanoma
(Fast Track)
Phase III
(781) 674-4400
Marqibo®
(Orphan Drug)
Talon Therapeutics
San Mateo, CA
malignant melanoma
other)
Phase II
(650) 588-6404
melanoma DNA vaccine
Ichor Medical Systems
San Diego, CA
Memorial Sloan-Kettering
Cancer Center
New York, NY
malignant melanoma
Phase I
(858) 550-2022
MORAb-004
Eisai
Woodcliff Lake, NJ
malignant melanoma
Phase II
(888) 422-4743
88
Skin Cancer
Product Name
Sponsor
Indication
Development Status
muparfostat (PI-88)
(Orphan Drug)
malignant melanoma
(see also liver)
Phase II
www.progen.com.au
MVax®
melanoma vaccine
AVAX Technologies
Philadelphia, PA
malignant melanoma
Phase III
(215) 241-9760
NX-101
NexGenix
New York, NY
dermal neurofibromatoses
Phase II
(212) 974-3006
Ontak®
denileukin diftitox
Eisai
Woodcliff Lake, NJ
malignant melanoma
Phase II
(888) 422-4743
(ADI-PEG 20)
San Diego, CA
(see also liver, prostate, other)
Phase II
(858) 452-6688
Picato®
ingenol mebutate
LEO Pharma
Parsippany, NJ
basal cell cancer
Phase II
(877) 494-4536
POL-103A
(melanoma vaccine)
(Orphan Drug)
Polynoma
San Diego, CA
malignant melanoma
Phase III
(858) 205-2501
PRAME antigen-specific cancer
immunotherapeutic
(recombinant)
GlaxoSmithKline
(see also lung)
Phase I
(888) 825-5349
PTI-188
Pain Therapeutics
Austin, TX
malignant melanoma
Phase I completed
(512) 501-2444
PV-10
(rose bengal sodium)
(Orphan Drug)
Provectus Pharmaceuticals
Knoxville, TN
malignant melanoma
(see also liver)
Phase II completed
(866) 594-5999
RAF265
(raf kinase inhibitor)
East Hanover, NJ
malignant melanoma
Phase I
(888) 669-6682
Reolysin®
reovirus
Oncolytics Biotech
Calgary, Canada
malignant melanoma
head/neck, lung, ovarian, pancreatic,
sarcoma, solid tumors)
Phase II
(403) 670-7377
RG7256
(BRAF kinase inhibitor)
Roche
Nutley, NJ
malignant melanoma
Phase I
(973) 235-5000
RG7636
Roche
Nutley, NJ
malignant melanoma
Phase I
(800) 626-3553
89
Skin Cancer
Product Name
Sponsor
Indication
Development Status
talminogene laherparepvec
Amgen
Thousand Oaks, CA
malignant melanoma
Phase III
(800) 772-6436
Tasigna®
nilotinib
East Hanover, NJ
malignant melanoma (c-Kit mutation)
(see also leukemia, stomach)
Phase III
(888) 669-6682
tesetaxel
(Orphan Drug)
Genta
malignant melanoma
(see also bladder, breast, prostate,
stomach)
Phase II
(908) 286-9800
TKI258
(dovitinib)
East Hanover, NJ
malignant melanoma
myeloma, prostate, other)
Phase I/II
(888) 669-6682
TNFerade™
GenVec
Gaithersburg, MD
malignant melanoma
(see also head/neck, prostate,
stomach)
Phase II
(877) 943-6832
trametinib
GlaxoSmithKline
malignant melanoma (monotherapy)
multiple myeloma, pancreatic)
-------------------------------------------------malignant melanoma (combination
therapy)
Phase III
(888) 825-5249
------------------------------------------Phase II
(888) 825-5249
veglin
(VEGF antisense)
Los Angeles, CA
Kaposi’s sarcoma
(see also lung, kidney)
Phase I
(323) 221-7818
YERVOY®
ipilimumab
Princeton, NJ
melanoma (adjuvant therapy),
melanoma brain metastases
in clinical trials
(800) 332-2056
Zadaxin®
thymalfasin alfa 1
(Orphan Drug)
SciClone Pharmaceuticals
Foster City, CA
malignant melanoma
(see also liver)
Phase II/III
(650) 358-3456
Product Name
Sponsor
Indication
Development Status
AbGn-7
AbGenomics
Los Altos, CA
Phase I
(650) 988-9912
ABI-009
(sirolimus albumin bound)
Celgene
Summit, NJ
Phase I
(908) 673-9000
Solid Tumors
90
Solid Tumors
Product Name
Sponsor
Indication
Development Status
ABT-348
(aurora kinase inhibitor)
Abbott Laboratories
Abbott Park, IL
late-stage solid tumors
(see also other)
Phase I
(847) 937-6100
ABT-700
(c-Met inhibitor)
Abbott Laboratories
Abbott Park, IL
Phase I
(847) 937-6100
ABT-767
(PARP inhibitor)
Abbott Laboratories
Abbott Park, IL
Phase I
(847) 937-6100
ABT-806
(EGFR inhibitor)
Abbott Laboratories
Abbott Park, IL
Phase I
(847) 937-6100
AC220
(quizartinib)
Ambit Biosciences
San Diego, CA
Astellas Pharma US
Deerfield, IL
(see also leukemia)
Phase I
(858) 334-2100
(800) 695-4321
AEZS-112
AEterna Zentaris
Basking Ridge, NJ
(see also lymphoma)
Phase I
(908) 626-5428
AI-850
Acusphere
Lexington, MA
Phase I
(617) 648-8800
ALB-109564(a)
(tubulin inhibitor)
AMRI
Albany, NY
Bessor Pharma
Framingham, MA
Phase I
www.amriglobal.com
AlloStim™
Immunovative Therapies
Shoham, Israel
(see also other)
Phase I/II
www.immunovative.co.il
Alocrest™
vinorelbine liposomal
Talon Therapeutics
San Mateo, CA
(see also lymphoma)
Phase I
(650) 588-6404
AMG 208
(c-Met inhibitor)
Amgen
Thousand Oaks, CA
Phase I
(800) 772-6436
AMG 337
(c-Met inhibitor)
Amgen
Thousand Oaks, CA
Phase I
(800) 772-6436
AMG 780
(angioprotein inhibitor)
Amgen
Thousand Oaks, CA
Phase I
(800) 772-6436
AMG 820
(c-fms antagonist)
Amgen
Thousand Oaks, CA
Phase I
(800) 772-6436
91
Solid Tumors
Product Name
Sponsor
Indication
Development Status
AMG 900
Amgen
Thousand Oaks, CA
(see also other)
Phase I
(800) 772-6436
AMP-224
Amplimmune
Gaithersburg, MD
Phase I
(301) 309-9800
anti-CD137
(BMS-663513)
Princeton, NJ
Phase I
(800) 332-2056
anti-IGF-1R mAb
Genentech
Phase I
(800) 626-3553
anti-PD-L1
(BMS-936559)
Princeton, NJ
Phase I
(800) 332-2056
Aplidin®
plitidepsin
PharmaMar
Madrid, Spain
myeloma)
Phase I
www.pharmamar.com
AR-12
Arno Therapeutics
Flemington, NJ
(see also lymphoma)
Phase I
(862) 703-7170
AR-67
Arno Therapeutics
Flemington, NJ
(see also brain, leukemia)
Phase I
(862) 703-7170
ARQ 092
(AKT inhibitor)
ArQule
Woburn, MA
Daiichi Sankyo
Parsippany, NJ
inoperable/unresectable late-stage
solid tumors
Phase I
(781) 994-0300
(973) 944-2600
ARQ 621
(Eg5 inhibitor)
ArQule
Woburn, MA
(see also other)
Phase I
(781) 994-0300
ARQ 736
(BRAF inhibitor)
ArQule
Woburn, MA
Phase I
(781) 994-0300
ARQ 761
(E2F1 stimulant)
ArQule
Woburn, MA
ARRY-162
(MEK inhibitor)
Array BioPharma
Boulder, CO
(see also skin)
Phase I
(877) 633-2436
ARRY-520
(KSP inhibitor)
Array BioPharma
Boulder, CO
(see also leukemia,
multiple myeloma)
Phase I
(877) 633-2436
92
Phase I
(781) 994-0300
Solid Tumors
Product Name
Sponsor
ASG-22ME
Agensys
Santa Monica, CA
Seattle Genetics
Bothell, WA
ASP3026
Astellas Pharma US
Deerfield, IL
(see also lymphoma)
Phase I
(800) 695-4321
AT7519
(CDK inhibitor)
Dublin, CA
multiple myeloma)
Phase I
(925) 560-0100
AT9283
Dublin, CA
multiple myeloma)
Phase I
(925) 560-0100
AT13387
(Hsp90 inhibitor)
Dublin, CA
refractory solid tumors
(see also stomach)
Phase I
(925) 560-0100
ATI-1123
(docetaxel liposomal)
Azaya Therapeutics
San Antonio, TX
Phase I
(210) 341-6600
AZD1480
(JAK1/JAK2 inhibitor)
AstraZeneca
Wilmington, DE
Phase I
(800) 236-9933
AZD2014
(TOR kinase inhibitor)
AstraZeneca
Wilmington, DE
Phase I
(800) 236-9933
AZD4547
(FGFR tyrosine kinase inhibitor)
AstraZeneca
Wilmington, DE
Phase II
(800) 236-9933
AZD5363
(AKT inhibitor)
Dublin, CA
AstraZeneca
Wilmington, DE
Phase I
(800) 236-9933
AZD8330
(ARRY-424704)
(MEK inhibitor)
Array BioPharma
Boulder, CO
AstraZeneca
Wilmington, DE
Phase I
(800) 236-9933
AZD8931
(erbB kinase inhibitor)
AstraZeneca
Wilmington, DE
(see also breast)
Phase II
(800) 236-9933
BAY 10-00394
(Pan-CDK inhibitor)
Wayne, NJ
Phase I
(888) 842-2937
BAY 79-4620
(antibody-drug conjugate)
Wayne, NJ
Indication
Development Status
Phase I
(800) 695-4321
(425) 527-4000
Phase I
(888) 842-2937
93
Solid Tumors
Product Name
Sponsor
BAY 80-6946
Wayne, NJ
Phase I
(888) 842-2937
BAY 87-2243
(HIF-1ἀ pathway inhibitor)
Wayne, NJ
Phase I
(888) 842-2937
BAY 94-9343
Wayne, NJ
Phase I
(888) 842-2937
BBI503
(stemness kinase inhibitor)
Boston Biomedical
Norwood, MA
Phase I
(781) 278-0900
BBI608
(stemness inhibitor)
Boston Biomedical
Norwood, MA
Phase I
(781) 278-0900
belotecan
OnKor Pharmaceuticals
Seattle, WA
Phase II
(206) 694-4424
BEZ235
(kinase inhibitor)
East Hanover, NJ
Phase I/II
(888) 669-6682
BGJ398
(FGF-R kinase inhibitor)
East Hanover, NJ
Phase I
(888) 669-6682
BGT226
(MTOR/PI3K inhibitor)
East Hanover, NJ
Phase I/II
(888) 669-6682
BHQ880
(mAb)
East Hanover, NJ
Phase I
(888) 669-6682
BI-811283
Pharmaceuticals
Ridgefield, CT
(see also leukemia)
Phase I
(800) 243-0127
BI-831266
Pharmaceuticals
Ridgefield, CT
Phase I
(800) 243-0127
BI-836845
(IgG1-lambda)
Pharmaceuticals
Ridgefield, CT
Phase I
(800) 243-0127
BI-847325
Pharmaceuticals
Ridgefield, CT
Phase I
(800) 243-0127
94
Indication
Development Status
Solid Tumors
Product Name
Sponsor
BI-853520
(TYK2 inhibitor)
Pharmaceuticals
Ridgefield, CT
Phase I
(800) 243-0127
BIIB 015
Biogen Idec
Cambridge, MA
Phase I completed
(617) 679-2000
BIIB 028
Biogen Idec
Cambridge, MA
Phase I completed
(617) 679-2000
BIND-014
(docetaxel nanopharmaceutical)
BIND Biosciences
Cambridge, MA
Phase I
(617) 491-3400
BMN-673
(PARP inhibitor)
BioMarin Pharmaceuticals
Novato, CA
BQS481
(Eg5 inhibitor)
East Hanover, NJ
BYL719
(PI3K-alpha inhibitor)
East Hanover, NJ
Phase I
(888) 669-6682
CA-18C3
XBiotech
Austin, TX
(see also cancer-related, other)
Phase I/II
(512) 386-2900
CALAA 01
(siRNA)
Calando Pharmaceuticals
Pasadena, CA
carfilzomib
Phase II
(650) 266-0000
CBP-501
(peptide mimetic)
CanBas
Shizouka, Japan
(see also lung)
Phase I
www.canbas.co.jp
CC-115
(kinase inhibitor)
Celgene
Summit, NJ
myeloma)
Phase I
(908) 673-9000
CC-122
Celgene
Summit, NJ
myeloma)
Phase I
(908) 673-9000
CDX-1127
Needham, MA
(see also other)
Phase I
(781) 433-0771
CDX-1401
(cancer vaccine)
Needham, MA
solid tumors expressing the
NY-ESO-1 protein
Phase I/II
(781) 433-0771
CEP-11981
(VEGF-R/TIE2 kinase inhibitor)
Cephalon
Frazer, PA
Indication
(see also other)
Development Status
Phase I/II
(415) 506-6700
Phase I
(888) 669-6682
Phase I
(626) 683-7200
Phase I completed
(610) 344-0200
95
Solid Tumors
Product Name
Sponsor
CG201
(cancer vaccine)
CG Therapeutics
Seattle, WA
CRLX101
Cerulean Pharma
Cambridge, MA
crolibulin
EpiCept
Tarrytown, NY
Phase I/II
(914) 606-3500
CUDC-101
Curis
Lexington, MA
Phase I
(617) 503-6500
CVX 060
(PF-04856884)
(Ang2 antagonist)
Pfizer
New York, NY
(see also kidney)
Phase I
(860) 732-5156
CX-4945
(CK2 inhibitor)
Cylene Pharmaceuticals
San Diego, CA
Phase I
(858) 875-5100
CYC116
(aurora kinase/VEGFR2
inhibitor)
Phase I
(908) 517-7330
CYT-6091
(Aurimune)
CytImmune Sciences
Rockville, MD
Phase I
(301) 825-3041
D-1MT
NewLink Genetics
Ames, IA
D-3263
(TRPM8 protein stimulant)
Dendreon
Seattle, WA
dacomitinib
(PF-00299804)
Pfizer
New York, NY
(see also lung)
Phase II
(860) 732-5156
darinaparsin
(ZIO-101)
ZIOPHARM Oncology
New York, NY
(see also liver, lymphoma,
multiple myeloma)
Phase I
(646) 214-0700
DS-2248
Daiichi Sankyo
Parsippany, NJ
Phase I
(973) 944-2600
DS-7423
Daiichi Sankyo
Parsippany, NJ
Phase I
(973) 944-2600
96
Indication
Development Status
Phase II
(206) 336-5604
(see also breast)
Phase I/II
(617) 551-9600
Phase I
(515) 296-5555
Phase I
(877) 256-4545
Solid Tumors
Product Name
Sponsor
Indication
Development Status
E7050
Eisai
Woodcliff Lake, NJ
metastatic solid tumors
skin, stomach)
Phase I/II
(888) 422-4743
EC17
Endocyte
West Lafayette, IN
Phase I
www.endocyte.com
EC0489
Endocyte
West Lafayette, IN
Phase I
www.endocyte.com
elsamitrucin
Henderson, NV
EMD-1214063
(c-Met kinase inhibitor)
EMD Serono
Rockland, MA
Phase I
(800) 283-8088
enavatuzumab
Abbott Laboratories
Abbott Park, IL
Phase I
(847) 937-6100
EP-100
Esperance Pharmaceuticals
Baton Rouge, LA
Phase I
(225) 615-8944
ETBX-011
cancer vaccine
Etubics
Seattle, WA
late-stage metastatic solid tumors
Phase I
(206) 838-5110
etirinotecan pegol
(NKTR-102)
Nektar Therapeutics
San Francisco, CA
combination therapy
(see also breast, colorectal, ovarian)
Phase I
(855) 482-6587
EZN-2208
Piscataway, NJ
solid tumors (pediatric)
-------------------------------------------------combination therapy
Phase I/II
(973) 980-4500
------------------------------------------Phase I
(973) 980-4500
EZN-2968
(HIF1-alpha inhibitor)
Piscataway, NJ
(see also lymphoma)
Phase I
(973) 980-4500
ficlatuzumab
(AV-299)
Cambridge, MA
(see also lung)
Phase I
(617) 299-5000
fluciclatide F-18
GE Healthcare
Waukesha, WI
National Cancer Institute
Bethesda, MD
solid tumors (diagnosis)
Phase II
(262) 513-4000
FP-1039/HGS1036
Five Prime Therapeutics
Rockville, MD
Phase I
(415) 365-5600
(301) 309-8504
Phase I
(702) 835-6300
97
Solid Tumors
Product Name
Sponsor
G-202
GenSpera
San Antonio, TX
Phase I
(210) 479-8112
GC1008
(fresolimumab)
Genzyme
Cambridge, MA
Phase I
(617) 252-7500
GDC-0032
(PI3 kinase inhibitor)
Genentech
GDC-0068
(Akt inhibitor)
Genentech
GDC-0349
(small molecule)
Genentech
(see also lymphoma)
Phase I
(800) 626-3553
GDC-0425
(ChK1 inhibitor)
Genentech
(see also lymphoma)
Phase I
(800) 626-3553
GDC-0575
Genentech
(see also lymphoma)
Phase I
(800) 626-3553
GDC-0623
(MEK inhibitor)
Genentech
Phase I
(800) 626-3553
GDC-0917
(IAP antagonist)
Genentech
(see also lymphoma)
Phase I
(800) 626-3553
GDC-0973
(MEK inhibitor)
Genentech
(see also skin cancer)
Phase I
(800) 626-3553
GDC-0980
inhibitor)
Genentech
(see also breast, lymphoma)
Phase I
(800) 626-3553
Genz644282
(toposisomerase-1 inhibitor)
Genzyme
Cambridge, MA
Phase I
(800) 981-2491
GGTI-2418
Kirax
Bonita Springs, FL
Phase I
(239) 444-5400
GI-6301
(brachyury peptide vaccine)
GlobeImmune
Louisville, CO
Phase I
(303) 625-2700
GL-ONC1
Genelux
San Diego, CA
Phase I
(858) 483-0024
GO-203-2c
Genus Oncology
Vernon Hills, IL
98
Indication
Development Status
Phase I
(800) 626-3553
Phase I/II
(800) 626-3553
Phase I
(847) 549-6500
Solid Tumors
Product Name
Sponsor
Indication
Development Status
GSK461364
(polio-like kinase inhibitor)
GlaxoSmithKline
(see also lymphoma)
Phase I
(888) 825-5249
GSK690693
(AKT kinase inhibitor)
GlaxoSmithKline
(see also lymphoma)
Phase I
(888) 825-5249
GSK1070916A
(selective aurora kinase B/C
inhibitor)
GlaxoSmithKline
GSK2126458
GlaxoSmithKline
(see also lymphoma)
Phase I
(888) 825-5249
GSK2141795
GlaxoSmithKline
(see also lymphoma)
Phase I
(888) 825-5249
GSK2256098
(FAK inhibitor)
GlaxoSmithKline
Phase I
(888) 825-5249
GSK2636771
(PI3K beta-selective inhibitor)
GlaxoSmithKline
Phase I
(888) 825-5249
HSP990
(heat shock protein)
East Hanover, NJ
Phase I
(888) 669-6682
IGF-1R antagonist
(BMS-754807)
Princeton, NJ
Phase II
(800) 332-2056
IMF-001
(cancer vaccine)
ImmunoFrontier
Tokyo, Japan
IMGN388
ImmunoGen
Waltham, MA
Phase I
(781) 895-0600
INC280
(c-Met inhibitor)
East Hanover, NJ
Phase I/II
(888) 669-6682
INCB24360
Incyte
Wilmington, DE
(see also skin)
Phase I/II
(855) 446-2983
indium-111 (ABT-806)
Abbott Laboratories
Abbott Park, IL
Phase I
(847) 937-6100
INK128
(mTOR inhibitor)
Intellikine
La Jolla, CA
myeloma)
Phase I
(858) 768-6500
INK1117
(PI3Kα inhibitor)
Intellikine
La Jolla, CA
Phase I
(888) 825-5249
NY-ESO-1 antigen-expressing solid
tumors
Phase I
www.immunofrontier.com
Phase I
(858) 768-6500
99
Solid Tumors
Product Name
Sponsor
Indication
Development Status
INNO-206
CytRx
Los Angeles, CA
(see also pancreatic, sarcoma)
Phase I/II
(310) 826-5648
INNO-305
(WT-1 vaccine)
CytRx
Los Angeles, CA
(see also leukemia)
Phase I
(310) 826-5648
JI-101
(angiogenesis inhibitor)
Jubilant Biosys
Malvern, PA
JNJ-26854165
(Hdm2 inhibitor)
Raritan, NJ
JX-929
San Francisco, CA
Karenitecin®
BNP1350
San Antonio, TX
solid tumors (adults and pediatric)
Phase I
(210) 614-1701
KHK-2866
Princeton, NJ
advanced solid tumors
(see also ovarian)
Phase I
(609) 919-1100
LBH589
(panobinostat)
East Hanover, NJ
(see also kidney, leukemia, multiple
myeloma, prostate)
Phase I
(888) 669-6682
LCI699
(aldosterone synthase inhibitor)
East Hanover, NJ
Phase II
(888) 669-6682
LCL161
(IAP inhibitor)
East Hanover, NJ
Phase I
(888) 669-6682
LDE225
(erismodegib)
East Hanover, NJ
LDK378
(ALK inhibitor)
East Hanover, NJ
LEE011
(CDK4/6 inhibitor)
East Hanover, NJ
LEQ506
(Smo antagonist)
East Hanover, NJ
Phase I
(888) 669-6682
L-MDAM
San Antonio, TX
Phase I
(210) 614-1701
LOR 253
(MTF-1 inhibitor)
Lorus Therapeutics
Toronto, Canada
100
Phase I/II
(610) 240-8690
Phase I
(800) 817-5286
Phase I
(415) 281-8886
solid tumors (adults and pediatric)
(see also leukemia, pancreatic, skin)
Phase I
(888) 669-6682
Phase I
(888) 669-6682
(see also lymphoma)
Phase I
(888) 669-6682
Phase I
(416) 798-1200
Solid Tumors
Product Name
Sponsor
LP-261
Locus Pharmaceuticals
Blue Bell, PA
lurbinectedin
PharmaMar
Madrid, Spain
(see also leukemia)
Phase I
www.pharmamar.com
ME-143
(NADH oxidase inhibitor)
Marshall Edwards
San Diego, CA
refractory solid tumors
Phase I
(858) 792-6300
MEDI-565
(anti-CEA BiTE)
AstraZeneca
Wilmington, DE
MedImmune
Gaithersburg, MD
Phase I
(800) 236-9933
(301) 398-0000
MEDI-573
(anti-IGF mAb)
AstraZeneca
Wilmington, DE
MedImmune
Gaithersburg, MD
Phase I
(800) 236-9933
(301) 398-0000
MEDI-0639
(anti-delta-like 4 mAb)
AstraZeneca
Wilmington, DE
MedImmune
Gaithersburg, MD
Phase I
(800) 236-9933
(301) 398-0000
MEDI-3617
(anti-ANG-2 mAb)
AstraZeneca
Wilmington, DE
MedImmune
Gaithersburg, MD
Phase I
(800) 236-9933
(301) 398-0000
MG-1102
Green Cross
Yongin, South Korea
Mogam Biotechnology Research
Institute
Yongin, South Korea
second-line solid tumors
Phase I
www.eng.greencross.com
MGA271
(anti-B7-H3)
MacroGenics
Rockville, MD
refractory metastatic solid tumors
Phase I
(301) 251-5172
MGAH22 (anti-HER2 mAb)
MacroGenics
Rockville, MD
Phase I
(301) 251-5172
MINT1526A
Genentech
Phase I
(800) 626-3553
MK-1496
Merck
Phase I completed
(800) 672-6372
Indication
Development Status
Phase I
(215) 358-2000
101
Solid Tumors
Product Name
Sponsor
Indication
Development Status
MK-3475
Merck
metastatic late-stage solid tumors
Phase I
(800) 672-6372
MK-4827
(PARP inhibitor)
Merck
Phase I
(800) 672-6372
MK-5108/VX-689
(aurora kinase A inhibitor)
Merck
Vertex Pharmaceuticals
Cambridge, MA
Phase I
(800) 672-6372
(617) 444-6100
MK-8242
Merck
(see also leukemia)
Phase I
(800) 672-6372
MLN0128
Cambridge, MA
(see also other)
Phase I
(800) 390-5663
MLN0518
(tandutinib)
Cambridge, MA
Phase I
(800) 390-5663
MLN1117
Cambridge, MA
Phase I
(800) 390-5663
MLN2480
Cambridge, MA
Phase I
(800) 390-5663
MLN4924
(NEDD8 inhibitor)
Cambridge, MA
(see also other)
Phase I
(800) 390-5663
MLN8237
(alisertib)
Cambridge, MA
(see also lymphoma)
Phase II
(800) 390-5663
MLN9708
(ixazomib)
Cambridge, MA
myeloma)
Phase I
(800) 390-5663
MM-151
(EGFR antagonist)
Cambridge, MA
mocetinostat
MethylGene
Montreal, Canada
MPDL-3280A
Genentech
102
Phase I
(617) 441-1000
Phase I/II
(514) 337-3333
Phase I
(800) 626-3553
Solid Tumors
Product Name
Sponsor
MSC2015103B
(MEK inhibitor)
EMD Serono
Rockland, MA
Phase I
(800) 283-8088
MTKi-328
BeiGene
Beijing, China
Phase I
www.beigene.com
MTRN-2696
Henderson, NV
Phase I
(702) 835-6300
NKP-1339
Niiki Pharma
Hoboken, NJ
Phase I
(201) 710-5512
NKTR-105
(pegylated docetaxel)
Nektar Therapeutics
San Francisco, CA
Phase I
(415) 482-5300
NMS-1116354
(CDC7 protein kinase inhibitor)
Nerviano Medical Services
Nerviano, Italy
Phase I
www.nervianoms.com
NMS-1286937
(PIK-1 inhibitor)
Nerviano, Italy
Phase I
www.nervianoms.com
NPI-0052
(marizomib)
San Diego, CA
olaparib
(PARP inhibitor)
AstraZeneca
Wilmington, DE
Omapro™
omacetaxine
Cephalon
Frazer, PA
OMP-18R5
(Wnt pathway)
Wayne, NJ
OncoMed Pharmaceuticals
Redwood City, CA
Phase I
(888) 842-2837
(650) 995-8200
OMP-21M18
(DLL4 inhibitor)
GlaxoSmithKline
Redwood City, CA
Phase I
(888) 825-5249
(650) 995-8200
OMP-59R5
(notch pathway)
GlaxoSmithKline
Redwood City, CA
Phase I
(888) 825-5249
(650) 995-8200
omtriptolide
Pharmagenesis
Redwood City, CA
Pierre Fabre Pharmaceuticals
Parsippany, NJ
Phase I
(650) 842-7060
www.pierre-fabre.com
Indication
myeloma)
Development Status
Phase I
(858) 587-4090
Phase I
(800) 236-9933
(see also leukemia)
Phase II
(610) 344-0200
103
Solid Tumors
Product Name
Sponsor
ONT-10
(cancer vaccine)
Oncothyreon
Seattle, WA
Phase I
(206) 769-9219
ONX-0801
Phase I
(650) 266-0000
OPB-51602
Otsuka America Pharmaceutical
Rockville, MD
Phase I
(800) 562-3974
oprozomib
Phase I
(650) 266-0000
oral azacitidine
Celgene
Summit, NJ
(see also leukemia, lung, lymphoma)
Phase II
(908) 673-9000
ortataxel
Henderson, NV
taxane-refractory solid tumors
Phase II
(702) 835-6300
OSI-930
(c-kit/VEGFR-2)
OSI Pharmaceuticals
Farmingdale, NY
Phase I
(631) 962-0600
p28 peptide
CDG Therapeutics
Chicago, IL
Phase I
www.cdgti.com
paclitaxel liposomal
Sun Pharma
Mumbai, India
Phase I
www.sunpharma.com
palifosfamide
(ZIO-201)
ZIOPHARM Oncology
New York, NY
pbi-shRNA™ STMN1 LP
(anti-stathim gene therapy)
Gradalis
Carrollton, TX
perifosine
AEterna Zentaris
Basking Ridge, NJ
PF-00337210
(VEGFR2 antagonist)
Pfizer
New York, NY
Phase I completed
(860) 732-5156
PF-03446962
(ALK-1 mAb)
Pfizer
New York, NY
Phase I
(860) 732-5156
104
Indication
Development Status
Phase I
(646) 214-0700
Phase I
(214) 442-8100
myeloma, sarcoma, stomach)
Phase I
(908) 626-5428
Solid Tumors
Product Name
Sponsor
PF-04605412
(anti-α5β1 integrin mAb)
Pfizer
New York, NY
PF-04691502
Pfizer
New York, NY
(see also other)
Phase I
(860) 732-5156
PF-05212384
(mTOR/PI3K inhibitor)
Pfizer
New York, NY
(see also other)
Phase I
(860) 732-5156
PG11047
(see also lymphoma)
Phase I
www.progen-pharma.com
PLX3397
Plexxikon
Berkeley, CA
(see also brain, leukemia, lymphoma)
Phase I
(510) 647-4000
PM-060184
PharmaMar
Madrid, Spain
Phase I
www.pharmamar.com
PNT2258
(bcl-2 oncogene inhibitor)
ProNAi Therapeutics
Ann Arbor, MI
Phase I
(269) 815-8098
PRI-724
(CBP/catenin inhibitor)
PRISM BioLab
Yokohama, Japan
Phase I
www.prismbiolab.com
PRLX93936
Prolexys Pharmaceuticals
Salt Lake City, UT
Phase I
PTC299
PTC Therapeutics
purine nucleoside
phosphorylase
gene therapy
PNP Therapeutics
Birmingham, AL
Phase I
www.pnptherapeutics.com
PWT33597
(PI3K alpha/mTOR kinase)
Pathway Therapeutics
San Francisco, CA
Phase I
www.pathwaytx.com
QBI-139
Quintessence Biosciences
Madison, WI
Phase I
(608) 441-2950
RAF265
East Hanover, NJ
Indication
Development Status
Phase I
(860) 732-5156
(see also breast, other)
(see also skin)
Phase II
(908) 222-7000
Phase I/II
(888) 669-6682
105
Solid Tumors
Product Name
Sponsor
Indication
Development Status
regorafenib
Wayne, NJ
stomach)
Phase I
(888) 842-2837
Reolysin®
reovirus
Oncolytics Biotech
Calgary, Canada
head/neck, lung, ovarian, pancreatic,
sarcoma, skin)
Phase I
(403) 670-7377
RG7112
(MDM2 antagonist)
Roche
Nutley, NJ
(see also other)
Phase I
(973) 235-5000
RG7116
(ErbB-3 receptor antagonist)
Roche
Nutley, NJ
Phase I
(973) 235-5000
RG7155
(anti-CSF-1R mAb)
Roche
Nutley, NJ
Phase I
(973) 235-5000
RG7167
(CIF/MEK inhibitor)
Roche
Nutley, NJ
Phase I
(973) 235-5000
RG7304
(MAP/raf inhibitor)
Roche
Nutley, NJ
Phase I
(973) 235-5000
RG7321
(PI3Kα inhibitor)
Genentech
Roche
Nutley, NJ
Phase II
(800) 626-3553
(973) 235-5000
RG7347
(NRP1 antagonist)
Genentech
Roche
Nutley, NJ
Phase I
(800) 626-3553
(973) 235-5000
RG7356
(CD44 antigen inhibitor)
Roche
Nutley, NJ
Phase I
(973) 235-5000
RG7388
(MDM2 inhibitor)
Roche
Nutley, NJ
(see also other)
Phase I
(973) 235-5000
RG7444
(HFGR-1877S)
Genentech
Phase I
(800) 626-3553
RG7446
(mAb)
Genentech
RG7594
(mAb)
Genentech
106
Phase I
(800) 626-3553
Phase I
(800) 626-3553
Solid Tumors
Product Name
Sponsor
Indication
Development Status
RG7602
Genentech
(see also lymphoma)
Phase I
(800) 626-3553
robatumumab
Merck
solid tumors (combination therapy)
(see also colorectal, sarcoma)
-------------------------------------------------solid tumors (pediatric)
Phase II
(800) 672-6372
------------------------------------------Phase I
(800) 672-6372
RRx-001
RadioRx
Mountain View, CA
sapacitabine
(CYC682)
SAR125844
(Met kinase inhibitor)
Sanofi US
Bridgewater, NJ
Phase I
(800) 981-2491
SAR153192
(anti-DLL4 mAb)
Sanofi US
Bridgewater, NJ
Phase I
(800) 981-2491
SAR245408/MSC1936369B
combination therapy
(PI3K inhibitor/MEK inhibitor)
Merck Serono
Geneva, Switzerland
Sanofi US
Bridgewater, NJ
Phase I
(800) 981-2491
SAR245409/MSC1936369B
combination therapy
(PI3K-mTOR inhibitor/MEK
inhibitor)
Merck Serono
Geneva, Switzerland
Sanofi US
Bridgewater, NJ
Phase I
(800) 981-2491
SAR256212
(MM-121)
Cambridge, MA
Sanofi US
Bridgewater, NJ
SAR307746
(REGN910)
(anti-Ang2 mAb)
Tarrytown, NY
Sanofi US
Bridgewater, NJ
SAR566658
(maytansin-loaded anti-DS6)
Sanofi US
Bridgewater, NJ
DS6-positive solid tumors
Phase I
(800) 981-2491
SB989
(pracinostat)
S*BIO
Oakland, CA
(see also leukemia, other)
Phase I
(650) 730-2860
Phase I
(650) 681-9885
Phase I
(908) 517-7330
Phase II
(800) 981-2491
Phase I
(914) 347-7000
(800) 981-2491
107
Solid Tumors
Product Name
Sponsor
SCH-900353
Merck
seliciclib
(CYC202)
selumetinib
(AZD6244/ARRY-142886)
(MEK inhibitor)
AstraZeneca
Wilmington, DE
Phase II
(800) 236-9933
selumetinib
(AZD6244/ARRY-142886)/
MK2206 combination
(MEK/AKT inhibitor)
AstraZeneca
Wilmington, DE
Merck
Phase I
(800) 236-9933
(800) 672-6372
SF1126
Indianapolis, IN
simotaxel IV
Taxolog
Fairfield, NJ
Phase I
(866) 829-6564
solid tumor immunotherapy
(mAb)
Genentech
Phase I
(800) 626-3553
sonepcizumab
Lpath
San Diego, CA
Phase I
(858) 678-0800
SPI-1620
(endothelin B receptor agonist)
Henderson, NV
Phase I
(702) 835-6300
TAG vaccine
Gradalis
Carrollton, TX
Phase I
(214) 442-8100
TAK-385
(gonadotrophin
hormone-releasing hormone
receptor antagonist)
Cambridge, MA
Phase I
(800) 390-5663
TAK-441
(hedgehog signaling pathway
inhibitor)
Cambridge, MA
Phase I
(800) 390-5663
TAK-701
(HGF inhibitor)
Cambridge, MA
Phase I
(800) 390-5663
TAK-733
(MEK inhibitor)
Cambridge, MA
Phase I
(800) 390-5663
108
Indication
Development Status
Phase I
(800) 672-6372
myeloma)
Phase I
(908) 517-7330
Phase I
(317) 876-3075
Solid Tumors
Product Name
Sponsor
TAK-960
(Plk1 inhibitor)
Cambridge, MA
teglarinad
Cephalon
Frazer, PA
(see also lymphoma)
Phase I
(610) 344-0200
terameprocol
Houston, TX
solid tumors (IV-infusion)
(see also brain, cervical, head/neck,
other)
Phase I
(713) 541-2000
TKM-PLK1
(RNAi)
Tekmira Pharmaceuticals
Burnaby, Canada
(see also lymphoma)
Phase I
(604) 419-3200
TL-32711
(birinapant)
TetraLogic Pharmaceuticals
Malvern, PA
(see also leukemia)
Phase I/II
(610) 889-9900
TLC-388
TLC Biopharmaceuticals
Phase I
(650) 872-8816
TRC093
(IgG1 mAb)
San Diego, CA
Phase I completed
(858) 550-0780
TRC102
(DNA repair inhibitor)
San Diego, CA
Phase I
(858) 550-0780
tremelimumab
(anti-CTLA4 mAb)
AstraZeneca
Wilmington, DE
MedImmune
Gaithersburg, MD
Phase II
(800) 236-9933
(301) 398-0000
TST-10088
Cangene
Winnipeg, Canada
Phase I
(204) 275-4200
U3-1565
(anti-HB-EGF antibody)
Amgen
Thousand Oaks, CA
Daiichi Sankyo US
Parsippany, NJ
Phase I
(800) 772-6436
(973) 944-2600
UNBS-5162
Drais Pharmaceuticals
Bridgewater, NJ
V934/V935
Merck
Phase I completed
(800) 672-6372
V935
(telomerase inhibitor vaccine)
Geron
Menlo Park, CA
Merck
Phase I
(650) 473-7700
(800) 672-6372
Indication
Development Status
Phase I
(800) 390-5663
(see also lymphoma)
Phase I
(908) 895-1200
109
Solid Tumors
Product Name
Sponsor
Indication
Development Status
VGX-100
(VEGF-C mAb)
Circadian Technologies
Victoria, Australia
VTX-2337
VentiRx Pharmaceuticals
Seattle, WA
VX15
Vaccinex
Rochester, NY
Phase I
(585) 271-2700
WX-UK1
Wilex
Munich, Germany
Phase I
www.wilex.de
X-82
(dual VEGFR/PDGFR inhibitor)
Tyrogenex
West Palm Beach, FL
Phase I
(561) 835-9356
Xalkori®
crizotinib
Pfizer
New York, NY
(see also lung)
Phase I
(860) 732-5156
XMT-1001
Mersana Therapeutics
Cambridge, MA
Phase I
(617) 498-0020
XMT-1107
Mersana Therapeutics
Cambridge, MA
Phase I
(617) 498-0020
Phase I
www.circadian.com.au
(see also lymphoma)
Phase I
(206) 689-2259
Stomach Cancer
Product Name
Sponsor
Indication
Development Status
AT-101
Malvern, PA
late-stage esophageal cancer
lymphoma, prostate)
Phase I/II
(610) 408-0301
AT13387
(Hsp90 inhibitor)
Dublin, CA
late-stage gastrointestinal stromal
tumors (GIST) (second-line therapy)
Phase II
(925) 560-0100
AUY922
(Hsp90 inhibitor)
East Hanover, NJ
second-line GIST
multiple myeloma)
Phase II
(888) 669-6682
BIIB 2024
Biogen Idec
Cambridge, MA
GIST
(see also breast)
Phase II completed
(617) 679-2000
110
Stomach Cancer
Product Name
Sponsor
Indication
Development Status
crenolanib
(CP-868-596)
AROG Pharmaceuticals
Dallas, TX
GIST
(see also brain)
Phase II
(214) 594-0002
E7050
Eisai
Woodcliff Lake, NJ
gastric cancer (combination therapy)
skin, solid tumors)
Phase I/II
(888) 422-4743
ERBITUX®
cetuximab
Princeton, NJ
Eli Lilly
Indianapolis, IN
gastric cancer
in clinical trials
(800) 332-2056
(800) 545-5979
ganetespib
(Hsp90i)
Lexington, MA
esophageal cancer, gastric cancer,
GIST
myeloma, pancreatic, prostate, skin)
Phase II
(781) 274-8200
masitinib
(Orphan Drug)
AB Science USA
Short Hills, NJ
GIST
Phase III
(973) 218-2437
Opaxio™
Cell Therapeutics
Seattle, WA
esophageal cancer
(see also brain, lung, ovarian, other)
Phase II
(800) 215-2355
perifosine
AEterna Zentaris
Basking Ridge, NJ
GIST
myeloma, sarcoma, solid tumors)
Phase II
(908) 626-5428
(Orphan Drug)
Cancer Advances
Durham, NC
gastric cancer
Phase III
(919) 361-2162
ramucirumab
(IMC-1121B)
Eli Lilly
Indianapolis, IN
ImClone
Bridgewater, NJ
gastric cancer
Phase III
(800) 545-5979
regorafenib
(Orphan Drug)
Wayne, NJ
GIST (Fast Track)
solid tumors)
Phase III
(888) 842-2837
S-1
Taiho Pharma U.S.A.
Princeton, NJ
gastric cancer
Phase III
(609) 750-5300
Tasigna®
nilotinib
(Orphan Drug)
East Hanover, NJ
GIST
(see also leukemia, skin)
Phase III
(888) 669-6682
111
Stomach Cancer
Product Name
Sponsor
Indication
Development Status
telatinib
(Orphan Drug)
ACT Biotech
San Francisco, CA
gastric cancer (combination therapy)
Phase II
(415) 230-3900
tesetaxel
(Orphan Drug)
Genta
gastric cancer
(see also bladder, breast, prostate,
skin)
Phase II
(908) 286-9800
TNFerade™
golnerminogene pradenovac
GenVec
Gaithersburg, MD
esophageal cancer
(see also head/neck, prostate, skin)
Phase II
(877) 943-6832
trebananib
(AMG386)
Amgen
Thousand Oaks, CA
esophageal cancer, gastric cancer
liver, ovarian, other)
Phase II
(800) 772-6436
Tykerb®
lapatinib
GlaxoSmithKline
gastric cancer
(see also breast, head/neck)
Phase III
(888) 825-5249
uridine triacetate
(PN401)
Wellstat Therapeutics
Gaithersburg, MD
gastric cancer
Phase II
(240) 631-2500
Xeloda®
capecitabine
Genentech
esophageal cancer
(see also brain, colorectal, liver)
Phase II
(800) 626-3553
Cancer/Chemotherapy-Related Conditions
Product Name
Sponsor
Indication
Development Status
AG103
ActoGenix
Zwijnaarde, Belgium
oral mucositis associated with cancer
treatment
Phase I
www.actogenix.com
AP1903
Houston, TX
graft-versus-host disease
(see also prostate)
Phase I
(713) 341-6472
ARX-02
(sufentanil sublingual)
AcelRx Pharmaceuticals
Redwood City, CA
breakthrough cancer pain
Phase II
(650) 216-3500
CA-18C3
XBiotech
Austin, TX
cancer-related cachexia
(see also other, solid tumors)
Phase I/II
(512) 386-2900
112
Product Name
Sponsor
Indication
Development Status
CD1400
(oltipraz)
Canopus BioPharma
Studio City, CA
chemotherapy- and radiation-induced
mucositis
Phase II
www.canopusbiopharma.com
CLT-008
Cellerant Therapeutics
San Carlos, CA
chemotherapy-related neutropenia
(see also other)
Phase I/II
(650) 232-2122
dronabinol oral solution
INSYS Therapeutics
Phoenix, AZ
chemotherapy-induced nausea and
vomiting
Phase III
(602) 910-2617
E6014
Eisai
Woodcliff Lake, NJ
oral mucositis
Phase III
(888) 422-4743
Emend®
aprepitant
Merck
vomiting (pediatric)
Phase III
(800) 672-6372
Emend® IV
aprepitant
Merck
vomiting (pediatric)
Phase I
(800) 672-6372
fentanyl inhalation
Akela Pharma
Austin, TX
cancer pain
Phase II/III
(512 834-0449
ferroportin mAb
Eli Lilly
Indianapolis, IN
anemia associated with cancer
Phase I
(800) 545-5979
fulranumab
Raritan, NJ
cancer pain (adjunctive treatment)
Phase II
(800) 817-5286
hepcidin mAb
Eli Lilly
Indianapolis, IN
anemia associated with cancer
Phase I
(800) 545-5979
LG631
Lentigen
Gaithersburg, MD
chemoprotection in patients
undergoing treatment for
glioblastoma
Phase I
(301) 527-4200
mesenchymal stem cell therapy
(Orphan Drug)
Mesoblast
New York, NY
for bone marrow regeneration in
patients undergoing bone marrow
transplantation
Phase III
(212) 880-2060
morphine intranasal
Marina Biotech
Bothell, WA
cancer pain
Phase II
(425) 908-3600
MultiStem®
stem cell therapy
(Orphan Drug)
Athersys
Cleveland, OH
graft-versus-host disease in patients
undergoing bone marrow transplant
Phase I
(216) 431-9900
113
Product Name
Sponsor
Indication
Development Status
nabiximols
Rockville, MD
Phase III
(800) 562-3974
netupitant/palonosetron
Helsinn Therapeutics
Bridgewater, NJ
vomiting
Phase III
(908) 231-1435
NP-2 gene therapy
(intradermal)
Diamyd Medical
Pittsburgh, PA
cancer pain
Phase II
(412) 770-1310
Nplate®
romiplostim
Amgen
Thousand Oaks, CA
chemotherapy-associated
thrombocytopenia
Phase II
(800) 772-6436
PHY906
PhytoCeutica
New Haven, CT
chemotherapy-induced
gastrointestinal disorders
(see also colorectal, liver, pancreatic)
Phase I/II
(203) 777-3462
Prochymal®
remestemcel-L
(Orphan Drug)
Osiris Therapeutics
Columbia, MD
Phase III
(443) 545-1800
ProDermaCel™
norepinephrine topical
ProCertus BioPharm
Madison, WI
prevention of oral mucositis,
prevention of radiation-induced skin
damage
Phase I/II
(608) 273-8862
Promacta®
eltrombopag
GlaxoSmithKline
thrombocytopenia
Phase II
(888) 669-6682
RGI-2001
REGiMMUNE
Santa Clara, CA
Phase I/II
www.regimmune.com
rolapitant
TESARO
Waltham, MA
vomiting
Phase III
(339) 970-0900
SGX201
Soligenix
Princeton, NJ
acute radiation enteritis in patients
with cancer
Phase I/II
(609) 538-8200
sotatercept
(ACE-011)
Celgene
Summit, NJ
chemotherapy-induced anemia
(see also other)
Phase II/III
(908) 673-9000
tanezumab
Pfizer
New York, NY
Phase II
(860) 732-5156
Tavocept®
dimesna
San Antonio, TX
chemoprotection
(see also lung)
Phase III
(210) 614-1701
114
Product Name
Sponsor
Indication
Development Status
T-cell replacement therapy
Houston, TX
graft-versus-host disease in patients
with late-stage cancer undergoing
bone marrow transplantation
Phase I
(713) 341-6472
TH-9402
(Orphan Drug)
Kiadis Pharma
Amsterdam, Netherlands
Phase I/II
www.kiadis.com
TXA127
Tarix Pharmaceuticals
Cambridge, MA
thrombocytopenia
Phase II
www.tarixpharma.com
Velcade®
bortezomib
Cambridge, MA
steroid-refractory graft-versus-host
disease
other)
Phase II
(800) 390-5663
XEN-2174
Xenome
cancer pain
Phase II
www.xenome.com
Xgeva™
denosumab
Amgen
Thousand Oaks, CA
prevention of cancer-related bone
damage or malignant hypercalcemia
Phase III
(800) 772-6436
Product Name
Sponsor
Indication
Development Status
8H9 I-131 mAb
United Therapeutics
Silver Spring, MD
peritoneal cancer
(see also brain, sarcoma)
Phase I
(301) 608-9292
Å6
Angstrom Pharmaceuticals
Solana Beach, CA
gynecologic cancer
(see also ovarian)
Phase I
(858) 314-2356
ABT-348
Abbott Laboratories
Abbott Park, IL
hematological malignancies
Phase I
(847) 937-6100
ABT-888
(veliparib)
(PARP inhibitor)
Abbott Laboratories
Abbott Park, IL
fallopian tube cancer
lung, lymphoma, ovarian, prostate,
skin)
Phase II
(847) 937-6100
AEZS-108
AEterna Zentaris
Basking Ridge, NJ
late-stage endometrial cancer
(see also bladder, ovarian, prostate)
Phase II
(908) 626-5428
AlloStim™
Immunovative Therapies
Shoham, Israel
Phase I/II
www.immunovative.co.il
Other Cancers
115
Other Cancers
Product Name
Sponsor
Indication
Development Status
Alpharadin®
radium-223 chloride
Wayne, NJ
bone metastases from
(888) 842-2837
ALT-801
Altor BioScience
Miramar, FL
urogenital cancer
(see also skin)
Phase I/II
(954) 443-8600
AMG 319
(PI3K-delta inhibitor)
Amgen
Thousand Oaks, CA
Phase I
(800) 772-6436
AMG 900
Amgen
Thousand Oaks, CA
Phase I
(800) 772-6436
anti-CD70 ADC
(BMS-936561)
Princeton, NJ
Phase I
(800) 332-2056
anti-CXCR4
(BMS-936564)
Princeton, NJ
Phase I
(800) 332-2056
ARQ 621
(Eg5 inhibitor)
ArQule
Woburn, MA
Phase I
(781) 994-0300
Avastin®
bevacizumab
Genentech
high-risk carcinoid tumor
lung, ovarian)
Phase III
(800) 626-3553
BAY 10-02670
Wayne, NJ
uterine leiomyoma
Phase I
(888) 842-2937
belinostat
Henderson, NV
peritoneal cancer, thymoma
lung, lymphoma, ovarian)
-------------------------------------------------first-line thymoma
Phase II
(702) 835-6300
-------------------------------------------------recurrent hematological malignancies
------------------------------------------Phase I/II
(702) 835-6300
------------------------------------------Phase I
(702) 835-6300
BKM120
(PI3K inhibitor)
East Hanover, NJ
second-line endometrial cancer,
second-line urogenital cancer
(see also brain, breast, lung)
Phase II
(888) 669-6682
BMN-673
(PARP inhibitor)
BioMarin Pharmaceuticals
Novato, CA
Phase I
(415) 506-6700
116
Other Cancers
Product Name
Sponsor
Indication
Development Status
BP-100-1-01
Bio-Path
Ogden, Utah
Phase I
(801) 580-2326
CA-18C3
XBiotech
Austin, TX
(see also cancer-related, solid
tumors)
Phase I
(512) 386-2900
cabozantinib
(XL184)
(Orphan Drug)
Exelixis
medullary thyroid cancer
ovarian, prostate)
Phase III
(650) 837-7000
catumaxomab
Fresenius Biotech North America
Waltham, MA
malignant ascites
(see also ovarian)
Phase II
www.fresenius-biotech.com
CDX-1127
Needham, MA
Phase I
(781) 433-0771
clodronic acid
Wayne, NJ
bone metastases
Phase III
(888) 842-2937
CLT-008
Cellerant Therapeutics
San Carlos, CA
Phase I
(650) 232-2122
CPI-613
(Orphan Drug)
Cornerstone Pharmaceuticals
Cranbury, NJ
Phase I
(609) 409-7050
dalotuzumab
(MK-0646)
Merck
neuroendocrine tumors
(see also breast, lung, pancreatic)
Phase II
(800) 672-6372
DMUC-5754A
Genentech
first-line fallopian tube cancer,
second-line peritoneal cancer
(see also ovarian)
Phase I
(800) 626-3553
DN24-02
(lapuleucel-T)
dendritic cell vaccine
Dendreon
Seattle, WA
high-risk, HER2-positive urogenital
cancer (adjuvant therapy)
Phase II
(877) 256-4545
E7080
(lenvatinib)
Eisai
Woodcliff Lake, NJ
thyroid cancer
(see also brain, skin)
-------------------------------------------------endometrial cancer
Phase III
(888) 422-4743
------------------------------------------Phase II
(888) 422-4743
E7850
(irofulven)
Eisai
Woodcliff Lake, NJ
thyroid cancer
Phase II
(888) 422-4743
efatutazone
Daiichi Sankyo
Parsippany, NJ
thyroid cancer
Phase I/II
(973) 944-2600
117
Other Cancers
Product Name
Sponsor
Indication
Development Status
EGEN-001
EGEN
Huntsville, AL
fallopian tube cancer,
peritoneal cancer
(see also colorectal, ovarian)
Phase II
(256) 512-0077
elagolix
Abbott Laboratories
Abbott Park, IL
Neurocrine Biosciences
San Diego, CA
uterine leiomyoma
Phase II
(847) 938-6100
(858) 617-7600
ENMD-2076
EntreMed
Rockville, MD
late-stage cancer
(see also multiple myeloma, ovarian)
Phase I
(240) 864-2600
Femara®
letrozole
East Hanover, NJ
recurrent, metastatic endometrial
Phase II
(888) 669-6682
vaccine
Galena Biopharma
Lake Oswego, OR
endometrial cancer
Phase I/II
(855) 855-4253
fostamatinib
(SYK inhibitor)
AstraZeneca
Wilmington, DE
Rigel Pharmaceuticals
Phase II
(800) 236-9933
(650) 624-1100
Gleevec®
imatinib
East Hanover, NJ
fibroma
(see also lung, prostate, skin)
Phase II
(888) 669-6682
Inlyta®
axitinib
Pfizer
New York, NY
thyroid cancer
(see also kidney, liver)
Phase II
(860) 732-5156
IPI-145
Cambridge, MA
Phase I
(617) 453-1000
Istodax®
romidepsin
Celgene
Summit, NJ
(see also kidney, pancreatic,
prostate)
Phase I
(908) 673-9000
IXEMPRA®
ixabepilone
Princeton, NJ
endometrial cancer
in clinical trials
(800) 332-2056
Jakafi™
ruxolitinib
Incyte
Wilmington, DE
Phase II
(855) 446-2983
KB004
KaloBios Pharmaceuticals
Phase I
(650) 243-3100
Marqibo®
Talon Therapeutics
San Mateo, CA
pediatric cancers
(see also leukemia, lymphoma, skin)
Phase I/II
(650) 588-6404
118
Other Cancers
Product Name
Sponsor
Indication
Development Status
MEDI-551
(anti-CD19 mAb)
AstraZeneca
Wilmington, DE
MedImmune
Gaithersburg, MD
Phase I
(800) 236-9933
(301) 398-0000
MER-101
(zoledronic acid oral)
Merrion Pharmaceuticals
Wilmington, NC
bone metastases
Phase II
www/merrionpharma.com
Mirena®
levonorgestrel-releasing
intrauterine system
Wayne, PA
endometrial cancer,
endometrial hyperplasia
Phase II
(888) 842-2937
MK-0752
(notch signaling pathway
inhibitor)
Merck
central nervous system (CNS) cancer
in patients ages 3-21
(see also breast)
Phase I
(800) 672-6372
MK-2206
(c-akt inhibitor)
Merck
inoperable/unresectable
(see also breast)
Phase II
(800) 672-6372
MLN0128
Cambridge, MA
Phase I
(800) 390-5663
MLN4924
(NEDD8 inhibitor)
Cambridge, MA
(see aslo solid tumors)
Phase I
(800) 390-5663
motesanib
Amgen
Thousand Oaks, CA
thyroid cancer
(see also breast, colorectal, lung)
Phase II
(800) 772-6436
moxetumomab pasudotox
(CAT-8015)
AstraZeneca
Wilmington, DE
MedImmune
Gaithersburg, MD
Phase I
(800) 236-9933
(301) 398-0000
MSC1936369B
EMD Serono
Rockland, MA
Phase I/II
(800) 283-8088
Nexavar®
sorafenib
Wayne, NJ
thyroid cancer
lung, multiple myeloma, ovarian)
-------------------------------------------------neuroendocrine tumors
Phase III
(888) 842-2937
Phase I/II
www.gamida-cell.com
NiCord®
umbilical cord blood stem cell
therapy
Gamida Cell
Jerusalem, Israel
------------------------------------------Phase I
(888) 842-2937
119
Other Cancers
Product Name
Sponsor
Indication
Development Status
NTX-010
Neotropix
Malvern, PA
(see also lung)
Phase I
www.neotropix.com
Opaxio™
Cell Therapeutics
Seattle, WA
peritoneal cancer
(see also brain, lung, ovarian,
stomach)
Phase III
(800) 215-2355
OPR-003
EUSA Pharma
Langhorne, PA
Vaccinex
Rochester, NY
Phase I
(800) 833-3533
(585) 271-2700
OSI-906
inhibitor)
OSI Pharmaceuticals
Farmingdale, NY
adrenocortical carcinoma
Phase III
(631) 962-0600
(ADI-PEG 20)
San Diego, CA
pediatric cancer
(see also liver, prostate, skin)
Phase I
(858) 452-6688
PF-04691502
Pfizer
New York, NY
endometrial cancer
Phase II
(860) 732-5156
PF-05212384
(mTOR/PI3K inhibitor)
Pfizer
New York, NY
endometrial cancer
Phase II
(860) 732-5156
PHA848125
Nerviano, Italy
thymoma
Phase II
www.nervianoms.com
phenoxodiol
Marshall Edwards
San Diego, CA
fallopian tube cancer (combination
therapy)
Phase I/II
(858) 792-6300
PM-00104
PharmaMar
Madrid, Spain
endometrial cancer
(see also cervical, sarcoma)
Phase II
www.pharmamar.com
PTC299
PTC Therapeutics
central nervous system (CNS) cancer
in children
Phase II
(908) 222-7000
RG7112
(MDM2 antagonist)
Roche
Nutley, NJ
Phase I
(973) 235-5000
RG7388
(MDM2 inhibitor)
Roche
Nutley, NJ
Phase I
(973) 235-5000
RG7593
(mAb)
Roche
Nutley, NJ
Phase I
(973) 235-5000
120
Other Cancers
Product Name
Sponsor
Indication
Development Status
RG7596
Genentech
Phase I
(800) 626-3553
ridaforolimus
Cambridge, MA
Merck
endometrial cancer
prostate, sarcoma)
Phase II
(800) 672-6372
rintatolimod
Hemispherx Biopharma
Philadelphia, PA
cancer vaccine adjuvant
Phase I/II
(215) 988-0080
injection
EUSA Pharma
Langhorne, PA
bone metastases
prostate, sarcoma)
Phase III
(800) 833-3533
SAR3419
(maytansin-loaded anti-CD19
mAb)
Sanofi US
Bridgewater, NJ
ImmunoGen
Needham, MA
B-cell malignancies
Phase II
(800) 981-2491
(781) 895-0600
SAR245408
(XL147)
(oral PI3K inhibitor)
Sanofi US
Bridgewater, NJ
Exelixis
endometrial cancer
(see also breast)
Phase II
(800) 981-2491
(650) 837-7000
SAR650984
(anti-CD38 naked mAb)
Sanofi US
Bridgewater, NJ
Phase I
(800) 981-2491
SB989
(pracinostat)
S*BIO
Oakland, CA
Phase I
(650) 730-2860
siltuximab
Janssen Biotech
Horsham, PA
giant lymph node hyperplasia
(see also multiple myeloma, prostate)
Phase II
(800) 526-7736
SOM230
(pasireotide)
East Hanover, NJ
carcinoid tumors
Phase III
(888) 669-6682
------------------------------------------Phase II
(888) 669-6682
sotatercept
(ACE-011)
Celgene
Summit, NJ
cancer metastases
Phase II
(908) 673-9000
SPRYCEL®
dasatinib
Princeton, NJ
pediatric cancer
(see also brain, breast, pancreatic,
prostate)
in clinical trials
(800) 332-2056
-------------------------------------------------meningioma, neuroendocrine tumors
121
Other Cancers
Product Name
Sponsor
Indication
Development Status
StemEx®
carlecortemcel-L
(Orphan Drug)
Gamida Cell
Jerusalem, Israel
Teva North America
North Wales, PA
(Fast Track)
Phase III
(888) 838-2872
TAK-901
Cambridge, MA
Phase I
(800) 390-5663
Tarceva®
erlotinib
Genentech
OSI Pharmaceuticals
Farmingdale, NY
gynecological cancer
leukemia, liver, lung)
Phase II
(800) 626-3553
(631) 962-0600
telapristone
Repros Therapeutics
The Woodlands, TX
uterine leiomyoma
Phase I/II
(281) 719-3400
terameprocol
Houston, TX
(intravenous)
(see also brain, cervical, head/neck,
solid tumors)
Phase I
(713) 541-2000
TG02
S*BIO
Oakland, CA
San Diego, CA
Phase I
(650) 235-5539
(858) 350-6900
tivantinib
(ARQ 197)
ArQule
Woburn, MA
Daiichi Sankyo
Parsippany, NJ
germ cell and embryonal neoplasms
lung, pancreatic, sarcoma)
Phase II
(781) 994-0300
(973) 944-2600
TKI258
(dovitinib)
East Hanover, NJ
second-line endometrial cancer,
urothelial carcinoma
myeloma, prostate, skin)
Phase II
(888) 669-6682
TRC 105
San Diego, CA
fallopian tube cancer, peritoneal
cancer
(see also breast, ovarian, prostate)
Phase II
(858) 550-0780
trebananib (AMG386)
Amgen
Thousand Oaks, CA
fallopian tube cancer, peritoneal
cancer
liver, stomach)
Phase III
(800) 772-6436
122
Other Cancers
Product Name
Sponsor
Indication
Development Status
ulipristal
Watson Pharmaceuticals
Parsippany, NJ
uterine leiomyoma
Phase III
(800) 900-1644
VB-111
VBL Therapeutics
Or Yehuda, Israel
thyroid cancer
(see also brain)
Phase I/II
www.vblrx.com
Velcade®
bortezomib
Cambridge, MA
adenocarcinoma (combination
therapy)
cancer-related)
Phase II
(800) 390-5663
volasertib
Pharmaceuticals
Ridgefield, CT
urogenital cancer
Phase II
(800) 243-0127
Votrient™
pazopanib
GlaxoSmithKline
peritoneal cancer
(see also kidney, ovarian)
Phase III
(888) 825-5249
Xgeva™
denosumab
Amgen
Thousand Oaks, CA
prevention of bone metastases in
men with castrate-resistant prostate
cancer
(see also cancer-related, multiple
myeloma)
-------------------------------------------------prevention of bone metastases
in women with early-stage breast
cancer
-------------------------------------------------giant cell tumor of bone
(800) 772-6436
------------------------------------------Phase III
(800) 772-6436
------------------------------------------Phase II
(800) 772-6436
Zelboraf®
vemurafenib
Genentech
Plexxikon
Berkeley, CA
inoperable/unresectable thyroid
cancer
(see also brain, colorectal)
Phase II
(800) 626-3553
(510) 647-4000
Zolinza®
vorinostat
Merck
gynecological cancer, peritoneal
cancer
lymphoma, multiple myeloma)
Phase I/II
(800) 672-6273
123
Unspecified Cancer
Product Name
Sponsor
Indication
Development Status
ABC294640
Apogee Biotechnology
Hummelstown, PA
late-stage disease
Phase I
(843) 792-3420
ABI-011
(nab®-5404)
Celgene
Summit, NJ
Phase I
(908) 673-9000
AFX-9901
Afecta Pharmaceuticals
Irvine, CA
in clinical trials
(949) 253-4688
AGS-6MF
Agensys
Santa Monica, CA
Astellas Pharma US
Deerfield, IL
Phase I
(800) 695-4321
AGS-16M8F
Agensys
Santa Monica, CA
Astellas Pharma US
Deerfield, IL
Phase I
(800) 695-4321
ALT-836
Altor BioScience
Miramar, FL
Phase I/II
(954) 443-8600
anti-KIR
(BMS-986015)
Princeton, NJ
Phase I
(800) 332-2056
anti-LAG3
(BMS-986016)
Princeton, NJ
Phase I
(800) 332-2056
ANX-514
(docetaxel for injectable
emulsion)
ADVENTRX Pharmaceuticals
San Diego, CA
Phase I
(858) 552-0866
ARRY-300
(MEK inhibitor)
Array BioPharma
Boulder, CO
East Hanover, NJ
Phase I
(877) 633-2436
(888) 669-6682
ARRY-382
(c-fms antagonist)
Array BioPharma
Boulder, CO
Celgene
Summit, NJ
metastatic cancer
Phase I
(877) 633-2436
(908) 673-9000
AVL-292
(Btk inhibitor)
Celgene
Summit, NJ
Phase I
(908) 673-9000
B7-2/GM-CSF
cancer gene therapy vaccine
NuVax Therapeutics
Tustin, CA
BAY 94-9392
(PET imaging)
Wayne, NJ
124
Phase I
(714) 505-4461
cancer (diagnosis)
Phase I
(888) 842-2937
Unspecified Cancer
Product Name
Sponsor
cancer vaccine
Immunitor USA
Vancouver, Canada
Phase I/II
www.immunitor.com
cancer vaccine
(fibrocyte vaccine)
Cytokine PharmaSciences
King of Prussia, PA
Phase I
(610) 687-1776
carboxyamidotriazole orotate
(CTO)
Tactical Therapeutics
New York, NY
Phase I
(212) 651-9653
CBLB502
Cleveland BioLabs
Buffalo, NY
Phase I
(716) 849-6810
CDK 4/6 inhibitor
(LY2835219)
Eli Lilly
Indianapolis, IN
Phase II
(800) 545-5979
CDX-301
(Fms-like tyrosine kinase 3
ligand)
Needham, MA
Phase I
(781) 433-0771
cell therapy
Cell Medica
London, United Kingdom
Center for Cell and Gene Therapy
Houston, TX
Phase II
www.cellmedica.co.uk
CEN-109
Centella Therapeutics
Palo Alto, CA
Chk1 inhibitor
Eli Lilly
Indianapolis, IN
Phase I
(800) 545-5979
c-Met inhibitor
Eli Lilly
Indianapolis, IN
Phase I
(800) 545-5979
c-Met mAb
(LY2875358)
Eli Lilly
Indianapolis, IN
Phase II
(800) 545-5979
CSF-1R mAb
(IMC-CS4)
Eli Lilly
Indianapolis, IN
ImClone
Bridgewater, NJ
Phase I
(800) 545-5979
curmucin
Signpath Pharma
Quakertown, PA
Phase I
(267) 772-0107
CXCR4 peptide inhibitor
(LY2510924)
Eli Lilly
Indianapolis, IN
Phase II
(800) 545-5979
Indication
cancer (diagnosis)
Development Status
Phase II
www.centellatx.com
125
Unspecified Cancer
Product Name
Sponsor
cytotropic heterogeneous
molecular lipids
(CHML)
Glory Pharmaceuticals
Vienna, VA
Phase I
(703) 204-1703
DM-CHOC-PEN
Dekk-Tec
New Orleans, LA
Phase I
(504) 583-6135
EC0225
Endocyte
West Lafayette, IN
Phase I
www.endocyte.com
EGFR/IGFR tandem adnectin
(BMS-964210)
Princeton, NJ
Phase I
(800) 332-2056
eIF-4E ASO
(LY2275796)
Eli Lilly
Indianapolis, IN
Phase II
(800) 545-5979
fenretinide intravenous
CerRx
Lubbock, TX
Phase I
www.cerrx.com
FGF receptor inhibitor
Eli Lilly
Indianapolis, IN
Phase I
(800) 545-5979
fluorapacin
ACEA Biosciences
San Diego, CA
Phase I
(866) 308-2232
gemcitabine prodrug
Eli Lilly
Indianapolis, IN
Phase I
(800) 545-5979
GI-6207
(cancer vaccine)
GlobeImmune
Louisville, CO
Phase I
(303) 625-2700
GSK3 inhibitor
(LY2090314)
Eli Lilly
Indianapolis, IN
Phase II
(800) 545-5979
HBI-8000
HUYA Bioscience International
San Diego, CA
Quintiles
Phase I
www.huyabio.com
hedgehog antagonist
(LY2940680)
Eli Lilly
Indianapolis, IN
Phase II
(800) 545-5979
hTERT plasmid DNA cancer
vaccine
Merck
Vical
San Diego, CA
Phase I
(800) 672-6372
126
Indication
Development Status
Unspecified Cancer
Product Name
Sponsor
IL-21
(BMS-982470)
Princeton, NJ
In-111-DAC
imaging agent
Mayo Clinic
Rochester, MN
Naviscan
San Diego, CA
ISIS-STAT3Rx
Carlsbad, CA
Phase I
(800) 679-4747
JAK2 inhibitor
Eli Lilly
Indianapolis, IN
Phase I
(800) 545-5979
masoprocol
TriAct Therapeutics
San Francisco, CA
Phase II
(415) 602-7497
MK-8033
(c-Met/RON protein inhibitor)
Merck
Phase I
(800) 672-6372
new molecular entity
Eli Lilly
Indianapolis, IN
Phase I
(800) 545-5979
notch inhibitor
Eli Lilly
Indianapolis, IN
Phase I
(800) 545-5979
notch inhibitor
(BMS-906024)
Princeton, NJ
Phase I
(800) 332-2056
OPB-31121
Rockville, MD
Phase I
(800) 562-3974
p38 MAP inhibitor (1)
Eli Lilly
Indianapolis, IN
Phase I
(800) 545-5979
p38 MAP inhibitor (2)
Eli Lilly
Indianapolis, IN
Phase I
(800) 545-5979
p70/AKT inhibitor
Eli Lilly
Indianapolis, IN
Phase I
(800) 545-5979
PB-357
Puma Biotechnology
Los Angeles, CA
Phase I
(424) 248-6500
Indication
Development Status
Phase I
(800) 332-2056
cancer (diagnosis)
Phase I
www.mayoclinic.org
127
Unspecified Cancer
Product Name
Sponsor
PBI-05204
Phoenix Biotechnology
San Antonio, TX
Phase I
(210) 828-4373
PD-0325901
Pfizer
New York, NY
Phase I
(860) 732-5156
PD-0332991
Pfizer
New York, NY
Phase II
(860) 732-5156
PF-03084014
(gamma-secretase inhibitor)
Pfizer
New York, NY
Phase I
(860) 732-5156
PF-04449913
(sonic hedgehog pathway
inhibitor)
Pfizer
New York, NY
Phase I
(860) 732-5156
PF-05082566
(CD137 antigen agonist mAb)
Pfizer
New York, NY
Phase I
(860) 732-5156
Proleukin®
aldesleukin
(subcutaneous)
Prometheus Laboratories
San Diego, CA
Phase II
(888) 892-8391
PRT6207
(Syk-specific inhibitor)
Biogen Idec
Cambridge, MA
Portola Pharmaceuticals
Phase I
(781) 464-2000
(650) 246-7000
RON mAb
(IMC-RON8)
Eli Lilly
Indianapolis, IN
ImClone Systems
Bridgewater, NJ
Phase I
(800) 545-5979
SB1578
(JAK2 inhibitor)
S*BIO
Oakland, CA
Phase I
(650) 235-5539
SCH-900776
Merck
Phase II
(800) 672-6372
SMO antagonist
(BMS-833923)
Princeton, NJ
Phase I
(800) 332-2056
SR13668
SRI International
Menlo Park, CA
V930/V932
(plasmid DNA vaccine)
Merck
Vical
San Diego, CA
128
Indication
Development Status
cancer (prevention)
Phase 0
(650) 859-2000
Phase I
(800) 672-6372
(858) 646-1100
Unspecified Cancer
Product Name
Sponsor
Indication
Development Status
VEGFR3 mAb
(IMC-3C5)
Eli Lilly
Indianapolis, IN
ImClone
Bridgewater, NJ
Phase I
(800) 545-5979
XmAb®
anti-cancer mAb
Pharmaceuticals
Ridgefield, CT
Xencor
Monrovia, CA
Phase I
(800) 243-0127
(626) 305-5900
The content of this report has been obtained through industry sources and the Adis “R&D Insight” database based on the latest information. Report
current as of May 16, 2012. The information may not be comprehensive. For more specific information about a particular product, contact the individual company directly or go to www.clinicaltrials.gov. The entire series of Medicines in Development is available on PhRMA’s web site.
A publication of PhRMA’s Communications & Public Affairs Department. (202) 835-3460
www.phrma.org | www.innovation.org | www.pparx.org | www.buysafedrugs.info
Provided as a Public Service by PhRMA. Founded in 1958 as the Pharmaceutical Manufacturers Association.
Copyright © 2012 by the Pharmaceutical Research and Manufacturers of America. Permission to reprint is awarded if proper credit is given.
Pharmaceutical Research and Manufacturers of America • 950 F Street, NW, Washington, DC 20004
129
Glossary
actinic keratoses—Roughness and thickening of the skin caused by overexposure to the
sun’s ultraviolet rays. It can degenerate into a
skin cancer called squamous cell carcinoma.
cutaneous—Pertaining to the skin.
adenocarcinoma—Malignant tumor derived
from a gland or glandular tissue.
GIST—Gastrointestinal (GI) stromal cancer
is an uncommon tumor of the GI tract. Not
all GISTs are cancerous; some are benign.
Although these cancers can arise anywhere
in the GI tract, they occur most often in the
stomach (60% to 70%) and less commonly
in the small intestine (20% to 30%). The rest
are found in the esophagus, large intestine,
rectum, and anus. About 80% of people diagnosed with GIST are older than 50. It is slightly
more common in men. Blacks are more likely
to develop GISTs than whites.
adjunctive treatment—An auxiliary treatment
that is secondary to the main treatment.
adjuvant—A substance or drug that aids
another substance in its action.
allogeneic—Refers to having cell types that
are distinct and cause reactions in the immune
system.
application submitted—An application for
marketing has been submitted by the company
to the Food and Drug Administration (FDA).
ascites—Excess fluid in the space between
the tissues lining the abdomen and abdominal
organs (the peritoneal cavity).
basal cell cancer—Cancer of the lower layers
of the skin.
B-cell—A class of white blood cells important
to the body’s immune system.
biliary—Relating to bile.
carcinoma—A malignant tumor that arises
from epithelial tissues, such as skin.
cervical—Relating to the neck of the uterus.
chemoprotection—A therapeutic technique in
which bone marrow cells are removed from an
individual with cancer and are genetically modified to withstand higher doses of chemotherapy
before being returned to the donor.
cholangiocarcinoma—A malignancy of the
biliary duct system that may originate in the
liver and extrahepatic bile ducts. More than 90
percent are adenocarcinomas, and the remainder are squamous cell tumors. Cholangiocarcinomas tend to grow slowly and to infiltrate the
walls of the ducts. Each year, approximately
2,500 cases occur, and the average incidence
is 1 case per 100,000 people per year.
130
hepatocellular cancer/carcinoma—A cancer
that begins in the liver cells.
dysplasia—Abnormal tissue development.
hyperuricemia—An abnormally high uric acid
level in the blood.
gastric—Of or relating to the stomach.
glioblastoma—A fast growing and highly
malignant type of brain tumor arising from glial
(supporting) cells within the brain. There are
about five to 10 new cases per million population per year in the United States.
glioma—A type of brain tumor arising from the
supporting glial cells within the brain. Gliomas
make up about 60 percent of all primary brain
tumors and are frequently malignant.
graft-versus-host disease (GVHD)—A
complication in bone marrow transplants where
immune system cells attack the transplant
recipient’s tissues.
head and neck cancer—The term given to a
variety of malignant tumors that develop in the
mouth, throat, paranasal sinuses, nasal cavity,
larynx, and salivary glands. Many authorities
also include skin tumors of the face and neck
and tumors of the cervical lymph nodes. There
are more than half a million survivors of oral,
head, and neck cancer living in the United
States today.
hematological malignancies—Cancers of the
blood or blood-forming tissues, such as leukemia, Hodgkin’s and non-Hodgkin’s lymphomas, AIDS-related malignancies, multiple
myeloma, myelodysplasia and myeloproliferative disorders.
imaging agent—A substance used to enhance
x-ray images of organs and spaces in the body.
intraepithelial neoplasia, anal (AIN) & cervical (CIN)—AIN is a consequence of chronic
human papillomavirus infection in the anal
canal and appears to be driven by high viral
loads of human papillomavirus. What is known
of its natural history resembles that of cervical
intraepithelial neoplasia. Dysplasia and cervical intraepithelial neoplasia (CIN) are different
terms or names for the same condition—it is
a precursor to cervical cancer. CIN may be
mild, moderate or severe.
Kaposi’s sarcoma—A rare, malignant skin
tumor that occurs in some AIDS patients. It
can be accompanied by fever, enlarged lymph
nodes and gastrointestinal problems.
Leiomyoma—A benign neoplasm derived from
smooth muscle.
leukemia—A form of cancer in which abnormally growing white blood cells are scattered
throughout the body and bone marrow. They
can take over the marrow and prevent it from
making enough normal blood cells (white,
red and platelets), leaving the patient highly
susceptible to serious infections, anemia and
bleeding episodes. The cells can also spill into
the blood, infiltrating and interfering with the
function of other organs. The four main types
of leukemia are: acute lympho blastic leukemia (ALL), acute myeloid leukemia (AML),
chronic lymphocytic leukemia (CLL), and
chronic myeloid leukemia (CML). The acute
types have a rapid onset, and overwhelming
infection or blood loss can cause death. The
chronic forms progress much more slowly.
lung cancer—The leading cause of cancer
deaths in both men and women. There are
several types of lung cancer, the most common
being squamous cell carcinoma, small (oat)
cell carcinoma, adenocarcinoma and large cell
Glossary
carcinoma. Each has a different growth pattern
and response to treatment. The squamous cell,
small cell and large cell types are all strongly
associated with tobacco abuse.
lymphoma—Cancers in which the cells of lymphoid tissue, found mainly in the lymph nodes
and spleen, multiply unchecked. Lymphomas
fall into two categories: Hodgkin disease, characterized by a particular kind of abnormal cell,
and non-Hodgkin lymphomas, which vary in
their malignancy according to the nature and
activity of the abnormal cells. Mantle cell lymphoma is a type of non-Hodgkin lymphoma.
macroglobulinemia—A disorder in which
plasma cells produce an excessive quantity
of macroglobulins (large antibodies) that accumulate in the blood. It results from a group
of abnormal, cancerous lymphocytes and
plasma cells. Men are affected more often than
women, and the average age at onset is 65.
mastocytosis—A condition characterized by
infiltration of mast cells into the tissues of the
body. Mast cells are connective tissue cells
which release chemicals including histamine
that are very irritating and cause itching, swelling, and fluid leakage from cells.
medullary—Relating to the medulla (any soft
marrow-like structure, especially the innermost
part) or marrow.
melanoma—A cancer made up of pigmented
(usually brown-colored) skin cells anywhere in
the body.
multiple myeloma—A malignant condition of
middle to old age, characterized by the uncontrolled proliferation and disordered function of
plasma cells in the bone marrow. The condition, which makes the patient particularly prone
to infection, is rare, with about three new cases
annually per 100,000 population.
myeloablation—A severe form of myelosuppression, a condition in which bone marrow
activity is decreased, resulting in fewer red
blood cells, white blood cells, and platelets. It is
a side effect of some cancer treatments.
myelodysplastic syndromes (MDS)—Blood
disorders that ultimately are fatal. Patients
usually succumb to infections or bleeding. The
term “preleukemia” has been used to describe
these disorders.
neoadjuvant therapy—Chemotherapy, radiation therapy, or hormone therapy given before
the primary or main treatment. Neo-adjuvant
therapy, like chemotherapy and radiation
therapy, is often given before surgery to reduce
the size of a tumor or to make surgery less
complicated.
neuroblastoma—A tumor of the adrenal
glands or sympathetic nervous system (the
part of the nervous system responsible for
certain automatic body functions, such as the
control of heart rate). Neuroblastomas are the
most common extracranial (outside the skull)
solid tumors of childhood.
mesothelioma—A tumor of the lining of the
lung and chest cavity (the pleura).
osteosarcoma—Cancer of the bone that occurs predominantly in adolescents and young
adults. It accounts for 5 percent of cancer in
children.
metastases/metastatic—Areas of secondary
cancer that have spread from the primary or
original cancer site.
peritoneal—Relating to the peritoneum, the
membrane that lines the abdominal cavity and
covers most of the abdominal organs.
mucositis—The swelling, irritation, and ulceration of the mucosal cells that line the digestive
tract. Mucositis can occur anywhere along the
digestive tract from the mouth to the anus. It
can be a very troublesome and painful side
effect of chemotherapy.
Phase 0—First-in-human trials conducted
in accordance with FDA’s 2006 guidance on
exploratory Investigational New Drug (IND)
studies designed to speed up development of
promising drugs by establishing very early on
whether the agent behaves in human subjects
as was anticipated from preclinical studies.
Phase I—Safety testing and pharmacological profiling of new drugs in small numbers of
humans.
Phase II—Effectiveness testing and identification of side effects of new drugs in humans.
Phase III—Extensive clinical trials in humans
to verify effectiveness and monitor adverse
reactions of new drugs.
prolactinoma—A noncancerous pituitary
tumor that produces a hormone called prolactin, which results in too much prolactin in the
blood.
refractory—Resistant to treatment or cure.
sarcoma—A malignant tumor that arises from
deep body tissues, such as muscle, bone or
fibrous tissue.
T-cell—One of two main classes of white blood
cells called lymphocytes, which are important
to the body’s disease-fighting immune system.
thrombocytopenia—A reduction in the
number of platelet cells in the blood, which
causes a tendency to bleed, especially from
the smaller blood vessels.
thymoma—Although rare, thymomas are the
most common tumor of the thymus, a small
organ located in the upper chest just below
the neck that produces certain types of white
blood cells (lymphocytes) before birth and
during childhood. Thymomas arise from thymic
epithelial cells, which make up the covering of
the thymus. Up to 40 percent of thymomas are
invasive. They affect men and women equally
and are usually diagnosed between the ages
of 40 and 60. Thymomas are uncommon in
children.
unresectable—Unable to be removed (resected) by surgery.
131
Selected Facts about Cancer in the United States
Overview1
• Cancer is the second leading cause of death by disease—nearly 1 of every 4 deaths—in the United States, exceeded only by heart disease.
•Men have slightly less than a 1 in 2 lifetime risk of developing cancer; for women, the risk is a little more than 1 in 3. About 77 percent of all
cancers are diagnosed in people ages 55 and older.
•This year alone, more than 1.6 million new cancer cases are expected to be diagnosed, and an estimated 577,190 people are expected to die of
cancer. That’s more than 1,500 people a day.
•Scientific evidence suggests that about one-third of the cancer deaths expected this year will be related to overweight or obesity, physical inactivity, and poor nutrition, and thus could be prevented.
•The National Cancer Institute estimates that nearly 12 million Americans with a history of cancer were alive in January 2008. The 5-year relative
survival rate for all cancers diagnosed between 2001 and 2007 is 67 percent, up from 49 percent in the mid-70s.
Costs1
•The National Institutes of Health estimates overall costs for cancer in 2007 at $226.8 billion:
$103.8 billion for direct medical costs (total of all
health expenditures) and $123 billion for indirect mortality costs (cost of lost productivity due to premature death).
Pain
•Studies have shown that pain occurs in 30 percent of all cancer patients, regardless of the stage of the disease, and 90 percent of patients with
advanced cancer experience severe pain. Half of patients may be undertreated for cancer pain.2
•The most common cause of cancer-related pain is from metastases to the bone. Up to 80 percent of cancer patients with bone metastases
experience pain. The second most common cause of cancer pain is related to tumors infiltrating the nerve and hollow viscus. Tumors near neural
structures may cause the most severe pain. The third most common cause of pain associated with cancer result from chemotherapy, radiation,
or surgery.2
•Breakthrough pain—pain that occurs even when taking regular pain medication—is common in cancer patients. Breakthrough cancer pain
occurs in 50 percent to 90 percent of oncology inpatient settings, 89 percent of home care and inpatient hospice settings, and 35 percent of
community-based oncology practices. People with breakthrough pain have a significantly higher rate of hospitalization than those without breakthrough pain (36.9 percent vs. 22.5 percent, respectively) and dramatically higher estimated annual costs of care ($1.7 million compared with
$192,000).3
132
New Cancer Cases/Deaths1
Cancer Type
Estimated 2012 New Cases
Estimated 2012 Deaths
All Sites ................................................................................... 1,638,910...................................................................................... 577,190
Male.............................................................................. 848,170...................................................................................... 301,820
Female.......................................................................... 790,740...................................................................................... 275,370
Acute Lymphocytic Leukemia........................................................... 6,050.......................................................................................... 1,440
Male.................................................................................. 3,450............................................................................................. 820
Female.............................................................................. 2,600............................................................................................. 620
Acute Myeloid Leukemia................................................................ 13,780........................................................................................ 10,200
Male.................................................................................. 7,350.......................................................................................... 5,790
Female.............................................................................. 6,430.......................................................................................... 4,410
Bladder Cancer............................................................................... 73,510........................................................................................ 14,880
Male................................................................................ 55,600........................................................................................ 10,510
Female............................................................................ 17,910.......................................................................................... 4,370
Bone Cancer (and joints).................................................................. 2,890.......................................................................................... 1,410
Male.................................................................................. 1,600............................................................................................. 790
Female.............................................................................. 1,290............................................................................................. 620
Brain Cancer (and other nervous system)...................................... 22,910........................................................................................ 13,700
Male................................................................................ 12,630.......................................................................................... 7,720
Female............................................................................ 10,280.......................................................................................... 5,980
Breast Cancer............................................................................... 229,060........................................................................................ 39,920
Male.................................................................................. 2,190............................................................................................. 410
Female.......................................................................... 226,870........................................................................................ 39,510
Cervical and Uterine Cancers......................................................... 59,300........................................................................................ 12,230
Male........................................................................................—................................................................................................—
Female............................................................................ 59,300........................................................................................ 12,230
Chronic Lymphocytic Leukemia...................................................... 16,060.......................................................................................... 4,580
Male.................................................................................. 9,490.......................................................................................... 2,730
Female.............................................................................. 6,570.......................................................................................... 1,850
Chronic Myeloid Leukemia............................................................... 5,430............................................................................................. 610
Male.................................................................................. 3,210............................................................................................. 370
Female.............................................................................. 2,220............................................................................................. 240
Colorectal Cancer......................................................................... 143,460........................................................................................ 51,690
Male................................................................................ 73,420........................................................................................ 26,470
Female............................................................................ 70,040........................................................................................ 25,220
133
New Cancer Cases/Deaths1 continued
Cancer Type
Esophageal Cancer........................................................................ 17,460........................................................................................ 15,070
Male................................................................................ 13,950........................................................................................ 12,040
Female.............................................................................. 3,510.......................................................................................... 3,030
Kidney Cancer (and renal pelvis)................................................... 64,770........................................................................................ 13,570
Male................................................................................ 40,250.......................................................................................... 8,650
Female............................................................................ 24,520.......................................................................................... 4,920
Leukemia (all types)....................................................................... 47,150........................................................................................ 23,540
Male................................................................................ 26,830........................................................................................ 13,500
Female............................................................................ 20,320........................................................................................ 10,040
Liver Cancer................................................................................... 28,720........................................................................................ 20,550
Male................................................................................ 21,370........................................................................................ 13,980
Female.............................................................................. 7,350.......................................................................................... 6,570
Lung Cancer (and bronchus)........................................................ 226,160...................................................................................... 160,340
Male...............................................................................116,470........................................................................................ 87,750
Female.......................................................................... 109,690........................................................................................ 72,590
Lymphoma (all types)..................................................................... 79,190........................................................................................ 20,130
Male................................................................................ 43,120........................................................................................ 10,990
Female............................................................................ 36,070.......................................................................................... 9,140
Lymphoma (non-Hodgkin’s)............................................................ 70,130........................................................................................ 18,940
Male................................................................................ 38,160........................................................................................ 10,320
Female............................................................................ 31,970.......................................................................................... 8,620
Melanoma-Skin Cancer.................................................................. 76,250.......................................................................................... 9,180
Male................................................................................ 44,250.......................................................................................... 6,060
Female............................................................................ 32,000.......................................................................................... 3,120
Multiple Myeloma............................................................................ 21,700........................................................................................ 10,710
Male................................................................................ 12,190.......................................................................................... 6,020
Female.............................................................................. 9,510.......................................................................................... 4,690
Ovarian Cancer.............................................................................. 22,280........................................................................................ 15,500
Male........................................................................................—................................................................................................—
Female............................................................................ 22,280........................................................................................ 15,500
Pancreatic Cancer.......................................................................... 43,920........................................................................................ 37,390
Male................................................................................ 22,090........................................................................................ 18,850
Female............................................................................ 21,830........................................................................................ 18,540
134
New Cancer Cases/Deaths1 continued
Cancer Type
Prostate Cancer............................................................................ 241,740........................................................................................ 28,170
Male.............................................................................. 241,740........................................................................................ 28,170
Female....................................................................................—................................................................................................—
Stomach Cancer............................................................................. 21,320........................................................................................ 10,540
Male................................................................................ 13,020.......................................................................................... 6,190
Female.............................................................................. 8,300.......................................................................................... 4,350
Sources:
1. Cancer Facts & Figures 2012, American Cancer Society (www.cancer.org)
2. Remedy Health Media, LLC (www.healthcommunities.com)
3. American Pain Foundation (www.painfoundation.org)
135
The Drug Discovery, Development and Approval Process
Developing a new medicine takes an average of 10-15 years;
For every 5,000-10,000 compounds in the pipeline, only 1 is approved.
The Drug Development and Approval Process
The U.S. system of new drug approvals is
perhaps the most rigorous in the world.
It takes 10-15 years, on average, for an
experimental drug to travel from lab to U.S.
patients, according to the Tufts Center for the
Study of Drug Development. Only five in 5,000
compounds that enter preclinical testing make
it to human testing. And only one of those five
is approved for sale.
On average, it costs a company $1.2 billion,
including the cost of failures, to get one new
medicine from the laboratory to U.S. patients,
according to a 2007 study by the Tufts Center
for the Study of Drug Development.
Once a new compound has been identified in
the laboratory, medicines are usually developed as follows:
Preclinical Testing. A pharmaceutical company conducts laboratory and animal studies
to show biological activity of the compound
against the targeted disease, and the compound is evaluated for safety.
Investigational New Drug Application (IND).
After completing preclinical testing, a company
files an IND with the U.S. Food and Drug
Administration (FDA) to begin to test the drug
in people. The IND shows results of previous
experiments; how, where and by whom the
new studies will be conducted; the chemical
structure of the compound; how it is thought
to work in the body; any toxic effects found in
the animal studies; and how the compound
is manufactured. All clinical trials must be
reviewed and approved by the Institutional
Review Board (IRB) where the trials will be
conducted. Progress reports on clinical trials
must be submitted at least annually to FDA and
the IRB.
Clinical Trials, Phase I. These tests usually
involve about 20 to 100 healthy volunteers. The
tests study a drug’s safety profile, including the
safe dosage range. The studies also determine
how a drug is absorbed, distributed, metabolized, and excreted as well as the duration of
its action.
Clinical Trials, Phase II. In this phase,
controlled trials of approximately 100 to 500
volunteer patients (people with the disease)
assess a drug’s effectiveness and determine
the early side effect profile.
Clinical Trials, Phase III. This phase usually
involves 1,000 to 5,000 patients in clinics and
hospitals. Physicians monitor patients closely to
confirm efficacy and identify adverse events.
New Drug Application (NDA)/Biologic
License Application (BLA). Following the
completion of all three phases of clinical trials,
a company analyzes all of the data and files an
NDA or BLA with FDA if the data successfully
demonstrate both safety and effectiveness.
The applications contain all of the scientific
information that the company has gathered.
Applications typically run 100,000 pages or
more.
Approval. Once FDA approves an NDA or
BLA, the new medicine becomes available
for physicians to prescribe. A company must
continue to submit periodic reports to FDA,
including any cases of adverse reactions and
appropriate quality-control records. For some
medicines, FDA requires additional trials
(Phase IV) to evaluate long-term effects.
Discovering and developing safe and effective
new medicines is a long, difficult, and expensive
process. PhRMA member companies invested
an estimated $49.5 billion in research and
development in 2011.

Medicines in Development for Cancer

Transcription

Similar documents

new report

Re-use of established drugs for anti-metastatic indications Prof. Dr